# PeptideScanner evidence objects: Lixisenatide

Every published version of the records placed with Lixisenatide, one section per evidence object. The section anchor is the object's path id; the JSON twin is https://peptidescanner.com/evidence/v1/peptides/lixisenatide.json. Selected public evidence only; not medical advice.

- Objects: 64
- Manifest: https://peptidescanner.com/evidence/v1/manifest.json

---

<a id="clinicaltrials-gov-nct02020629-lixisenatide-v1"></a>

## ClinicalTrials.gov record NCT02020629

> PeptideScanner retained ClinicalTrials.gov record NCT02020629 at 2026-07-30T21:39:57.678Z. Its registry update date was 2015-12-15, and PeptideScanner's reviewed identity mapping was lixisenatide.

- Evidence object: `story:clinicaltrials-gov-nct02020629-lixisenatide:v1`
- Evidence domain: Clinical trials
- Date in source: 2015-12-15
- Source checked: 2026-07-30
- Published by PeptideScanner: 2026-08-09
- Story landing page: https://peptidescanner.com/stories/clinicaltrials-gov-nct02020629-lixisenatide/
- JSON record: https://peptidescanner.com/evidence/v1/peptides/lixisenatide.json#clinicaltrials-gov-nct02020629-lixisenatide-v1
- Content SHA-256: `e7804a50a848a5f25ff66ee6bea290ea2c3213c3bcc622b37a7dd6ef36b96031`

### Claims and source pins

#### Headline

ClinicalTrials.gov record NCT02020629 ([`ctg-observation-nct02020629-2015-12-15-1826448515fe`](#source-ctg-observation-nct02020629-2015-12-15-1826448515fe))

#### Summary

PeptideScanner retained ClinicalTrials.gov record NCT02020629 at 2026-07-30T21:39:57.678Z. Its registry update date was 2015-12-15, and PeptideScanner's reviewed identity mapping was lixisenatide. ([`ctg-observation-nct02020629-2015-12-15-1826448515fe`](#source-ctg-observation-nct02020629-2015-12-15-1826448515fe))

#### Paragraph 1

PeptideScanner retained ClinicalTrials.gov record NCT02020629 at 2026-07-30T21:39:57.678Z. Its registry update date was 2015-12-15, and PeptideScanner's reviewed identity mapping was lixisenatide. ([`ctg-observation-nct02020629-2015-12-15-1826448515fe`](#source-ctg-observation-nct02020629-2015-12-15-1826448515fe))

#### Paragraph 2

This page reports a dated retained registry observation and does not assert the record's current status; registration is not evidence that an intervention is safe or effective. ([`ctg-observation-nct02020629-2015-12-15-1826448515fe`](#source-ctg-observation-nct02020629-2015-12-15-1826448515fe))

### Sources

<a id="source-ctg-observation-nct02020629-2015-12-15-1826448515fe"></a>
- **ClinicalTrials.gov record NCT02020629 · retained source version 2015-12-15:1826448515fe317ebd0379b42b81b9a6d0cb291144698164d932b2b91275325b** — ClinicalTrials.gov; class A. [Open source](https://clinicaltrials.gov/study/NCT02020629) (`ctg-observation-nct02020629-2015-12-15-1826448515fe`)

### Correction lineage

No correction is recorded for this version.

### Reporting boundaries and unknowns

PeptideScanner reports the cited trial-registry entry and its status at observation. Registration or completion does not establish safety, effectiveness, or regulatory approval.

- Sources outside the selected public PeptideScanner bundle may exist and are not represented by this object.
- This object does not determine whether cited records agree, corroborate one another, or establish scientific truth.
- This object does not determine safety, efficacy, causality, or suitability for any person.

Methodology: https://peptidescanner.com/methodology/
Medical disclaimer: https://peptidescanner.com/medical-disclaimer/

### Suggested citation

PeptideScanner. "ClinicalTrials.gov record NCT02020629." Version 1, published 2026-08-09. https://peptidescanner.com/evidence/v1/peptides/lixisenatide.json#clinicaltrials-gov-nct02020629-lixisenatide-v1 SHA-256: e7804a50a848a5f25ff66ee6bea290ea2c3213c3bcc622b37a7dd6ef36b96031.

---

<a id="clinicaltrials-gov-nct02049034-lixisenatide-v1"></a>

## ClinicalTrials.gov record NCT02049034

> PeptideScanner retained ClinicalTrials.gov record NCT02049034 at 2026-07-30T18:37:14.684Z. Its registry update date was 2024-12-16, and PeptideScanner's reviewed identity mapping was lixisenatide.

- Evidence object: `story:clinicaltrials-gov-nct02049034-lixisenatide:v1`
- Evidence domain: Clinical trials
- Date in source: 2024-12-16
- Source checked: 2026-07-30
- Published by PeptideScanner: 2026-08-14
- Story landing page: https://peptidescanner.com/stories/clinicaltrials-gov-nct02049034-lixisenatide/
- JSON record: https://peptidescanner.com/evidence/v1/peptides/lixisenatide.json#clinicaltrials-gov-nct02049034-lixisenatide-v1
- Content SHA-256: `74ee080b119df92673d698f1f3fea13e94f4927a7a6c53e9c6b90f4bc301fabc`

### Claims and source pins

#### Headline

ClinicalTrials.gov record NCT02049034 ([`ctg-observation-nct02049034-2024-12-16-9b9d70157c5b`](#source-ctg-observation-nct02049034-2024-12-16-9b9d70157c5b))

#### Summary

PeptideScanner retained ClinicalTrials.gov record NCT02049034 at 2026-07-30T18:37:14.684Z. Its registry update date was 2024-12-16, and PeptideScanner's reviewed identity mapping was lixisenatide. ([`ctg-observation-nct02049034-2024-12-16-9b9d70157c5b`](#source-ctg-observation-nct02049034-2024-12-16-9b9d70157c5b))

#### Paragraph 1

PeptideScanner retained ClinicalTrials.gov record NCT02049034 at 2026-07-30T18:37:14.684Z. Its registry update date was 2024-12-16, and PeptideScanner's reviewed identity mapping was lixisenatide. ([`ctg-observation-nct02049034-2024-12-16-9b9d70157c5b`](#source-ctg-observation-nct02049034-2024-12-16-9b9d70157c5b))

#### Paragraph 2

This page reports a dated retained registry observation and does not assert the record's current status; registration is not evidence that an intervention is safe or effective. ([`ctg-observation-nct02049034-2024-12-16-9b9d70157c5b`](#source-ctg-observation-nct02049034-2024-12-16-9b9d70157c5b))

### Sources

<a id="source-ctg-observation-nct02049034-2024-12-16-9b9d70157c5b"></a>
- **ClinicalTrials.gov record NCT02049034 · retained source version 2024-12-16:9b9d70157c5bb521afbfc018957c1d0ce504d6a3867b0aca79f22426b20c713c** — ClinicalTrials.gov; class A. [Open source](https://clinicaltrials.gov/study/NCT02049034) (`ctg-observation-nct02049034-2024-12-16-9b9d70157c5b`)

### Correction lineage

No correction is recorded for this version.

### Reporting boundaries and unknowns

PeptideScanner reports the cited trial-registry entry and its status at observation. Registration or completion does not establish safety, effectiveness, or regulatory approval.

- Sources outside the selected public PeptideScanner bundle may exist and are not represented by this object.
- This object does not determine whether cited records agree, corroborate one another, or establish scientific truth.
- This object does not determine safety, efficacy, causality, or suitability for any person.

Methodology: https://peptidescanner.com/methodology/
Medical disclaimer: https://peptidescanner.com/medical-disclaimer/

### Suggested citation

PeptideScanner. "ClinicalTrials.gov record NCT02049034." Version 1, published 2026-08-14. https://peptidescanner.com/evidence/v1/peptides/lixisenatide.json#clinicaltrials-gov-nct02049034-lixisenatide-v1 SHA-256: 74ee080b119df92673d698f1f3fea13e94f4927a7a6c53e9c6b90f4bc301fabc.

---

<a id="clinicaltrials-gov-nct02276196-lixisenatide-v1"></a>

## ClinicalTrials.gov record NCT02276196

> PeptideScanner retained ClinicalTrials.gov record NCT02276196 at 2026-07-30T21:37:20.821Z. Its registry update date was 2016-04-29, and PeptideScanner's reviewed identity mapping was lixisenatide.

- Evidence object: `story:clinicaltrials-gov-nct02276196-lixisenatide:v1`
- Evidence domain: Clinical trials
- Date in source: 2016-04-29
- Source checked: 2026-07-30
- Published by PeptideScanner: 2026-08-09
- Story landing page: https://peptidescanner.com/stories/clinicaltrials-gov-nct02276196-lixisenatide/
- JSON record: https://peptidescanner.com/evidence/v1/peptides/lixisenatide.json#clinicaltrials-gov-nct02276196-lixisenatide-v1
- Content SHA-256: `11072a854c8fbf6c7ab464c89d12a9ff4118eefbd74c7d70e9d3603597690d82`

### Claims and source pins

#### Headline

ClinicalTrials.gov record NCT02276196 ([`ctg-observation-nct02276196-2016-04-29-4d69686a040e`](#source-ctg-observation-nct02276196-2016-04-29-4d69686a040e))

#### Summary

PeptideScanner retained ClinicalTrials.gov record NCT02276196 at 2026-07-30T21:37:20.821Z. Its registry update date was 2016-04-29, and PeptideScanner's reviewed identity mapping was lixisenatide. ([`ctg-observation-nct02276196-2016-04-29-4d69686a040e`](#source-ctg-observation-nct02276196-2016-04-29-4d69686a040e))

#### Paragraph 1

PeptideScanner retained ClinicalTrials.gov record NCT02276196 at 2026-07-30T21:37:20.821Z. Its registry update date was 2016-04-29, and PeptideScanner's reviewed identity mapping was lixisenatide. ([`ctg-observation-nct02276196-2016-04-29-4d69686a040e`](#source-ctg-observation-nct02276196-2016-04-29-4d69686a040e))

#### Paragraph 2

This page reports a dated retained registry observation and does not assert the record's current status; registration is not evidence that an intervention is safe or effective. ([`ctg-observation-nct02276196-2016-04-29-4d69686a040e`](#source-ctg-observation-nct02276196-2016-04-29-4d69686a040e))

### Sources

<a id="source-ctg-observation-nct02276196-2016-04-29-4d69686a040e"></a>
- **ClinicalTrials.gov record NCT02276196 · retained source version 2016-04-29:4d69686a040e223cc2cccf74e887ecc2fc0e57230db87247fba79e1f3ed4c101** — ClinicalTrials.gov; class A. [Open source](https://clinicaltrials.gov/study/NCT02276196) (`ctg-observation-nct02276196-2016-04-29-4d69686a040e`)

### Correction lineage

No correction is recorded for this version.

### Reporting boundaries and unknowns

PeptideScanner reports the cited trial-registry entry and its status at observation. Registration or completion does not establish safety, effectiveness, or regulatory approval.

- Sources outside the selected public PeptideScanner bundle may exist and are not represented by this object.
- This object does not determine whether cited records agree, corroborate one another, or establish scientific truth.
- This object does not determine safety, efficacy, causality, or suitability for any person.

Methodology: https://peptidescanner.com/methodology/
Medical disclaimer: https://peptidescanner.com/medical-disclaimer/

### Suggested citation

PeptideScanner. "ClinicalTrials.gov record NCT02276196." Version 1, published 2026-08-09. https://peptidescanner.com/evidence/v1/peptides/lixisenatide.json#clinicaltrials-gov-nct02276196-lixisenatide-v1 SHA-256: 11072a854c8fbf6c7ab464c89d12a9ff4118eefbd74c7d70e9d3603597690d82.

---

<a id="clinicaltrials-gov-nct02640118-lixisenatide-v1"></a>

## ClinicalTrials.gov record NCT02640118

> PeptideScanner retained ClinicalTrials.gov record NCT02640118 at 2026-07-30T20:27:50.520Z. Its registry update date was 2020-05-07, and PeptideScanner's reviewed identity mapping was lixisenatide.

- Evidence object: `story:clinicaltrials-gov-nct02640118-lixisenatide:v1`
- Evidence domain: Clinical trials
- Date in source: 2020-05-07
- Source checked: 2026-07-30
- Published by PeptideScanner: 2026-08-08
- Story landing page: https://peptidescanner.com/stories/clinicaltrials-gov-nct02640118-lixisenatide/
- JSON record: https://peptidescanner.com/evidence/v1/peptides/lixisenatide.json#clinicaltrials-gov-nct02640118-lixisenatide-v1
- Content SHA-256: `b4727f06fab564299f7bd9d78f299810085d53f946095c76edfcc791dca07b1e`

### Claims and source pins

#### Headline

ClinicalTrials.gov record NCT02640118 ([`ctg-observation-nct02640118-2020-05-07-2324e26bccb0`](#source-ctg-observation-nct02640118-2020-05-07-2324e26bccb0))

#### Summary

PeptideScanner retained ClinicalTrials.gov record NCT02640118 at 2026-07-30T20:27:50.520Z. Its registry update date was 2020-05-07, and PeptideScanner's reviewed identity mapping was lixisenatide. ([`ctg-observation-nct02640118-2020-05-07-2324e26bccb0`](#source-ctg-observation-nct02640118-2020-05-07-2324e26bccb0))

#### Paragraph 1

PeptideScanner retained ClinicalTrials.gov record NCT02640118 at 2026-07-30T20:27:50.520Z. Its registry update date was 2020-05-07, and PeptideScanner's reviewed identity mapping was lixisenatide. ([`ctg-observation-nct02640118-2020-05-07-2324e26bccb0`](#source-ctg-observation-nct02640118-2020-05-07-2324e26bccb0))

#### Paragraph 2

This page reports a dated retained registry observation and does not assert the record's current status; registration is not evidence that an intervention is safe or effective. ([`ctg-observation-nct02640118-2020-05-07-2324e26bccb0`](#source-ctg-observation-nct02640118-2020-05-07-2324e26bccb0))

### Sources

<a id="source-ctg-observation-nct02640118-2020-05-07-2324e26bccb0"></a>
- **ClinicalTrials.gov record NCT02640118 · retained source version 2020-05-07:2324e26bccb0b4d60bf9527e0d62f4377a8ad13ad89723f82a4939a0aa52a7a4** — ClinicalTrials.gov; class A. [Open source](https://clinicaltrials.gov/study/NCT02640118) (`ctg-observation-nct02640118-2020-05-07-2324e26bccb0`)

### Correction lineage

No correction is recorded for this version.

### Reporting boundaries and unknowns

PeptideScanner reports the cited trial-registry entry and its status at observation. Registration or completion does not establish safety, effectiveness, or regulatory approval.

- Sources outside the selected public PeptideScanner bundle may exist and are not represented by this object.
- This object does not determine whether cited records agree, corroborate one another, or establish scientific truth.
- This object does not determine safety, efficacy, causality, or suitability for any person.

Methodology: https://peptidescanner.com/methodology/
Medical disclaimer: https://peptidescanner.com/medical-disclaimer/

### Suggested citation

PeptideScanner. "ClinicalTrials.gov record NCT02640118." Version 1, published 2026-08-08. https://peptidescanner.com/evidence/v1/peptides/lixisenatide.json#clinicaltrials-gov-nct02640118-lixisenatide-v1 SHA-256: b4727f06fab564299f7bd9d78f299810085d53f946095c76edfcc791dca07b1e.

---

<a id="clinicaltrials-gov-nct02745470-lixisenatide-v1"></a>

## ClinicalTrials.gov record NCT02745470

> PeptideScanner retained ClinicalTrials.gov record NCT02745470 at 2026-07-30T21:22:00.254Z. Its registry update date was 2017-11-29, and PeptideScanner's reviewed identity mapping was lixisenatide.

- Evidence object: `story:clinicaltrials-gov-nct02745470-lixisenatide:v1`
- Evidence domain: Clinical trials
- Date in source: 2017-11-29
- Source checked: 2026-07-30
- Published by PeptideScanner: 2026-09-09
- Story landing page: https://peptidescanner.com/stories/clinicaltrials-gov-nct02745470-lixisenatide/
- JSON record: https://peptidescanner.com/evidence/v1/peptides/lixisenatide.json#clinicaltrials-gov-nct02745470-lixisenatide-v1
- Content SHA-256: `bc6f04def112ce0f721baa5b39ec0e7453cdbb6ece0e8965e68f90eed11c68ea`

### Claims and source pins

#### Headline

ClinicalTrials.gov record NCT02745470 ([`ctg-observation-nct02745470-2017-11-29-a102fad058be`](#source-ctg-observation-nct02745470-2017-11-29-a102fad058be))

#### Summary

PeptideScanner retained ClinicalTrials.gov record NCT02745470 at 2026-07-30T21:22:00.254Z. Its registry update date was 2017-11-29, and PeptideScanner's reviewed identity mapping was lixisenatide. ([`ctg-observation-nct02745470-2017-11-29-a102fad058be`](#source-ctg-observation-nct02745470-2017-11-29-a102fad058be))

#### Paragraph 1

PeptideScanner retained ClinicalTrials.gov record NCT02745470 at 2026-07-30T21:22:00.254Z. Its registry update date was 2017-11-29, and PeptideScanner's reviewed identity mapping was lixisenatide. ([`ctg-observation-nct02745470-2017-11-29-a102fad058be`](#source-ctg-observation-nct02745470-2017-11-29-a102fad058be))

#### Paragraph 2

This page reports a dated retained registry observation and does not assert the record's current status; registration is not evidence that an intervention is safe or effective. ([`ctg-observation-nct02745470-2017-11-29-a102fad058be`](#source-ctg-observation-nct02745470-2017-11-29-a102fad058be))

### Sources

<a id="source-ctg-observation-nct02745470-2017-11-29-a102fad058be"></a>
- **ClinicalTrials.gov record NCT02745470 · retained source version 2017-11-29:a102fad058beb9a3137fc76cc024611e51469ccaa5fceeb7aec44ee1ce8226a3** — ClinicalTrials.gov; class A. [Open source](https://clinicaltrials.gov/study/NCT02745470) (`ctg-observation-nct02745470-2017-11-29-a102fad058be`)

### Correction lineage

No correction is recorded for this version.

### Reporting boundaries and unknowns

PeptideScanner reports the cited trial-registry entry and its status at observation. Registration or completion does not establish safety, effectiveness, or regulatory approval.

- Sources outside the selected public PeptideScanner bundle may exist and are not represented by this object.
- This object does not determine whether cited records agree, corroborate one another, or establish scientific truth.
- This object does not determine safety, efficacy, causality, or suitability for any person.

Methodology: https://peptidescanner.com/methodology/
Medical disclaimer: https://peptidescanner.com/medical-disclaimer/

### Suggested citation

PeptideScanner. "ClinicalTrials.gov record NCT02745470." Version 1, published 2026-09-09. https://peptidescanner.com/evidence/v1/peptides/lixisenatide.json#clinicaltrials-gov-nct02745470-lixisenatide-v1 SHA-256: bc6f04def112ce0f721baa5b39ec0e7453cdbb6ece0e8965e68f90eed11c68ea.

---

<a id="clinicaltrials-gov-nct03439943-lixisenatide-v1"></a>

## ClinicalTrials.gov record NCT03439943

> PeptideScanner retained ClinicalTrials.gov record NCT03439943 at 2026-07-30T18:19:48.216Z. Its registry update date was 2025-11-28, and PeptideScanner's reviewed identity mapping was lixisenatide.

- Evidence object: `story:clinicaltrials-gov-nct03439943-lixisenatide:v1`
- Evidence domain: Clinical trials
- Date in source: 2025-11-28
- Source checked: 2026-07-30
- Published by PeptideScanner: 2026-08-08
- Story landing page: https://peptidescanner.com/stories/clinicaltrials-gov-nct03439943-lixisenatide/
- JSON record: https://peptidescanner.com/evidence/v1/peptides/lixisenatide.json#clinicaltrials-gov-nct03439943-lixisenatide-v1
- Content SHA-256: `cf0312b4e3b165c18cad1ed589d5ed93a3154a35ddbe53453fdc41ff0a8fae28`

### Claims and source pins

#### Headline

ClinicalTrials.gov record NCT03439943 ([`ctg-observation-nct03439943-2025-11-28-e2cdd6e285aa`](#source-ctg-observation-nct03439943-2025-11-28-e2cdd6e285aa))

#### Summary

PeptideScanner retained ClinicalTrials.gov record NCT03439943 at 2026-07-30T18:19:48.216Z. Its registry update date was 2025-11-28, and PeptideScanner's reviewed identity mapping was lixisenatide. ([`ctg-observation-nct03439943-2025-11-28-e2cdd6e285aa`](#source-ctg-observation-nct03439943-2025-11-28-e2cdd6e285aa))

#### Paragraph 1

PeptideScanner retained ClinicalTrials.gov record NCT03439943 at 2026-07-30T18:19:48.216Z. Its registry update date was 2025-11-28, and PeptideScanner's reviewed identity mapping was lixisenatide. ([`ctg-observation-nct03439943-2025-11-28-e2cdd6e285aa`](#source-ctg-observation-nct03439943-2025-11-28-e2cdd6e285aa))

#### Paragraph 2

This page reports a dated retained registry observation and does not assert the record's current status; registration is not evidence that an intervention is safe or effective. ([`ctg-observation-nct03439943-2025-11-28-e2cdd6e285aa`](#source-ctg-observation-nct03439943-2025-11-28-e2cdd6e285aa))

### Sources

<a id="source-ctg-observation-nct03439943-2025-11-28-e2cdd6e285aa"></a>
- **ClinicalTrials.gov record NCT03439943 · retained source version 2025-11-28:e2cdd6e285aac13a00f38a3d2f833c86f7158b70b2914cf3851a8dc62cf24ad1** — ClinicalTrials.gov; class A. [Open source](https://clinicaltrials.gov/study/NCT03439943) (`ctg-observation-nct03439943-2025-11-28-e2cdd6e285aa`)

### Correction lineage

No correction is recorded for this version.

### Reporting boundaries and unknowns

PeptideScanner reports the cited trial-registry entry and its status at observation. Registration or completion does not establish safety, effectiveness, or regulatory approval.

- Sources outside the selected public PeptideScanner bundle may exist and are not represented by this object.
- This object does not determine whether cited records agree, corroborate one another, or establish scientific truth.
- This object does not determine safety, efficacy, causality, or suitability for any person.

Methodology: https://peptidescanner.com/methodology/
Medical disclaimer: https://peptidescanner.com/medical-disclaimer/

### Suggested citation

PeptideScanner. "ClinicalTrials.gov record NCT03439943." Version 1, published 2026-08-08. https://peptidescanner.com/evidence/v1/peptides/lixisenatide.json#clinicaltrials-gov-nct03439943-lixisenatide-v1 SHA-256: cf0312b4e3b165c18cad1ed589d5ed93a3154a35ddbe53453fdc41ff0a8fae28.

---

<a id="dailymed-label-lixisenatide-4bba538b-cf7c-4310-ae8f-cb711ed21bcc-v10-v1"></a>

## Lixisenatide DailyMed SPL version 10

> DailyMed lists Structured Product Labeling version 10 for the reviewed Lixisenatide label family with a published date of 2019-12-12. PeptideScanner retained the exact versioned ZIP byte count and SHA-256 receipt without republishing its contents.

- Evidence object: `story:dailymed-label-lixisenatide-4bba538b-cf7c-4310-ae8f-cb711ed21bcc-v10:v1`
- Evidence domain: Regulatory
- Date in source: 2019-12-12
- Source checked: 2026-08-22
- Published by PeptideScanner: 2026-08-22
- Story landing page: https://peptidescanner.com/stories/dailymed-label-lixisenatide-4bba538b-cf7c-4310-ae8f-cb711ed21bcc-v10/
- JSON record: https://peptidescanner.com/evidence/v1/peptides/lixisenatide.json#dailymed-label-lixisenatide-4bba538b-cf7c-4310-ae8f-cb711ed21bcc-v10-v1
- Content SHA-256: `e77dcfb1dbe84951b8f3321f0bb1697b395218f62259157f1a3374c4d9e96cc4`

### Claims and source pins

#### Headline

Lixisenatide DailyMed SPL version 10 ([`dailymed-lixisenatide-4bba538b-cf7c-4310-ae8f-cb711ed21bcc-v10-history`](#source-dailymed-lixisenatide-4bba538b-cf7c-4310-ae8f-cb711ed21bcc-v10-history))

#### Summary

DailyMed lists Structured Product Labeling version 10 for the reviewed Lixisenatide label family with a published date of 2019-12-12. PeptideScanner retained the exact versioned ZIP byte count and SHA-256 receipt without republishing its contents. ([`dailymed-lixisenatide-4bba538b-cf7c-4310-ae8f-cb711ed21bcc-v10-history`](#source-dailymed-lixisenatide-4bba538b-cf7c-4310-ae8f-cb711ed21bcc-v10-history))

#### Paragraph 1

DailyMed lists Structured Product Labeling version 10 for the reviewed Lixisenatide label family with a published date of 2019-12-12. PeptideScanner retained the exact versioned ZIP byte count and SHA-256 receipt without republishing its contents. ([`dailymed-lixisenatide-4bba538b-cf7c-4310-ae8f-cb711ed21bcc-v10-history`](#source-dailymed-lixisenatide-4bba538b-cf7c-4310-ae8f-cb711ed21bcc-v10-history))

#### Paragraph 2

This page reports that DailyMed lists an available Structured Product Labeling version for the reviewed label family and links the exact historical ZIP. It does not reproduce label text, identify which sections changed, establish FDA approval, interpret safety or effectiveness, or provide medical guidance. ([`dailymed-lixisenatide-4bba538b-cf7c-4310-ae8f-cb711ed21bcc-v10-history`](#source-dailymed-lixisenatide-4bba538b-cf7c-4310-ae8f-cb711ed21bcc-v10-history))

### Sources

<a id="source-dailymed-lixisenatide-4bba538b-cf7c-4310-ae8f-cb711ed21bcc-v10-history"></a>
- **DailyMed SPL SET ID 4bba538b-cf7c-4310-ae8f-cb711ed21bcc · SPL version 10 · published 2019-12-12 · retained ZIP SHA-256 71f6871a4a3ba2fb825a44e9471c94a883aefd967d48195fd8ab7862bde0ece8** — DailyMed · U.S. National Library of Medicine; class A. [Open source](https://dailymed.nlm.nih.gov/dailymed/getFile.cfm?type=zip&setid=4bba538b-cf7c-4310-ae8f-cb711ed21bcc&version=10) (`dailymed-lixisenatide-4bba538b-cf7c-4310-ae8f-cb711ed21bcc-v10-history`)

### Correction lineage

No correction is recorded for this version.

### Reporting boundaries and unknowns

PeptideScanner reports the cited regulator or label record. It does not extend that record into broader safety, effectiveness, or approval claims.

- Sources outside the selected public PeptideScanner bundle may exist and are not represented by this object.
- This object does not determine whether cited records agree, corroborate one another, or establish scientific truth.
- This object does not determine safety, efficacy, causality, or suitability for any person.

Methodology: https://peptidescanner.com/methodology/
Medical disclaimer: https://peptidescanner.com/medical-disclaimer/

### Suggested citation

PeptideScanner. "Lixisenatide DailyMed SPL version 10." Version 1, published 2026-08-22. https://peptidescanner.com/evidence/v1/peptides/lixisenatide.json#dailymed-label-lixisenatide-4bba538b-cf7c-4310-ae8f-cb711ed21bcc-v10-v1 SHA-256: e77dcfb1dbe84951b8f3321f0bb1697b395218f62259157f1a3374c4d9e96cc4.

---

<a id="dailymed-label-lixisenatide-4bba538b-cf7c-4310-ae8f-cb711ed21bcc-v11-v1"></a>

## Lixisenatide DailyMed SPL version 11

> DailyMed lists Structured Product Labeling version 11 for the reviewed Lixisenatide label family with a published date of 2019-12-19. PeptideScanner retained the exact versioned ZIP byte count and SHA-256 receipt without republishing its contents.

- Evidence object: `story:dailymed-label-lixisenatide-4bba538b-cf7c-4310-ae8f-cb711ed21bcc-v11:v1`
- Evidence domain: Regulatory
- Date in source: 2019-12-19
- Source checked: 2026-08-22
- Published by PeptideScanner: 2026-08-22
- Story landing page: https://peptidescanner.com/stories/dailymed-label-lixisenatide-4bba538b-cf7c-4310-ae8f-cb711ed21bcc-v11/
- JSON record: https://peptidescanner.com/evidence/v1/peptides/lixisenatide.json#dailymed-label-lixisenatide-4bba538b-cf7c-4310-ae8f-cb711ed21bcc-v11-v1
- Content SHA-256: `bf5cf5f5e66854cae4973abfa0f422234c3b4ef156719acd8d12a95af3be66bd`

### Claims and source pins

#### Headline

Lixisenatide DailyMed SPL version 11 ([`dailymed-lixisenatide-4bba538b-cf7c-4310-ae8f-cb711ed21bcc-v11-history`](#source-dailymed-lixisenatide-4bba538b-cf7c-4310-ae8f-cb711ed21bcc-v11-history))

#### Summary

DailyMed lists Structured Product Labeling version 11 for the reviewed Lixisenatide label family with a published date of 2019-12-19. PeptideScanner retained the exact versioned ZIP byte count and SHA-256 receipt without republishing its contents. ([`dailymed-lixisenatide-4bba538b-cf7c-4310-ae8f-cb711ed21bcc-v11-history`](#source-dailymed-lixisenatide-4bba538b-cf7c-4310-ae8f-cb711ed21bcc-v11-history))

#### Paragraph 1

DailyMed lists Structured Product Labeling version 11 for the reviewed Lixisenatide label family with a published date of 2019-12-19. PeptideScanner retained the exact versioned ZIP byte count and SHA-256 receipt without republishing its contents. ([`dailymed-lixisenatide-4bba538b-cf7c-4310-ae8f-cb711ed21bcc-v11-history`](#source-dailymed-lixisenatide-4bba538b-cf7c-4310-ae8f-cb711ed21bcc-v11-history))

#### Paragraph 2

This page reports that DailyMed lists an available Structured Product Labeling version for the reviewed label family and links the exact historical ZIP. It does not reproduce label text, identify which sections changed, establish FDA approval, interpret safety or effectiveness, or provide medical guidance. ([`dailymed-lixisenatide-4bba538b-cf7c-4310-ae8f-cb711ed21bcc-v11-history`](#source-dailymed-lixisenatide-4bba538b-cf7c-4310-ae8f-cb711ed21bcc-v11-history))

### Sources

<a id="source-dailymed-lixisenatide-4bba538b-cf7c-4310-ae8f-cb711ed21bcc-v11-history"></a>
- **DailyMed SPL SET ID 4bba538b-cf7c-4310-ae8f-cb711ed21bcc · SPL version 11 · published 2019-12-19 · retained ZIP SHA-256 b93ac488bafd9746ddd86e49de76cfd0ea8fba5c86bd5b51e71cb18ba04586a7** — DailyMed · U.S. National Library of Medicine; class A. [Open source](https://dailymed.nlm.nih.gov/dailymed/getFile.cfm?type=zip&setid=4bba538b-cf7c-4310-ae8f-cb711ed21bcc&version=11) (`dailymed-lixisenatide-4bba538b-cf7c-4310-ae8f-cb711ed21bcc-v11-history`)

### Correction lineage

No correction is recorded for this version.

### Reporting boundaries and unknowns

PeptideScanner reports the cited regulator or label record. It does not extend that record into broader safety, effectiveness, or approval claims.

- Sources outside the selected public PeptideScanner bundle may exist and are not represented by this object.
- This object does not determine whether cited records agree, corroborate one another, or establish scientific truth.
- This object does not determine safety, efficacy, causality, or suitability for any person.

Methodology: https://peptidescanner.com/methodology/
Medical disclaimer: https://peptidescanner.com/medical-disclaimer/

### Suggested citation

PeptideScanner. "Lixisenatide DailyMed SPL version 11." Version 1, published 2026-08-22. https://peptidescanner.com/evidence/v1/peptides/lixisenatide.json#dailymed-label-lixisenatide-4bba538b-cf7c-4310-ae8f-cb711ed21bcc-v11-v1 SHA-256: bf5cf5f5e66854cae4973abfa0f422234c3b4ef156719acd8d12a95af3be66bd.

---

<a id="dailymed-label-lixisenatide-4bba538b-cf7c-4310-ae8f-cb711ed21bcc-v12-v1"></a>

## Lixisenatide DailyMed SPL version 12

> DailyMed lists Structured Product Labeling version 12 for the reviewed Lixisenatide label family with a published date of 2020-01-24. PeptideScanner retained the exact versioned ZIP byte count and SHA-256 receipt without republishing its contents.

- Evidence object: `story:dailymed-label-lixisenatide-4bba538b-cf7c-4310-ae8f-cb711ed21bcc-v12:v1`
- Evidence domain: Regulatory
- Date in source: 2020-01-24
- Source checked: 2026-08-22
- Published by PeptideScanner: 2026-08-22
- Story landing page: https://peptidescanner.com/stories/dailymed-label-lixisenatide-4bba538b-cf7c-4310-ae8f-cb711ed21bcc-v12/
- JSON record: https://peptidescanner.com/evidence/v1/peptides/lixisenatide.json#dailymed-label-lixisenatide-4bba538b-cf7c-4310-ae8f-cb711ed21bcc-v12-v1
- Content SHA-256: `7ab349bc6f1545307ab4cfc30548162b98d147fc50923c398c7f478f86c66b15`

### Claims and source pins

#### Headline

Lixisenatide DailyMed SPL version 12 ([`dailymed-lixisenatide-4bba538b-cf7c-4310-ae8f-cb711ed21bcc-v12-history`](#source-dailymed-lixisenatide-4bba538b-cf7c-4310-ae8f-cb711ed21bcc-v12-history))

#### Summary

DailyMed lists Structured Product Labeling version 12 for the reviewed Lixisenatide label family with a published date of 2020-01-24. PeptideScanner retained the exact versioned ZIP byte count and SHA-256 receipt without republishing its contents. ([`dailymed-lixisenatide-4bba538b-cf7c-4310-ae8f-cb711ed21bcc-v12-history`](#source-dailymed-lixisenatide-4bba538b-cf7c-4310-ae8f-cb711ed21bcc-v12-history))

#### Paragraph 1

DailyMed lists Structured Product Labeling version 12 for the reviewed Lixisenatide label family with a published date of 2020-01-24. PeptideScanner retained the exact versioned ZIP byte count and SHA-256 receipt without republishing its contents. ([`dailymed-lixisenatide-4bba538b-cf7c-4310-ae8f-cb711ed21bcc-v12-history`](#source-dailymed-lixisenatide-4bba538b-cf7c-4310-ae8f-cb711ed21bcc-v12-history))

#### Paragraph 2

This page reports that DailyMed lists an available Structured Product Labeling version for the reviewed label family and links the exact historical ZIP. It does not reproduce label text, identify which sections changed, establish FDA approval, interpret safety or effectiveness, or provide medical guidance. ([`dailymed-lixisenatide-4bba538b-cf7c-4310-ae8f-cb711ed21bcc-v12-history`](#source-dailymed-lixisenatide-4bba538b-cf7c-4310-ae8f-cb711ed21bcc-v12-history))

### Sources

<a id="source-dailymed-lixisenatide-4bba538b-cf7c-4310-ae8f-cb711ed21bcc-v12-history"></a>
- **DailyMed SPL SET ID 4bba538b-cf7c-4310-ae8f-cb711ed21bcc · SPL version 12 · published 2020-01-24 · retained ZIP SHA-256 f5a3a92b73d3075456224c735bc5abd5d5752d8a10e156950c78230131095897** — DailyMed · U.S. National Library of Medicine; class A. [Open source](https://dailymed.nlm.nih.gov/dailymed/getFile.cfm?type=zip&setid=4bba538b-cf7c-4310-ae8f-cb711ed21bcc&version=12) (`dailymed-lixisenatide-4bba538b-cf7c-4310-ae8f-cb711ed21bcc-v12-history`)

### Correction lineage

No correction is recorded for this version.

### Reporting boundaries and unknowns

PeptideScanner reports the cited regulator or label record. It does not extend that record into broader safety, effectiveness, or approval claims.

- Sources outside the selected public PeptideScanner bundle may exist and are not represented by this object.
- This object does not determine whether cited records agree, corroborate one another, or establish scientific truth.
- This object does not determine safety, efficacy, causality, or suitability for any person.

Methodology: https://peptidescanner.com/methodology/
Medical disclaimer: https://peptidescanner.com/medical-disclaimer/

### Suggested citation

PeptideScanner. "Lixisenatide DailyMed SPL version 12." Version 1, published 2026-08-22. https://peptidescanner.com/evidence/v1/peptides/lixisenatide.json#dailymed-label-lixisenatide-4bba538b-cf7c-4310-ae8f-cb711ed21bcc-v12-v1 SHA-256: 7ab349bc6f1545307ab4cfc30548162b98d147fc50923c398c7f478f86c66b15.

---

<a id="dailymed-label-lixisenatide-4bba538b-cf7c-4310-ae8f-cb711ed21bcc-v13-v1"></a>

## Lixisenatide DailyMed SPL version 13

> DailyMed lists Structured Product Labeling version 13 for the reviewed Lixisenatide label family with a published date of 2020-03-31. PeptideScanner retained the exact versioned ZIP byte count and SHA-256 receipt without republishing its contents.

- Evidence object: `story:dailymed-label-lixisenatide-4bba538b-cf7c-4310-ae8f-cb711ed21bcc-v13:v1`
- Evidence domain: Regulatory
- Date in source: 2020-03-31
- Source checked: 2026-08-22
- Published by PeptideScanner: 2026-08-22
- Story landing page: https://peptidescanner.com/stories/dailymed-label-lixisenatide-4bba538b-cf7c-4310-ae8f-cb711ed21bcc-v13/
- JSON record: https://peptidescanner.com/evidence/v1/peptides/lixisenatide.json#dailymed-label-lixisenatide-4bba538b-cf7c-4310-ae8f-cb711ed21bcc-v13-v1
- Content SHA-256: `c50713d9cf848775cb182994437a4b9d8383e33de0b4eeed98b717cc7f253504`

### Claims and source pins

#### Headline

Lixisenatide DailyMed SPL version 13 ([`dailymed-lixisenatide-4bba538b-cf7c-4310-ae8f-cb711ed21bcc-v13-history`](#source-dailymed-lixisenatide-4bba538b-cf7c-4310-ae8f-cb711ed21bcc-v13-history))

#### Summary

DailyMed lists Structured Product Labeling version 13 for the reviewed Lixisenatide label family with a published date of 2020-03-31. PeptideScanner retained the exact versioned ZIP byte count and SHA-256 receipt without republishing its contents. ([`dailymed-lixisenatide-4bba538b-cf7c-4310-ae8f-cb711ed21bcc-v13-history`](#source-dailymed-lixisenatide-4bba538b-cf7c-4310-ae8f-cb711ed21bcc-v13-history))

#### Paragraph 1

DailyMed lists Structured Product Labeling version 13 for the reviewed Lixisenatide label family with a published date of 2020-03-31. PeptideScanner retained the exact versioned ZIP byte count and SHA-256 receipt without republishing its contents. ([`dailymed-lixisenatide-4bba538b-cf7c-4310-ae8f-cb711ed21bcc-v13-history`](#source-dailymed-lixisenatide-4bba538b-cf7c-4310-ae8f-cb711ed21bcc-v13-history))

#### Paragraph 2

This page reports that DailyMed lists an available Structured Product Labeling version for the reviewed label family and links the exact historical ZIP. It does not reproduce label text, identify which sections changed, establish FDA approval, interpret safety or effectiveness, or provide medical guidance. ([`dailymed-lixisenatide-4bba538b-cf7c-4310-ae8f-cb711ed21bcc-v13-history`](#source-dailymed-lixisenatide-4bba538b-cf7c-4310-ae8f-cb711ed21bcc-v13-history))

### Sources

<a id="source-dailymed-lixisenatide-4bba538b-cf7c-4310-ae8f-cb711ed21bcc-v13-history"></a>
- **DailyMed SPL SET ID 4bba538b-cf7c-4310-ae8f-cb711ed21bcc · SPL version 13 · published 2020-03-31 · retained ZIP SHA-256 25180c5514fa1658a64abde56423819ad8cee2d865c834729a7693bab876177d** — DailyMed · U.S. National Library of Medicine; class A. [Open source](https://dailymed.nlm.nih.gov/dailymed/getFile.cfm?type=zip&setid=4bba538b-cf7c-4310-ae8f-cb711ed21bcc&version=13) (`dailymed-lixisenatide-4bba538b-cf7c-4310-ae8f-cb711ed21bcc-v13-history`)

### Correction lineage

No correction is recorded for this version.

### Reporting boundaries and unknowns

PeptideScanner reports the cited regulator or label record. It does not extend that record into broader safety, effectiveness, or approval claims.

- Sources outside the selected public PeptideScanner bundle may exist and are not represented by this object.
- This object does not determine whether cited records agree, corroborate one another, or establish scientific truth.
- This object does not determine safety, efficacy, causality, or suitability for any person.

Methodology: https://peptidescanner.com/methodology/
Medical disclaimer: https://peptidescanner.com/medical-disclaimer/

### Suggested citation

PeptideScanner. "Lixisenatide DailyMed SPL version 13." Version 1, published 2026-08-22. https://peptidescanner.com/evidence/v1/peptides/lixisenatide.json#dailymed-label-lixisenatide-4bba538b-cf7c-4310-ae8f-cb711ed21bcc-v13-v1 SHA-256: c50713d9cf848775cb182994437a4b9d8383e33de0b4eeed98b717cc7f253504.

---

<a id="dailymed-label-lixisenatide-4bba538b-cf7c-4310-ae8f-cb711ed21bcc-v14-v1"></a>

## Lixisenatide DailyMed SPL version 14

> DailyMed lists Structured Product Labeling version 14 for the reviewed Lixisenatide label family with a published date of 2020-07-16. PeptideScanner retained the exact versioned ZIP byte count and SHA-256 receipt without republishing its contents.

- Evidence object: `story:dailymed-label-lixisenatide-4bba538b-cf7c-4310-ae8f-cb711ed21bcc-v14:v1`
- Evidence domain: Regulatory
- Date in source: 2020-07-16
- Source checked: 2026-08-22
- Published by PeptideScanner: 2026-08-22
- Story landing page: https://peptidescanner.com/stories/dailymed-label-lixisenatide-4bba538b-cf7c-4310-ae8f-cb711ed21bcc-v14/
- JSON record: https://peptidescanner.com/evidence/v1/peptides/lixisenatide.json#dailymed-label-lixisenatide-4bba538b-cf7c-4310-ae8f-cb711ed21bcc-v14-v1
- Content SHA-256: `e4d09fd8df84c53c1dddb9bb29aeb74cefe50ac479a25fa9808fc3b1c8f06729`

### Claims and source pins

#### Headline

Lixisenatide DailyMed SPL version 14 ([`dailymed-lixisenatide-4bba538b-cf7c-4310-ae8f-cb711ed21bcc-v14-history`](#source-dailymed-lixisenatide-4bba538b-cf7c-4310-ae8f-cb711ed21bcc-v14-history))

#### Summary

DailyMed lists Structured Product Labeling version 14 for the reviewed Lixisenatide label family with a published date of 2020-07-16. PeptideScanner retained the exact versioned ZIP byte count and SHA-256 receipt without republishing its contents. ([`dailymed-lixisenatide-4bba538b-cf7c-4310-ae8f-cb711ed21bcc-v14-history`](#source-dailymed-lixisenatide-4bba538b-cf7c-4310-ae8f-cb711ed21bcc-v14-history))

#### Paragraph 1

DailyMed lists Structured Product Labeling version 14 for the reviewed Lixisenatide label family with a published date of 2020-07-16. PeptideScanner retained the exact versioned ZIP byte count and SHA-256 receipt without republishing its contents. ([`dailymed-lixisenatide-4bba538b-cf7c-4310-ae8f-cb711ed21bcc-v14-history`](#source-dailymed-lixisenatide-4bba538b-cf7c-4310-ae8f-cb711ed21bcc-v14-history))

#### Paragraph 2

This page reports that DailyMed lists an available Structured Product Labeling version for the reviewed label family and links the exact historical ZIP. It does not reproduce label text, identify which sections changed, establish FDA approval, interpret safety or effectiveness, or provide medical guidance. ([`dailymed-lixisenatide-4bba538b-cf7c-4310-ae8f-cb711ed21bcc-v14-history`](#source-dailymed-lixisenatide-4bba538b-cf7c-4310-ae8f-cb711ed21bcc-v14-history))

### Sources

<a id="source-dailymed-lixisenatide-4bba538b-cf7c-4310-ae8f-cb711ed21bcc-v14-history"></a>
- **DailyMed SPL SET ID 4bba538b-cf7c-4310-ae8f-cb711ed21bcc · SPL version 14 · published 2020-07-16 · retained ZIP SHA-256 d3b44926d71e3d53995a567901d1cbb656d9319645199bc9b5053ef88291171e** — DailyMed · U.S. National Library of Medicine; class A. [Open source](https://dailymed.nlm.nih.gov/dailymed/getFile.cfm?type=zip&setid=4bba538b-cf7c-4310-ae8f-cb711ed21bcc&version=14) (`dailymed-lixisenatide-4bba538b-cf7c-4310-ae8f-cb711ed21bcc-v14-history`)

### Correction lineage

No correction is recorded for this version.

### Reporting boundaries and unknowns

PeptideScanner reports the cited regulator or label record. It does not extend that record into broader safety, effectiveness, or approval claims.

- Sources outside the selected public PeptideScanner bundle may exist and are not represented by this object.
- This object does not determine whether cited records agree, corroborate one another, or establish scientific truth.
- This object does not determine safety, efficacy, causality, or suitability for any person.

Methodology: https://peptidescanner.com/methodology/
Medical disclaimer: https://peptidescanner.com/medical-disclaimer/

### Suggested citation

PeptideScanner. "Lixisenatide DailyMed SPL version 14." Version 1, published 2026-08-22. https://peptidescanner.com/evidence/v1/peptides/lixisenatide.json#dailymed-label-lixisenatide-4bba538b-cf7c-4310-ae8f-cb711ed21bcc-v14-v1 SHA-256: e4d09fd8df84c53c1dddb9bb29aeb74cefe50ac479a25fa9808fc3b1c8f06729.

---

<a id="dailymed-label-lixisenatide-4bba538b-cf7c-4310-ae8f-cb711ed21bcc-v15-v1"></a>

## Lixisenatide DailyMed SPL version 15

> DailyMed lists Structured Product Labeling version 15 for the reviewed Lixisenatide label family with a published date of 2020-12-04. PeptideScanner retained the exact versioned ZIP byte count and SHA-256 receipt without republishing its contents.

- Evidence object: `story:dailymed-label-lixisenatide-4bba538b-cf7c-4310-ae8f-cb711ed21bcc-v15:v1`
- Evidence domain: Regulatory
- Date in source: 2020-12-04
- Source checked: 2026-08-22
- Published by PeptideScanner: 2026-08-22
- Story landing page: https://peptidescanner.com/stories/dailymed-label-lixisenatide-4bba538b-cf7c-4310-ae8f-cb711ed21bcc-v15/
- JSON record: https://peptidescanner.com/evidence/v1/peptides/lixisenatide.json#dailymed-label-lixisenatide-4bba538b-cf7c-4310-ae8f-cb711ed21bcc-v15-v1
- Content SHA-256: `b8366ed59d0f49a41b8b12728b4136a051e8cd6736ab83f97c0369684ba6b4e5`

### Claims and source pins

#### Headline

Lixisenatide DailyMed SPL version 15 ([`dailymed-lixisenatide-4bba538b-cf7c-4310-ae8f-cb711ed21bcc-v15-history`](#source-dailymed-lixisenatide-4bba538b-cf7c-4310-ae8f-cb711ed21bcc-v15-history))

#### Summary

DailyMed lists Structured Product Labeling version 15 for the reviewed Lixisenatide label family with a published date of 2020-12-04. PeptideScanner retained the exact versioned ZIP byte count and SHA-256 receipt without republishing its contents. ([`dailymed-lixisenatide-4bba538b-cf7c-4310-ae8f-cb711ed21bcc-v15-history`](#source-dailymed-lixisenatide-4bba538b-cf7c-4310-ae8f-cb711ed21bcc-v15-history))

#### Paragraph 1

DailyMed lists Structured Product Labeling version 15 for the reviewed Lixisenatide label family with a published date of 2020-12-04. PeptideScanner retained the exact versioned ZIP byte count and SHA-256 receipt without republishing its contents. ([`dailymed-lixisenatide-4bba538b-cf7c-4310-ae8f-cb711ed21bcc-v15-history`](#source-dailymed-lixisenatide-4bba538b-cf7c-4310-ae8f-cb711ed21bcc-v15-history))

#### Paragraph 2

This page reports that DailyMed lists an available Structured Product Labeling version for the reviewed label family and links the exact historical ZIP. It does not reproduce label text, identify which sections changed, establish FDA approval, interpret safety or effectiveness, or provide medical guidance. ([`dailymed-lixisenatide-4bba538b-cf7c-4310-ae8f-cb711ed21bcc-v15-history`](#source-dailymed-lixisenatide-4bba538b-cf7c-4310-ae8f-cb711ed21bcc-v15-history))

### Sources

<a id="source-dailymed-lixisenatide-4bba538b-cf7c-4310-ae8f-cb711ed21bcc-v15-history"></a>
- **DailyMed SPL SET ID 4bba538b-cf7c-4310-ae8f-cb711ed21bcc · SPL version 15 · published 2020-12-04 · retained ZIP SHA-256 c6a2ceb696198bf83233840a7f155d78df08e5c4cb79dccf8670a9cdcf854941** — DailyMed · U.S. National Library of Medicine; class A. [Open source](https://dailymed.nlm.nih.gov/dailymed/getFile.cfm?type=zip&setid=4bba538b-cf7c-4310-ae8f-cb711ed21bcc&version=15) (`dailymed-lixisenatide-4bba538b-cf7c-4310-ae8f-cb711ed21bcc-v15-history`)

### Correction lineage

No correction is recorded for this version.

### Reporting boundaries and unknowns

PeptideScanner reports the cited regulator or label record. It does not extend that record into broader safety, effectiveness, or approval claims.

- Sources outside the selected public PeptideScanner bundle may exist and are not represented by this object.
- This object does not determine whether cited records agree, corroborate one another, or establish scientific truth.
- This object does not determine safety, efficacy, causality, or suitability for any person.

Methodology: https://peptidescanner.com/methodology/
Medical disclaimer: https://peptidescanner.com/medical-disclaimer/

### Suggested citation

PeptideScanner. "Lixisenatide DailyMed SPL version 15." Version 1, published 2026-08-22. https://peptidescanner.com/evidence/v1/peptides/lixisenatide.json#dailymed-label-lixisenatide-4bba538b-cf7c-4310-ae8f-cb711ed21bcc-v15-v1 SHA-256: b8366ed59d0f49a41b8b12728b4136a051e8cd6736ab83f97c0369684ba6b4e5.

---

<a id="dailymed-label-lixisenatide-4bba538b-cf7c-4310-ae8f-cb711ed21bcc-v16-v1"></a>

## Lixisenatide DailyMed SPL version 16

> DailyMed lists Structured Product Labeling version 16 for the reviewed Lixisenatide label family with a published date of 2021-08-09. PeptideScanner retained the exact versioned ZIP byte count and SHA-256 receipt without republishing its contents.

- Evidence object: `story:dailymed-label-lixisenatide-4bba538b-cf7c-4310-ae8f-cb711ed21bcc-v16:v1`
- Evidence domain: Regulatory
- Date in source: 2021-08-09
- Source checked: 2026-08-22
- Published by PeptideScanner: 2026-08-22
- Story landing page: https://peptidescanner.com/stories/dailymed-label-lixisenatide-4bba538b-cf7c-4310-ae8f-cb711ed21bcc-v16/
- JSON record: https://peptidescanner.com/evidence/v1/peptides/lixisenatide.json#dailymed-label-lixisenatide-4bba538b-cf7c-4310-ae8f-cb711ed21bcc-v16-v1
- Content SHA-256: `03ae3c5fd4e28318e13ab0dff11f4dac5571876da1e08364f927b551347f853f`

### Claims and source pins

#### Headline

Lixisenatide DailyMed SPL version 16 ([`dailymed-lixisenatide-4bba538b-cf7c-4310-ae8f-cb711ed21bcc-v16-history`](#source-dailymed-lixisenatide-4bba538b-cf7c-4310-ae8f-cb711ed21bcc-v16-history))

#### Summary

DailyMed lists Structured Product Labeling version 16 for the reviewed Lixisenatide label family with a published date of 2021-08-09. PeptideScanner retained the exact versioned ZIP byte count and SHA-256 receipt without republishing its contents. ([`dailymed-lixisenatide-4bba538b-cf7c-4310-ae8f-cb711ed21bcc-v16-history`](#source-dailymed-lixisenatide-4bba538b-cf7c-4310-ae8f-cb711ed21bcc-v16-history))

#### Paragraph 1

DailyMed lists Structured Product Labeling version 16 for the reviewed Lixisenatide label family with a published date of 2021-08-09. PeptideScanner retained the exact versioned ZIP byte count and SHA-256 receipt without republishing its contents. ([`dailymed-lixisenatide-4bba538b-cf7c-4310-ae8f-cb711ed21bcc-v16-history`](#source-dailymed-lixisenatide-4bba538b-cf7c-4310-ae8f-cb711ed21bcc-v16-history))

#### Paragraph 2

This page reports that DailyMed lists an available Structured Product Labeling version for the reviewed label family and links the exact historical ZIP. It does not reproduce label text, identify which sections changed, establish FDA approval, interpret safety or effectiveness, or provide medical guidance. ([`dailymed-lixisenatide-4bba538b-cf7c-4310-ae8f-cb711ed21bcc-v16-history`](#source-dailymed-lixisenatide-4bba538b-cf7c-4310-ae8f-cb711ed21bcc-v16-history))

### Sources

<a id="source-dailymed-lixisenatide-4bba538b-cf7c-4310-ae8f-cb711ed21bcc-v16-history"></a>
- **DailyMed SPL SET ID 4bba538b-cf7c-4310-ae8f-cb711ed21bcc · SPL version 16 · published 2021-08-09 · retained ZIP SHA-256 e4cd4354775572f96e0335a40e8d231cc2ca30709c66e8dc08c7185b046ce446** — DailyMed · U.S. National Library of Medicine; class A. [Open source](https://dailymed.nlm.nih.gov/dailymed/getFile.cfm?type=zip&setid=4bba538b-cf7c-4310-ae8f-cb711ed21bcc&version=16) (`dailymed-lixisenatide-4bba538b-cf7c-4310-ae8f-cb711ed21bcc-v16-history`)

### Correction lineage

No correction is recorded for this version.

### Reporting boundaries and unknowns

PeptideScanner reports the cited regulator or label record. It does not extend that record into broader safety, effectiveness, or approval claims.

- Sources outside the selected public PeptideScanner bundle may exist and are not represented by this object.
- This object does not determine whether cited records agree, corroborate one another, or establish scientific truth.
- This object does not determine safety, efficacy, causality, or suitability for any person.

Methodology: https://peptidescanner.com/methodology/
Medical disclaimer: https://peptidescanner.com/medical-disclaimer/

### Suggested citation

PeptideScanner. "Lixisenatide DailyMed SPL version 16." Version 1, published 2026-08-22. https://peptidescanner.com/evidence/v1/peptides/lixisenatide.json#dailymed-label-lixisenatide-4bba538b-cf7c-4310-ae8f-cb711ed21bcc-v16-v1 SHA-256: 03ae3c5fd4e28318e13ab0dff11f4dac5571876da1e08364f927b551347f853f.

---

<a id="dailymed-label-lixisenatide-4bba538b-cf7c-4310-ae8f-cb711ed21bcc-v17-v1"></a>

## Lixisenatide DailyMed SPL version 17

> DailyMed lists Structured Product Labeling version 17 for the reviewed Lixisenatide label family with a published date of 2022-06-20. PeptideScanner retained the exact versioned ZIP byte count and SHA-256 receipt without republishing its contents.

- Evidence object: `story:dailymed-label-lixisenatide-4bba538b-cf7c-4310-ae8f-cb711ed21bcc-v17:v1`
- Evidence domain: Regulatory
- Date in source: 2022-06-20
- Source checked: 2026-08-22
- Published by PeptideScanner: 2026-08-22
- Story landing page: https://peptidescanner.com/stories/dailymed-label-lixisenatide-4bba538b-cf7c-4310-ae8f-cb711ed21bcc-v17/
- JSON record: https://peptidescanner.com/evidence/v1/peptides/lixisenatide.json#dailymed-label-lixisenatide-4bba538b-cf7c-4310-ae8f-cb711ed21bcc-v17-v1
- Content SHA-256: `4a563399d92fb85cf2c40d3b332977f4eedb5eba4a027e261ad742d0809a1e3d`

### Claims and source pins

#### Headline

Lixisenatide DailyMed SPL version 17 ([`dailymed-lixisenatide-4bba538b-cf7c-4310-ae8f-cb711ed21bcc-v17-history`](#source-dailymed-lixisenatide-4bba538b-cf7c-4310-ae8f-cb711ed21bcc-v17-history))

#### Summary

DailyMed lists Structured Product Labeling version 17 for the reviewed Lixisenatide label family with a published date of 2022-06-20. PeptideScanner retained the exact versioned ZIP byte count and SHA-256 receipt without republishing its contents. ([`dailymed-lixisenatide-4bba538b-cf7c-4310-ae8f-cb711ed21bcc-v17-history`](#source-dailymed-lixisenatide-4bba538b-cf7c-4310-ae8f-cb711ed21bcc-v17-history))

#### Paragraph 1

DailyMed lists Structured Product Labeling version 17 for the reviewed Lixisenatide label family with a published date of 2022-06-20. PeptideScanner retained the exact versioned ZIP byte count and SHA-256 receipt without republishing its contents. ([`dailymed-lixisenatide-4bba538b-cf7c-4310-ae8f-cb711ed21bcc-v17-history`](#source-dailymed-lixisenatide-4bba538b-cf7c-4310-ae8f-cb711ed21bcc-v17-history))

#### Paragraph 2

This page reports that DailyMed lists an available Structured Product Labeling version for the reviewed label family and links the exact historical ZIP. It does not reproduce label text, identify which sections changed, establish FDA approval, interpret safety or effectiveness, or provide medical guidance. ([`dailymed-lixisenatide-4bba538b-cf7c-4310-ae8f-cb711ed21bcc-v17-history`](#source-dailymed-lixisenatide-4bba538b-cf7c-4310-ae8f-cb711ed21bcc-v17-history))

### Sources

<a id="source-dailymed-lixisenatide-4bba538b-cf7c-4310-ae8f-cb711ed21bcc-v17-history"></a>
- **DailyMed SPL SET ID 4bba538b-cf7c-4310-ae8f-cb711ed21bcc · SPL version 17 · published 2022-06-20 · retained ZIP SHA-256 6a742f31957eb85cbc605ac32b3a317fbb6cac7c6a097f63d1b02c50a1eb113b** — DailyMed · U.S. National Library of Medicine; class A. [Open source](https://dailymed.nlm.nih.gov/dailymed/getFile.cfm?type=zip&setid=4bba538b-cf7c-4310-ae8f-cb711ed21bcc&version=17) (`dailymed-lixisenatide-4bba538b-cf7c-4310-ae8f-cb711ed21bcc-v17-history`)

### Correction lineage

No correction is recorded for this version.

### Reporting boundaries and unknowns

PeptideScanner reports the cited regulator or label record. It does not extend that record into broader safety, effectiveness, or approval claims.

- Sources outside the selected public PeptideScanner bundle may exist and are not represented by this object.
- This object does not determine whether cited records agree, corroborate one another, or establish scientific truth.
- This object does not determine safety, efficacy, causality, or suitability for any person.

Methodology: https://peptidescanner.com/methodology/
Medical disclaimer: https://peptidescanner.com/medical-disclaimer/

### Suggested citation

PeptideScanner. "Lixisenatide DailyMed SPL version 17." Version 1, published 2026-08-22. https://peptidescanner.com/evidence/v1/peptides/lixisenatide.json#dailymed-label-lixisenatide-4bba538b-cf7c-4310-ae8f-cb711ed21bcc-v17-v1 SHA-256: 4a563399d92fb85cf2c40d3b332977f4eedb5eba4a027e261ad742d0809a1e3d.

---

<a id="dailymed-label-lixisenatide-4bba538b-cf7c-4310-ae8f-cb711ed21bcc-v18-v1"></a>

## Lixisenatide DailyMed SPL version 18

> DailyMed lists Structured Product Labeling version 18 for the reviewed Lixisenatide label family with a published date of 2023-10-12. PeptideScanner retained the exact versioned ZIP byte count and SHA-256 receipt without republishing its contents.

- Evidence object: `story:dailymed-label-lixisenatide-4bba538b-cf7c-4310-ae8f-cb711ed21bcc-v18:v1`
- Evidence domain: Regulatory
- Date in source: 2023-10-12
- Source checked: 2026-08-22
- Published by PeptideScanner: 2026-08-22
- Story landing page: https://peptidescanner.com/stories/dailymed-label-lixisenatide-4bba538b-cf7c-4310-ae8f-cb711ed21bcc-v18/
- JSON record: https://peptidescanner.com/evidence/v1/peptides/lixisenatide.json#dailymed-label-lixisenatide-4bba538b-cf7c-4310-ae8f-cb711ed21bcc-v18-v1
- Content SHA-256: `d690c8fe35b7e96e31da1caaba53c0bb4ab1a10941913e4493c9472330345905`

### Claims and source pins

#### Headline

Lixisenatide DailyMed SPL version 18 ([`dailymed-lixisenatide-4bba538b-cf7c-4310-ae8f-cb711ed21bcc-v18-history`](#source-dailymed-lixisenatide-4bba538b-cf7c-4310-ae8f-cb711ed21bcc-v18-history))

#### Summary

DailyMed lists Structured Product Labeling version 18 for the reviewed Lixisenatide label family with a published date of 2023-10-12. PeptideScanner retained the exact versioned ZIP byte count and SHA-256 receipt without republishing its contents. ([`dailymed-lixisenatide-4bba538b-cf7c-4310-ae8f-cb711ed21bcc-v18-history`](#source-dailymed-lixisenatide-4bba538b-cf7c-4310-ae8f-cb711ed21bcc-v18-history))

#### Paragraph 1

DailyMed lists Structured Product Labeling version 18 for the reviewed Lixisenatide label family with a published date of 2023-10-12. PeptideScanner retained the exact versioned ZIP byte count and SHA-256 receipt without republishing its contents. ([`dailymed-lixisenatide-4bba538b-cf7c-4310-ae8f-cb711ed21bcc-v18-history`](#source-dailymed-lixisenatide-4bba538b-cf7c-4310-ae8f-cb711ed21bcc-v18-history))

#### Paragraph 2

This page reports that DailyMed lists an available Structured Product Labeling version for the reviewed label family and links the exact historical ZIP. It does not reproduce label text, identify which sections changed, establish FDA approval, interpret safety or effectiveness, or provide medical guidance. ([`dailymed-lixisenatide-4bba538b-cf7c-4310-ae8f-cb711ed21bcc-v18-history`](#source-dailymed-lixisenatide-4bba538b-cf7c-4310-ae8f-cb711ed21bcc-v18-history))

### Sources

<a id="source-dailymed-lixisenatide-4bba538b-cf7c-4310-ae8f-cb711ed21bcc-v18-history"></a>
- **DailyMed SPL SET ID 4bba538b-cf7c-4310-ae8f-cb711ed21bcc · SPL version 18 · published 2023-10-12 · retained ZIP SHA-256 8ae2716528244f84813ebba3ff51da003922f203cb3fcdfd9f80042875019500** — DailyMed · U.S. National Library of Medicine; class A. [Open source](https://dailymed.nlm.nih.gov/dailymed/getFile.cfm?type=zip&setid=4bba538b-cf7c-4310-ae8f-cb711ed21bcc&version=18) (`dailymed-lixisenatide-4bba538b-cf7c-4310-ae8f-cb711ed21bcc-v18-history`)

### Correction lineage

No correction is recorded for this version.

### Reporting boundaries and unknowns

PeptideScanner reports the cited regulator or label record. It does not extend that record into broader safety, effectiveness, or approval claims.

- Sources outside the selected public PeptideScanner bundle may exist and are not represented by this object.
- This object does not determine whether cited records agree, corroborate one another, or establish scientific truth.
- This object does not determine safety, efficacy, causality, or suitability for any person.

Methodology: https://peptidescanner.com/methodology/
Medical disclaimer: https://peptidescanner.com/medical-disclaimer/

### Suggested citation

PeptideScanner. "Lixisenatide DailyMed SPL version 18." Version 1, published 2026-08-22. https://peptidescanner.com/evidence/v1/peptides/lixisenatide.json#dailymed-label-lixisenatide-4bba538b-cf7c-4310-ae8f-cb711ed21bcc-v18-v1 SHA-256: d690c8fe35b7e96e31da1caaba53c0bb4ab1a10941913e4493c9472330345905.

---

<a id="dailymed-label-lixisenatide-4bba538b-cf7c-4310-ae8f-cb711ed21bcc-v19-v1"></a>

## Lixisenatide DailyMed SPL version 19

> DailyMed lists Structured Product Labeling version 19 for the reviewed Lixisenatide label family with a published date of 2024-11-14. PeptideScanner retained the exact versioned ZIP byte count and SHA-256 receipt without republishing its contents.

- Evidence object: `story:dailymed-label-lixisenatide-4bba538b-cf7c-4310-ae8f-cb711ed21bcc-v19:v1`
- Evidence domain: Regulatory
- Date in source: 2024-11-14
- Source checked: 2026-08-22
- Published by PeptideScanner: 2026-08-22
- Story landing page: https://peptidescanner.com/stories/dailymed-label-lixisenatide-4bba538b-cf7c-4310-ae8f-cb711ed21bcc-v19/
- JSON record: https://peptidescanner.com/evidence/v1/peptides/lixisenatide.json#dailymed-label-lixisenatide-4bba538b-cf7c-4310-ae8f-cb711ed21bcc-v19-v1
- Content SHA-256: `a339fed55d84d67cc5cc87cbe6ea08746c901b1657ef5921aa88c624266cf736`

### Claims and source pins

#### Headline

Lixisenatide DailyMed SPL version 19 ([`dailymed-lixisenatide-4bba538b-cf7c-4310-ae8f-cb711ed21bcc-v19-history`](#source-dailymed-lixisenatide-4bba538b-cf7c-4310-ae8f-cb711ed21bcc-v19-history))

#### Summary

DailyMed lists Structured Product Labeling version 19 for the reviewed Lixisenatide label family with a published date of 2024-11-14. PeptideScanner retained the exact versioned ZIP byte count and SHA-256 receipt without republishing its contents. ([`dailymed-lixisenatide-4bba538b-cf7c-4310-ae8f-cb711ed21bcc-v19-history`](#source-dailymed-lixisenatide-4bba538b-cf7c-4310-ae8f-cb711ed21bcc-v19-history))

#### Paragraph 1

DailyMed lists Structured Product Labeling version 19 for the reviewed Lixisenatide label family with a published date of 2024-11-14. PeptideScanner retained the exact versioned ZIP byte count and SHA-256 receipt without republishing its contents. ([`dailymed-lixisenatide-4bba538b-cf7c-4310-ae8f-cb711ed21bcc-v19-history`](#source-dailymed-lixisenatide-4bba538b-cf7c-4310-ae8f-cb711ed21bcc-v19-history))

#### Paragraph 2

This page reports that DailyMed lists an available Structured Product Labeling version for the reviewed label family and links the exact historical ZIP. It does not reproduce label text, identify which sections changed, establish FDA approval, interpret safety or effectiveness, or provide medical guidance. ([`dailymed-lixisenatide-4bba538b-cf7c-4310-ae8f-cb711ed21bcc-v19-history`](#source-dailymed-lixisenatide-4bba538b-cf7c-4310-ae8f-cb711ed21bcc-v19-history))

### Sources

<a id="source-dailymed-lixisenatide-4bba538b-cf7c-4310-ae8f-cb711ed21bcc-v19-history"></a>
- **DailyMed SPL SET ID 4bba538b-cf7c-4310-ae8f-cb711ed21bcc · SPL version 19 · published 2024-11-14 · retained ZIP SHA-256 af0908969b3ea9a6869d34dfe7e5cdf05cd50be775107c6c46f1bc9580e48f04** — DailyMed · U.S. National Library of Medicine; class A. [Open source](https://dailymed.nlm.nih.gov/dailymed/getFile.cfm?type=zip&setid=4bba538b-cf7c-4310-ae8f-cb711ed21bcc&version=19) (`dailymed-lixisenatide-4bba538b-cf7c-4310-ae8f-cb711ed21bcc-v19-history`)

### Correction lineage

No correction is recorded for this version.

### Reporting boundaries and unknowns

PeptideScanner reports the cited regulator or label record. It does not extend that record into broader safety, effectiveness, or approval claims.

- Sources outside the selected public PeptideScanner bundle may exist and are not represented by this object.
- This object does not determine whether cited records agree, corroborate one another, or establish scientific truth.
- This object does not determine safety, efficacy, causality, or suitability for any person.

Methodology: https://peptidescanner.com/methodology/
Medical disclaimer: https://peptidescanner.com/medical-disclaimer/

### Suggested citation

PeptideScanner. "Lixisenatide DailyMed SPL version 19." Version 1, published 2026-08-22. https://peptidescanner.com/evidence/v1/peptides/lixisenatide.json#dailymed-label-lixisenatide-4bba538b-cf7c-4310-ae8f-cb711ed21bcc-v19-v1 SHA-256: a339fed55d84d67cc5cc87cbe6ea08746c901b1657ef5921aa88c624266cf736.

---

<a id="dailymed-label-lixisenatide-4bba538b-cf7c-4310-ae8f-cb711ed21bcc-v1-v1"></a>

## Lixisenatide DailyMed SPL version 1

> DailyMed lists Structured Product Labeling version 1 for the reviewed Lixisenatide label family with a published date of 2016-11-22. PeptideScanner retained the exact versioned ZIP byte count and SHA-256 receipt without republishing its contents.

- Evidence object: `story:dailymed-label-lixisenatide-4bba538b-cf7c-4310-ae8f-cb711ed21bcc-v1:v1`
- Evidence domain: Regulatory
- Date in source: 2016-11-22
- Source checked: 2026-08-22
- Published by PeptideScanner: 2026-08-22
- Story landing page: https://peptidescanner.com/stories/dailymed-label-lixisenatide-4bba538b-cf7c-4310-ae8f-cb711ed21bcc-v1/
- JSON record: https://peptidescanner.com/evidence/v1/peptides/lixisenatide.json#dailymed-label-lixisenatide-4bba538b-cf7c-4310-ae8f-cb711ed21bcc-v1-v1
- Content SHA-256: `1786fee42d0e688875314636aa41eca0d149bdd357990be038960039d743215f`

### Claims and source pins

#### Headline

Lixisenatide DailyMed SPL version 1 ([`dailymed-lixisenatide-4bba538b-cf7c-4310-ae8f-cb711ed21bcc-v1-history`](#source-dailymed-lixisenatide-4bba538b-cf7c-4310-ae8f-cb711ed21bcc-v1-history))

#### Summary

DailyMed lists Structured Product Labeling version 1 for the reviewed Lixisenatide label family with a published date of 2016-11-22. PeptideScanner retained the exact versioned ZIP byte count and SHA-256 receipt without republishing its contents. ([`dailymed-lixisenatide-4bba538b-cf7c-4310-ae8f-cb711ed21bcc-v1-history`](#source-dailymed-lixisenatide-4bba538b-cf7c-4310-ae8f-cb711ed21bcc-v1-history))

#### Paragraph 1

DailyMed lists Structured Product Labeling version 1 for the reviewed Lixisenatide label family with a published date of 2016-11-22. PeptideScanner retained the exact versioned ZIP byte count and SHA-256 receipt without republishing its contents. ([`dailymed-lixisenatide-4bba538b-cf7c-4310-ae8f-cb711ed21bcc-v1-history`](#source-dailymed-lixisenatide-4bba538b-cf7c-4310-ae8f-cb711ed21bcc-v1-history))

#### Paragraph 2

This page reports that DailyMed lists an available Structured Product Labeling version for the reviewed label family and links the exact historical ZIP. It does not reproduce label text, identify which sections changed, establish FDA approval, interpret safety or effectiveness, or provide medical guidance. ([`dailymed-lixisenatide-4bba538b-cf7c-4310-ae8f-cb711ed21bcc-v1-history`](#source-dailymed-lixisenatide-4bba538b-cf7c-4310-ae8f-cb711ed21bcc-v1-history))

### Sources

<a id="source-dailymed-lixisenatide-4bba538b-cf7c-4310-ae8f-cb711ed21bcc-v1-history"></a>
- **DailyMed SPL SET ID 4bba538b-cf7c-4310-ae8f-cb711ed21bcc · SPL version 1 · published 2016-11-22 · retained ZIP SHA-256 f4ce2e1e4bf682a1c6c4e3b0daa72e8b5bcab4862c3a7be636067bf5d9e2e02e** — DailyMed · U.S. National Library of Medicine; class A. [Open source](https://dailymed.nlm.nih.gov/dailymed/getFile.cfm?type=zip&setid=4bba538b-cf7c-4310-ae8f-cb711ed21bcc&version=1) (`dailymed-lixisenatide-4bba538b-cf7c-4310-ae8f-cb711ed21bcc-v1-history`)

### Correction lineage

No correction is recorded for this version.

### Reporting boundaries and unknowns

PeptideScanner reports the cited regulator or label record. It does not extend that record into broader safety, effectiveness, or approval claims.

- Sources outside the selected public PeptideScanner bundle may exist and are not represented by this object.
- This object does not determine whether cited records agree, corroborate one another, or establish scientific truth.
- This object does not determine safety, efficacy, causality, or suitability for any person.

Methodology: https://peptidescanner.com/methodology/
Medical disclaimer: https://peptidescanner.com/medical-disclaimer/

### Suggested citation

PeptideScanner. "Lixisenatide DailyMed SPL version 1." Version 1, published 2026-08-22. https://peptidescanner.com/evidence/v1/peptides/lixisenatide.json#dailymed-label-lixisenatide-4bba538b-cf7c-4310-ae8f-cb711ed21bcc-v1-v1 SHA-256: 1786fee42d0e688875314636aa41eca0d149bdd357990be038960039d743215f.

---

<a id="dailymed-label-lixisenatide-4bba538b-cf7c-4310-ae8f-cb711ed21bcc-v22-v1"></a>

## Lixisenatide DailyMed SPL version 22

> DailyMed lists Structured Product Labeling version 22 for the reviewed Lixisenatide label family with a published date of 2025-06-13. PeptideScanner retained the exact versioned ZIP byte count and SHA-256 receipt without republishing its contents.

- Evidence object: `story:dailymed-label-lixisenatide-4bba538b-cf7c-4310-ae8f-cb711ed21bcc-v22:v1`
- Evidence domain: Regulatory
- Date in source: 2025-06-13
- Source checked: 2026-08-22
- Published by PeptideScanner: 2026-08-22
- Story landing page: https://peptidescanner.com/stories/dailymed-label-lixisenatide-4bba538b-cf7c-4310-ae8f-cb711ed21bcc-v22/
- JSON record: https://peptidescanner.com/evidence/v1/peptides/lixisenatide.json#dailymed-label-lixisenatide-4bba538b-cf7c-4310-ae8f-cb711ed21bcc-v22-v1
- Content SHA-256: `e7c40b03be626f3b5347a473a815f642303f399e134e9839faa94fba6ac9344d`

### Claims and source pins

#### Headline

Lixisenatide DailyMed SPL version 22 ([`dailymed-lixisenatide-4bba538b-cf7c-4310-ae8f-cb711ed21bcc-v22-history`](#source-dailymed-lixisenatide-4bba538b-cf7c-4310-ae8f-cb711ed21bcc-v22-history))

#### Summary

DailyMed lists Structured Product Labeling version 22 for the reviewed Lixisenatide label family with a published date of 2025-06-13. PeptideScanner retained the exact versioned ZIP byte count and SHA-256 receipt without republishing its contents. ([`dailymed-lixisenatide-4bba538b-cf7c-4310-ae8f-cb711ed21bcc-v22-history`](#source-dailymed-lixisenatide-4bba538b-cf7c-4310-ae8f-cb711ed21bcc-v22-history))

#### Paragraph 1

DailyMed lists Structured Product Labeling version 22 for the reviewed Lixisenatide label family with a published date of 2025-06-13. PeptideScanner retained the exact versioned ZIP byte count and SHA-256 receipt without republishing its contents. ([`dailymed-lixisenatide-4bba538b-cf7c-4310-ae8f-cb711ed21bcc-v22-history`](#source-dailymed-lixisenatide-4bba538b-cf7c-4310-ae8f-cb711ed21bcc-v22-history))

#### Paragraph 2

This page reports that DailyMed lists an available Structured Product Labeling version for the reviewed label family and links the exact historical ZIP. It does not reproduce label text, identify which sections changed, establish FDA approval, interpret safety or effectiveness, or provide medical guidance. ([`dailymed-lixisenatide-4bba538b-cf7c-4310-ae8f-cb711ed21bcc-v22-history`](#source-dailymed-lixisenatide-4bba538b-cf7c-4310-ae8f-cb711ed21bcc-v22-history))

### Sources

<a id="source-dailymed-lixisenatide-4bba538b-cf7c-4310-ae8f-cb711ed21bcc-v22-history"></a>
- **DailyMed SPL SET ID 4bba538b-cf7c-4310-ae8f-cb711ed21bcc · SPL version 22 · published 2025-06-13 · retained ZIP SHA-256 9b3ef7156a698e16d6ea03900b81a8ce9b70fb667f921c1f4e8343020e10e5c0** — DailyMed · U.S. National Library of Medicine; class A. [Open source](https://dailymed.nlm.nih.gov/dailymed/getFile.cfm?type=zip&setid=4bba538b-cf7c-4310-ae8f-cb711ed21bcc&version=22) (`dailymed-lixisenatide-4bba538b-cf7c-4310-ae8f-cb711ed21bcc-v22-history`)

### Correction lineage

No correction is recorded for this version.

### Reporting boundaries and unknowns

PeptideScanner reports the cited regulator or label record. It does not extend that record into broader safety, effectiveness, or approval claims.

- Sources outside the selected public PeptideScanner bundle may exist and are not represented by this object.
- This object does not determine whether cited records agree, corroborate one another, or establish scientific truth.
- This object does not determine safety, efficacy, causality, or suitability for any person.

Methodology: https://peptidescanner.com/methodology/
Medical disclaimer: https://peptidescanner.com/medical-disclaimer/

### Suggested citation

PeptideScanner. "Lixisenatide DailyMed SPL version 22." Version 1, published 2026-08-22. https://peptidescanner.com/evidence/v1/peptides/lixisenatide.json#dailymed-label-lixisenatide-4bba538b-cf7c-4310-ae8f-cb711ed21bcc-v22-v1 SHA-256: e7c40b03be626f3b5347a473a815f642303f399e134e9839faa94fba6ac9344d.

---

<a id="dailymed-label-lixisenatide-4bba538b-cf7c-4310-ae8f-cb711ed21bcc-v23-v1"></a>

## Lixisenatide DailyMed SPL version 23

> DailyMed lists Structured Product Labeling version 23 for the reviewed Lixisenatide label family with a published date of 2025-08-01. PeptideScanner retained the exact versioned ZIP byte count and SHA-256 receipt without republishing its contents.

- Evidence object: `story:dailymed-label-lixisenatide-4bba538b-cf7c-4310-ae8f-cb711ed21bcc-v23:v1`
- Evidence domain: Regulatory
- Date in source: 2025-08-01
- Source checked: 2026-08-22
- Published by PeptideScanner: 2026-08-22
- Story landing page: https://peptidescanner.com/stories/dailymed-label-lixisenatide-4bba538b-cf7c-4310-ae8f-cb711ed21bcc-v23/
- JSON record: https://peptidescanner.com/evidence/v1/peptides/lixisenatide.json#dailymed-label-lixisenatide-4bba538b-cf7c-4310-ae8f-cb711ed21bcc-v23-v1
- Content SHA-256: `161d066291531ce53ecc1c36e3e8e0619e1ccfa4e0ad9cf1bf2bd23cb9a08284`

### Claims and source pins

#### Headline

Lixisenatide DailyMed SPL version 23 ([`dailymed-lixisenatide-4bba538b-cf7c-4310-ae8f-cb711ed21bcc-v23-history`](#source-dailymed-lixisenatide-4bba538b-cf7c-4310-ae8f-cb711ed21bcc-v23-history))

#### Summary

DailyMed lists Structured Product Labeling version 23 for the reviewed Lixisenatide label family with a published date of 2025-08-01. PeptideScanner retained the exact versioned ZIP byte count and SHA-256 receipt without republishing its contents. ([`dailymed-lixisenatide-4bba538b-cf7c-4310-ae8f-cb711ed21bcc-v23-history`](#source-dailymed-lixisenatide-4bba538b-cf7c-4310-ae8f-cb711ed21bcc-v23-history))

#### Paragraph 1

DailyMed lists Structured Product Labeling version 23 for the reviewed Lixisenatide label family with a published date of 2025-08-01. PeptideScanner retained the exact versioned ZIP byte count and SHA-256 receipt without republishing its contents. ([`dailymed-lixisenatide-4bba538b-cf7c-4310-ae8f-cb711ed21bcc-v23-history`](#source-dailymed-lixisenatide-4bba538b-cf7c-4310-ae8f-cb711ed21bcc-v23-history))

#### Paragraph 2

This page reports that DailyMed lists an available Structured Product Labeling version for the reviewed label family and links the exact historical ZIP. It does not reproduce label text, identify which sections changed, establish FDA approval, interpret safety or effectiveness, or provide medical guidance. ([`dailymed-lixisenatide-4bba538b-cf7c-4310-ae8f-cb711ed21bcc-v23-history`](#source-dailymed-lixisenatide-4bba538b-cf7c-4310-ae8f-cb711ed21bcc-v23-history))

### Sources

<a id="source-dailymed-lixisenatide-4bba538b-cf7c-4310-ae8f-cb711ed21bcc-v23-history"></a>
- **DailyMed SPL SET ID 4bba538b-cf7c-4310-ae8f-cb711ed21bcc · SPL version 23 · published 2025-08-01 · retained ZIP SHA-256 a8b9de04de704bc9f4f97c3a4923dd52ec9f9ecb683a14733a55c778711820fb** — DailyMed · U.S. National Library of Medicine; class A. [Open source](https://dailymed.nlm.nih.gov/dailymed/getFile.cfm?type=zip&setid=4bba538b-cf7c-4310-ae8f-cb711ed21bcc&version=23) (`dailymed-lixisenatide-4bba538b-cf7c-4310-ae8f-cb711ed21bcc-v23-history`)

### Correction lineage

No correction is recorded for this version.

### Reporting boundaries and unknowns

PeptideScanner reports the cited regulator or label record. It does not extend that record into broader safety, effectiveness, or approval claims.

- Sources outside the selected public PeptideScanner bundle may exist and are not represented by this object.
- This object does not determine whether cited records agree, corroborate one another, or establish scientific truth.
- This object does not determine safety, efficacy, causality, or suitability for any person.

Methodology: https://peptidescanner.com/methodology/
Medical disclaimer: https://peptidescanner.com/medical-disclaimer/

### Suggested citation

PeptideScanner. "Lixisenatide DailyMed SPL version 23." Version 1, published 2026-08-22. https://peptidescanner.com/evidence/v1/peptides/lixisenatide.json#dailymed-label-lixisenatide-4bba538b-cf7c-4310-ae8f-cb711ed21bcc-v23-v1 SHA-256: 161d066291531ce53ecc1c36e3e8e0619e1ccfa4e0ad9cf1bf2bd23cb9a08284.

---

<a id="dailymed-label-lixisenatide-4bba538b-cf7c-4310-ae8f-cb711ed21bcc-v25-v1"></a>

## Lixisenatide DailyMed SPL version 25

> DailyMed lists Structured Product Labeling version 25 for the reviewed Lixisenatide label family with a published date of 2026-03-20. PeptideScanner retained the exact versioned ZIP byte count and SHA-256 receipt without republishing its contents.

- Evidence object: `story:dailymed-label-lixisenatide-4bba538b-cf7c-4310-ae8f-cb711ed21bcc-v25:v1`
- Evidence domain: Regulatory
- Date in source: 2026-03-20
- Source checked: 2026-08-22
- Published by PeptideScanner: 2026-08-22
- Story landing page: https://peptidescanner.com/stories/dailymed-label-lixisenatide-4bba538b-cf7c-4310-ae8f-cb711ed21bcc-v25/
- JSON record: https://peptidescanner.com/evidence/v1/peptides/lixisenatide.json#dailymed-label-lixisenatide-4bba538b-cf7c-4310-ae8f-cb711ed21bcc-v25-v1
- Content SHA-256: `82a70fbb25d31cbeb0a6a107589412ab08d0528c3480316792e2255efe63dc13`

### Claims and source pins

#### Headline

Lixisenatide DailyMed SPL version 25 ([`dailymed-lixisenatide-4bba538b-cf7c-4310-ae8f-cb711ed21bcc-v25-history`](#source-dailymed-lixisenatide-4bba538b-cf7c-4310-ae8f-cb711ed21bcc-v25-history))

#### Summary

DailyMed lists Structured Product Labeling version 25 for the reviewed Lixisenatide label family with a published date of 2026-03-20. PeptideScanner retained the exact versioned ZIP byte count and SHA-256 receipt without republishing its contents. ([`dailymed-lixisenatide-4bba538b-cf7c-4310-ae8f-cb711ed21bcc-v25-history`](#source-dailymed-lixisenatide-4bba538b-cf7c-4310-ae8f-cb711ed21bcc-v25-history))

#### Paragraph 1

DailyMed lists Structured Product Labeling version 25 for the reviewed Lixisenatide label family with a published date of 2026-03-20. PeptideScanner retained the exact versioned ZIP byte count and SHA-256 receipt without republishing its contents. ([`dailymed-lixisenatide-4bba538b-cf7c-4310-ae8f-cb711ed21bcc-v25-history`](#source-dailymed-lixisenatide-4bba538b-cf7c-4310-ae8f-cb711ed21bcc-v25-history))

#### Paragraph 2

This page reports that DailyMed lists an available Structured Product Labeling version for the reviewed label family and links the exact historical ZIP. It does not reproduce label text, identify which sections changed, establish FDA approval, interpret safety or effectiveness, or provide medical guidance. ([`dailymed-lixisenatide-4bba538b-cf7c-4310-ae8f-cb711ed21bcc-v25-history`](#source-dailymed-lixisenatide-4bba538b-cf7c-4310-ae8f-cb711ed21bcc-v25-history))

### Sources

<a id="source-dailymed-lixisenatide-4bba538b-cf7c-4310-ae8f-cb711ed21bcc-v25-history"></a>
- **DailyMed SPL SET ID 4bba538b-cf7c-4310-ae8f-cb711ed21bcc · SPL version 25 · published 2026-03-20 · retained ZIP SHA-256 e0f67a6ccd0f62da65ec8f242c02ed3ad281d23d699636bd527c75259404d0e9** — DailyMed · U.S. National Library of Medicine; class A. [Open source](https://dailymed.nlm.nih.gov/dailymed/getFile.cfm?type=zip&setid=4bba538b-cf7c-4310-ae8f-cb711ed21bcc&version=25) (`dailymed-lixisenatide-4bba538b-cf7c-4310-ae8f-cb711ed21bcc-v25-history`)

### Correction lineage

No correction is recorded for this version.

### Reporting boundaries and unknowns

PeptideScanner reports the cited regulator or label record. It does not extend that record into broader safety, effectiveness, or approval claims.

- Sources outside the selected public PeptideScanner bundle may exist and are not represented by this object.
- This object does not determine whether cited records agree, corroborate one another, or establish scientific truth.
- This object does not determine safety, efficacy, causality, or suitability for any person.

Methodology: https://peptidescanner.com/methodology/
Medical disclaimer: https://peptidescanner.com/medical-disclaimer/

### Suggested citation

PeptideScanner. "Lixisenatide DailyMed SPL version 25." Version 1, published 2026-08-22. https://peptidescanner.com/evidence/v1/peptides/lixisenatide.json#dailymed-label-lixisenatide-4bba538b-cf7c-4310-ae8f-cb711ed21bcc-v25-v1 SHA-256: 82a70fbb25d31cbeb0a6a107589412ab08d0528c3480316792e2255efe63dc13.

---

<a id="dailymed-label-lixisenatide-4bba538b-cf7c-4310-ae8f-cb711ed21bcc-v4-v1"></a>

## Lixisenatide DailyMed SPL version 4

> DailyMed lists Structured Product Labeling version 4 for the reviewed Lixisenatide label family with a published date of 2017-09-07. PeptideScanner retained the exact versioned ZIP byte count and SHA-256 receipt without republishing its contents.

- Evidence object: `story:dailymed-label-lixisenatide-4bba538b-cf7c-4310-ae8f-cb711ed21bcc-v4:v1`
- Evidence domain: Regulatory
- Date in source: 2017-09-07
- Source checked: 2026-08-22
- Published by PeptideScanner: 2026-08-22
- Story landing page: https://peptidescanner.com/stories/dailymed-label-lixisenatide-4bba538b-cf7c-4310-ae8f-cb711ed21bcc-v4/
- JSON record: https://peptidescanner.com/evidence/v1/peptides/lixisenatide.json#dailymed-label-lixisenatide-4bba538b-cf7c-4310-ae8f-cb711ed21bcc-v4-v1
- Content SHA-256: `4055d3ed8ae6985bda0c62f5de1153f7592d4608f25c9301fd0d5c7aaf82529a`

### Claims and source pins

#### Headline

Lixisenatide DailyMed SPL version 4 ([`dailymed-lixisenatide-4bba538b-cf7c-4310-ae8f-cb711ed21bcc-v4-history`](#source-dailymed-lixisenatide-4bba538b-cf7c-4310-ae8f-cb711ed21bcc-v4-history))

#### Summary

DailyMed lists Structured Product Labeling version 4 for the reviewed Lixisenatide label family with a published date of 2017-09-07. PeptideScanner retained the exact versioned ZIP byte count and SHA-256 receipt without republishing its contents. ([`dailymed-lixisenatide-4bba538b-cf7c-4310-ae8f-cb711ed21bcc-v4-history`](#source-dailymed-lixisenatide-4bba538b-cf7c-4310-ae8f-cb711ed21bcc-v4-history))

#### Paragraph 1

DailyMed lists Structured Product Labeling version 4 for the reviewed Lixisenatide label family with a published date of 2017-09-07. PeptideScanner retained the exact versioned ZIP byte count and SHA-256 receipt without republishing its contents. ([`dailymed-lixisenatide-4bba538b-cf7c-4310-ae8f-cb711ed21bcc-v4-history`](#source-dailymed-lixisenatide-4bba538b-cf7c-4310-ae8f-cb711ed21bcc-v4-history))

#### Paragraph 2

This page reports that DailyMed lists an available Structured Product Labeling version for the reviewed label family and links the exact historical ZIP. It does not reproduce label text, identify which sections changed, establish FDA approval, interpret safety or effectiveness, or provide medical guidance. ([`dailymed-lixisenatide-4bba538b-cf7c-4310-ae8f-cb711ed21bcc-v4-history`](#source-dailymed-lixisenatide-4bba538b-cf7c-4310-ae8f-cb711ed21bcc-v4-history))

### Sources

<a id="source-dailymed-lixisenatide-4bba538b-cf7c-4310-ae8f-cb711ed21bcc-v4-history"></a>
- **DailyMed SPL SET ID 4bba538b-cf7c-4310-ae8f-cb711ed21bcc · SPL version 4 · published 2017-09-07 · retained ZIP SHA-256 8a7d4c463976b7b7b3579e03714cf805726de32c61122530da5f2b36aa13d10c** — DailyMed · U.S. National Library of Medicine; class A. [Open source](https://dailymed.nlm.nih.gov/dailymed/getFile.cfm?type=zip&setid=4bba538b-cf7c-4310-ae8f-cb711ed21bcc&version=4) (`dailymed-lixisenatide-4bba538b-cf7c-4310-ae8f-cb711ed21bcc-v4-history`)

### Correction lineage

No correction is recorded for this version.

### Reporting boundaries and unknowns

PeptideScanner reports the cited regulator or label record. It does not extend that record into broader safety, effectiveness, or approval claims.

- Sources outside the selected public PeptideScanner bundle may exist and are not represented by this object.
- This object does not determine whether cited records agree, corroborate one another, or establish scientific truth.
- This object does not determine safety, efficacy, causality, or suitability for any person.

Methodology: https://peptidescanner.com/methodology/
Medical disclaimer: https://peptidescanner.com/medical-disclaimer/

### Suggested citation

PeptideScanner. "Lixisenatide DailyMed SPL version 4." Version 1, published 2026-08-22. https://peptidescanner.com/evidence/v1/peptides/lixisenatide.json#dailymed-label-lixisenatide-4bba538b-cf7c-4310-ae8f-cb711ed21bcc-v4-v1 SHA-256: 4055d3ed8ae6985bda0c62f5de1153f7592d4608f25c9301fd0d5c7aaf82529a.

---

<a id="dailymed-label-lixisenatide-4bba538b-cf7c-4310-ae8f-cb711ed21bcc-v5-v1"></a>

## Lixisenatide DailyMed SPL version 5

> DailyMed lists Structured Product Labeling version 5 for the reviewed Lixisenatide label family with a published date of 2017-10-12. PeptideScanner retained the exact versioned ZIP byte count and SHA-256 receipt without republishing its contents.

- Evidence object: `story:dailymed-label-lixisenatide-4bba538b-cf7c-4310-ae8f-cb711ed21bcc-v5:v1`
- Evidence domain: Regulatory
- Date in source: 2017-10-12
- Source checked: 2026-08-22
- Published by PeptideScanner: 2026-08-22
- Story landing page: https://peptidescanner.com/stories/dailymed-label-lixisenatide-4bba538b-cf7c-4310-ae8f-cb711ed21bcc-v5/
- JSON record: https://peptidescanner.com/evidence/v1/peptides/lixisenatide.json#dailymed-label-lixisenatide-4bba538b-cf7c-4310-ae8f-cb711ed21bcc-v5-v1
- Content SHA-256: `72a40c0e2acad96361ceddfbbfba8250623cf541d8c7d570cc0ed1552990579a`

### Claims and source pins

#### Headline

Lixisenatide DailyMed SPL version 5 ([`dailymed-lixisenatide-4bba538b-cf7c-4310-ae8f-cb711ed21bcc-v5-history`](#source-dailymed-lixisenatide-4bba538b-cf7c-4310-ae8f-cb711ed21bcc-v5-history))

#### Summary

DailyMed lists Structured Product Labeling version 5 for the reviewed Lixisenatide label family with a published date of 2017-10-12. PeptideScanner retained the exact versioned ZIP byte count and SHA-256 receipt without republishing its contents. ([`dailymed-lixisenatide-4bba538b-cf7c-4310-ae8f-cb711ed21bcc-v5-history`](#source-dailymed-lixisenatide-4bba538b-cf7c-4310-ae8f-cb711ed21bcc-v5-history))

#### Paragraph 1

DailyMed lists Structured Product Labeling version 5 for the reviewed Lixisenatide label family with a published date of 2017-10-12. PeptideScanner retained the exact versioned ZIP byte count and SHA-256 receipt without republishing its contents. ([`dailymed-lixisenatide-4bba538b-cf7c-4310-ae8f-cb711ed21bcc-v5-history`](#source-dailymed-lixisenatide-4bba538b-cf7c-4310-ae8f-cb711ed21bcc-v5-history))

#### Paragraph 2

This page reports that DailyMed lists an available Structured Product Labeling version for the reviewed label family and links the exact historical ZIP. It does not reproduce label text, identify which sections changed, establish FDA approval, interpret safety or effectiveness, or provide medical guidance. ([`dailymed-lixisenatide-4bba538b-cf7c-4310-ae8f-cb711ed21bcc-v5-history`](#source-dailymed-lixisenatide-4bba538b-cf7c-4310-ae8f-cb711ed21bcc-v5-history))

### Sources

<a id="source-dailymed-lixisenatide-4bba538b-cf7c-4310-ae8f-cb711ed21bcc-v5-history"></a>
- **DailyMed SPL SET ID 4bba538b-cf7c-4310-ae8f-cb711ed21bcc · SPL version 5 · published 2017-10-12 · retained ZIP SHA-256 ce9ac08282bcdcc142df791946a8ad777117f11d5de8e89b042c4600bfe57d1f** — DailyMed · U.S. National Library of Medicine; class A. [Open source](https://dailymed.nlm.nih.gov/dailymed/getFile.cfm?type=zip&setid=4bba538b-cf7c-4310-ae8f-cb711ed21bcc&version=5) (`dailymed-lixisenatide-4bba538b-cf7c-4310-ae8f-cb711ed21bcc-v5-history`)

### Correction lineage

No correction is recorded for this version.

### Reporting boundaries and unknowns

PeptideScanner reports the cited regulator or label record. It does not extend that record into broader safety, effectiveness, or approval claims.

- Sources outside the selected public PeptideScanner bundle may exist and are not represented by this object.
- This object does not determine whether cited records agree, corroborate one another, or establish scientific truth.
- This object does not determine safety, efficacy, causality, or suitability for any person.

Methodology: https://peptidescanner.com/methodology/
Medical disclaimer: https://peptidescanner.com/medical-disclaimer/

### Suggested citation

PeptideScanner. "Lixisenatide DailyMed SPL version 5." Version 1, published 2026-08-22. https://peptidescanner.com/evidence/v1/peptides/lixisenatide.json#dailymed-label-lixisenatide-4bba538b-cf7c-4310-ae8f-cb711ed21bcc-v5-v1 SHA-256: 72a40c0e2acad96361ceddfbbfba8250623cf541d8c7d570cc0ed1552990579a.

---

<a id="dailymed-label-lixisenatide-4bba538b-cf7c-4310-ae8f-cb711ed21bcc-v6-v1"></a>

## Lixisenatide DailyMed SPL version 6

> DailyMed lists Structured Product Labeling version 6 for the reviewed Lixisenatide label family with a published date of 2018-03-07. PeptideScanner retained the exact versioned ZIP byte count and SHA-256 receipt without republishing its contents.

- Evidence object: `story:dailymed-label-lixisenatide-4bba538b-cf7c-4310-ae8f-cb711ed21bcc-v6:v1`
- Evidence domain: Regulatory
- Date in source: 2018-03-07
- Source checked: 2026-08-22
- Published by PeptideScanner: 2026-08-22
- Story landing page: https://peptidescanner.com/stories/dailymed-label-lixisenatide-4bba538b-cf7c-4310-ae8f-cb711ed21bcc-v6/
- JSON record: https://peptidescanner.com/evidence/v1/peptides/lixisenatide.json#dailymed-label-lixisenatide-4bba538b-cf7c-4310-ae8f-cb711ed21bcc-v6-v1
- Content SHA-256: `7a31851961b686f6f36ac6e9c2d4e678b0061ddb422cbbfbbe686291681843fb`

### Claims and source pins

#### Headline

Lixisenatide DailyMed SPL version 6 ([`dailymed-lixisenatide-4bba538b-cf7c-4310-ae8f-cb711ed21bcc-v6-history`](#source-dailymed-lixisenatide-4bba538b-cf7c-4310-ae8f-cb711ed21bcc-v6-history))

#### Summary

DailyMed lists Structured Product Labeling version 6 for the reviewed Lixisenatide label family with a published date of 2018-03-07. PeptideScanner retained the exact versioned ZIP byte count and SHA-256 receipt without republishing its contents. ([`dailymed-lixisenatide-4bba538b-cf7c-4310-ae8f-cb711ed21bcc-v6-history`](#source-dailymed-lixisenatide-4bba538b-cf7c-4310-ae8f-cb711ed21bcc-v6-history))

#### Paragraph 1

DailyMed lists Structured Product Labeling version 6 for the reviewed Lixisenatide label family with a published date of 2018-03-07. PeptideScanner retained the exact versioned ZIP byte count and SHA-256 receipt without republishing its contents. ([`dailymed-lixisenatide-4bba538b-cf7c-4310-ae8f-cb711ed21bcc-v6-history`](#source-dailymed-lixisenatide-4bba538b-cf7c-4310-ae8f-cb711ed21bcc-v6-history))

#### Paragraph 2

This page reports that DailyMed lists an available Structured Product Labeling version for the reviewed label family and links the exact historical ZIP. It does not reproduce label text, identify which sections changed, establish FDA approval, interpret safety or effectiveness, or provide medical guidance. ([`dailymed-lixisenatide-4bba538b-cf7c-4310-ae8f-cb711ed21bcc-v6-history`](#source-dailymed-lixisenatide-4bba538b-cf7c-4310-ae8f-cb711ed21bcc-v6-history))

### Sources

<a id="source-dailymed-lixisenatide-4bba538b-cf7c-4310-ae8f-cb711ed21bcc-v6-history"></a>
- **DailyMed SPL SET ID 4bba538b-cf7c-4310-ae8f-cb711ed21bcc · SPL version 6 · published 2018-03-07 · retained ZIP SHA-256 8d5461f681a8af0c565822193856558efa6a1adb78386de624437895a24c7f26** — DailyMed · U.S. National Library of Medicine; class A. [Open source](https://dailymed.nlm.nih.gov/dailymed/getFile.cfm?type=zip&setid=4bba538b-cf7c-4310-ae8f-cb711ed21bcc&version=6) (`dailymed-lixisenatide-4bba538b-cf7c-4310-ae8f-cb711ed21bcc-v6-history`)

### Correction lineage

No correction is recorded for this version.

### Reporting boundaries and unknowns

PeptideScanner reports the cited regulator or label record. It does not extend that record into broader safety, effectiveness, or approval claims.

- Sources outside the selected public PeptideScanner bundle may exist and are not represented by this object.
- This object does not determine whether cited records agree, corroborate one another, or establish scientific truth.
- This object does not determine safety, efficacy, causality, or suitability for any person.

Methodology: https://peptidescanner.com/methodology/
Medical disclaimer: https://peptidescanner.com/medical-disclaimer/

### Suggested citation

PeptideScanner. "Lixisenatide DailyMed SPL version 6." Version 1, published 2026-08-22. https://peptidescanner.com/evidence/v1/peptides/lixisenatide.json#dailymed-label-lixisenatide-4bba538b-cf7c-4310-ae8f-cb711ed21bcc-v6-v1 SHA-256: 7a31851961b686f6f36ac6e9c2d4e678b0061ddb422cbbfbbe686291681843fb.

---

<a id="dailymed-label-lixisenatide-4bba538b-cf7c-4310-ae8f-cb711ed21bcc-v7-v1"></a>

## Lixisenatide DailyMed SPL version 7

> DailyMed lists Structured Product Labeling version 7 for the reviewed Lixisenatide label family with a published date of 2019-03-05. PeptideScanner retained the exact versioned ZIP byte count and SHA-256 receipt without republishing its contents.

- Evidence object: `story:dailymed-label-lixisenatide-4bba538b-cf7c-4310-ae8f-cb711ed21bcc-v7:v1`
- Evidence domain: Regulatory
- Date in source: 2019-03-05
- Source checked: 2026-08-22
- Published by PeptideScanner: 2026-08-22
- Story landing page: https://peptidescanner.com/stories/dailymed-label-lixisenatide-4bba538b-cf7c-4310-ae8f-cb711ed21bcc-v7/
- JSON record: https://peptidescanner.com/evidence/v1/peptides/lixisenatide.json#dailymed-label-lixisenatide-4bba538b-cf7c-4310-ae8f-cb711ed21bcc-v7-v1
- Content SHA-256: `f038494aca12b6a3e82f79e71e1f86f3410d0593f635e1c1420a48827c6d7c6b`

### Claims and source pins

#### Headline

Lixisenatide DailyMed SPL version 7 ([`dailymed-lixisenatide-4bba538b-cf7c-4310-ae8f-cb711ed21bcc-v7-history`](#source-dailymed-lixisenatide-4bba538b-cf7c-4310-ae8f-cb711ed21bcc-v7-history))

#### Summary

DailyMed lists Structured Product Labeling version 7 for the reviewed Lixisenatide label family with a published date of 2019-03-05. PeptideScanner retained the exact versioned ZIP byte count and SHA-256 receipt without republishing its contents. ([`dailymed-lixisenatide-4bba538b-cf7c-4310-ae8f-cb711ed21bcc-v7-history`](#source-dailymed-lixisenatide-4bba538b-cf7c-4310-ae8f-cb711ed21bcc-v7-history))

#### Paragraph 1

DailyMed lists Structured Product Labeling version 7 for the reviewed Lixisenatide label family with a published date of 2019-03-05. PeptideScanner retained the exact versioned ZIP byte count and SHA-256 receipt without republishing its contents. ([`dailymed-lixisenatide-4bba538b-cf7c-4310-ae8f-cb711ed21bcc-v7-history`](#source-dailymed-lixisenatide-4bba538b-cf7c-4310-ae8f-cb711ed21bcc-v7-history))

#### Paragraph 2

This page reports that DailyMed lists an available Structured Product Labeling version for the reviewed label family and links the exact historical ZIP. It does not reproduce label text, identify which sections changed, establish FDA approval, interpret safety or effectiveness, or provide medical guidance. ([`dailymed-lixisenatide-4bba538b-cf7c-4310-ae8f-cb711ed21bcc-v7-history`](#source-dailymed-lixisenatide-4bba538b-cf7c-4310-ae8f-cb711ed21bcc-v7-history))

### Sources

<a id="source-dailymed-lixisenatide-4bba538b-cf7c-4310-ae8f-cb711ed21bcc-v7-history"></a>
- **DailyMed SPL SET ID 4bba538b-cf7c-4310-ae8f-cb711ed21bcc · SPL version 7 · published 2019-03-05 · retained ZIP SHA-256 3dc7f7cd3eef29e61a5dfd17694fb87f69546068901bc60e5449372566d07c37** — DailyMed · U.S. National Library of Medicine; class A. [Open source](https://dailymed.nlm.nih.gov/dailymed/getFile.cfm?type=zip&setid=4bba538b-cf7c-4310-ae8f-cb711ed21bcc&version=7) (`dailymed-lixisenatide-4bba538b-cf7c-4310-ae8f-cb711ed21bcc-v7-history`)

### Correction lineage

No correction is recorded for this version.

### Reporting boundaries and unknowns

PeptideScanner reports the cited regulator or label record. It does not extend that record into broader safety, effectiveness, or approval claims.

- Sources outside the selected public PeptideScanner bundle may exist and are not represented by this object.
- This object does not determine whether cited records agree, corroborate one another, or establish scientific truth.
- This object does not determine safety, efficacy, causality, or suitability for any person.

Methodology: https://peptidescanner.com/methodology/
Medical disclaimer: https://peptidescanner.com/medical-disclaimer/

### Suggested citation

PeptideScanner. "Lixisenatide DailyMed SPL version 7." Version 1, published 2026-08-22. https://peptidescanner.com/evidence/v1/peptides/lixisenatide.json#dailymed-label-lixisenatide-4bba538b-cf7c-4310-ae8f-cb711ed21bcc-v7-v1 SHA-256: f038494aca12b6a3e82f79e71e1f86f3410d0593f635e1c1420a48827c6d7c6b.

---

<a id="dailymed-label-lixisenatide-4bba538b-cf7c-4310-ae8f-cb711ed21bcc-v8-v1"></a>

## Lixisenatide DailyMed SPL version 8

> DailyMed lists Structured Product Labeling version 8 for the reviewed Lixisenatide label family with a published date of 2019-11-26. PeptideScanner retained the exact versioned ZIP byte count and SHA-256 receipt without republishing its contents.

- Evidence object: `story:dailymed-label-lixisenatide-4bba538b-cf7c-4310-ae8f-cb711ed21bcc-v8:v1`
- Evidence domain: Regulatory
- Date in source: 2019-11-26
- Source checked: 2026-08-22
- Published by PeptideScanner: 2026-08-22
- Story landing page: https://peptidescanner.com/stories/dailymed-label-lixisenatide-4bba538b-cf7c-4310-ae8f-cb711ed21bcc-v8/
- JSON record: https://peptidescanner.com/evidence/v1/peptides/lixisenatide.json#dailymed-label-lixisenatide-4bba538b-cf7c-4310-ae8f-cb711ed21bcc-v8-v1
- Content SHA-256: `985b0d0429c38f5a3e0876a8df536cabfc89137918dad07d9c9b44a53e186667`

### Claims and source pins

#### Headline

Lixisenatide DailyMed SPL version 8 ([`dailymed-lixisenatide-4bba538b-cf7c-4310-ae8f-cb711ed21bcc-v8-history`](#source-dailymed-lixisenatide-4bba538b-cf7c-4310-ae8f-cb711ed21bcc-v8-history))

#### Summary

DailyMed lists Structured Product Labeling version 8 for the reviewed Lixisenatide label family with a published date of 2019-11-26. PeptideScanner retained the exact versioned ZIP byte count and SHA-256 receipt without republishing its contents. ([`dailymed-lixisenatide-4bba538b-cf7c-4310-ae8f-cb711ed21bcc-v8-history`](#source-dailymed-lixisenatide-4bba538b-cf7c-4310-ae8f-cb711ed21bcc-v8-history))

#### Paragraph 1

DailyMed lists Structured Product Labeling version 8 for the reviewed Lixisenatide label family with a published date of 2019-11-26. PeptideScanner retained the exact versioned ZIP byte count and SHA-256 receipt without republishing its contents. ([`dailymed-lixisenatide-4bba538b-cf7c-4310-ae8f-cb711ed21bcc-v8-history`](#source-dailymed-lixisenatide-4bba538b-cf7c-4310-ae8f-cb711ed21bcc-v8-history))

#### Paragraph 2

This page reports that DailyMed lists an available Structured Product Labeling version for the reviewed label family and links the exact historical ZIP. It does not reproduce label text, identify which sections changed, establish FDA approval, interpret safety or effectiveness, or provide medical guidance. ([`dailymed-lixisenatide-4bba538b-cf7c-4310-ae8f-cb711ed21bcc-v8-history`](#source-dailymed-lixisenatide-4bba538b-cf7c-4310-ae8f-cb711ed21bcc-v8-history))

### Sources

<a id="source-dailymed-lixisenatide-4bba538b-cf7c-4310-ae8f-cb711ed21bcc-v8-history"></a>
- **DailyMed SPL SET ID 4bba538b-cf7c-4310-ae8f-cb711ed21bcc · SPL version 8 · published 2019-11-26 · retained ZIP SHA-256 d1d88d5d87046879d69947ed3e2a578c7b8e6b35a7807bc19ec7496c2a605611** — DailyMed · U.S. National Library of Medicine; class A. [Open source](https://dailymed.nlm.nih.gov/dailymed/getFile.cfm?type=zip&setid=4bba538b-cf7c-4310-ae8f-cb711ed21bcc&version=8) (`dailymed-lixisenatide-4bba538b-cf7c-4310-ae8f-cb711ed21bcc-v8-history`)

### Correction lineage

No correction is recorded for this version.

### Reporting boundaries and unknowns

PeptideScanner reports the cited regulator or label record. It does not extend that record into broader safety, effectiveness, or approval claims.

- Sources outside the selected public PeptideScanner bundle may exist and are not represented by this object.
- This object does not determine whether cited records agree, corroborate one another, or establish scientific truth.
- This object does not determine safety, efficacy, causality, or suitability for any person.

Methodology: https://peptidescanner.com/methodology/
Medical disclaimer: https://peptidescanner.com/medical-disclaimer/

### Suggested citation

PeptideScanner. "Lixisenatide DailyMed SPL version 8." Version 1, published 2026-08-22. https://peptidescanner.com/evidence/v1/peptides/lixisenatide.json#dailymed-label-lixisenatide-4bba538b-cf7c-4310-ae8f-cb711ed21bcc-v8-v1 SHA-256: 985b0d0429c38f5a3e0876a8df536cabfc89137918dad07d9c9b44a53e186667.

---

<a id="dailymed-label-lixisenatide-4bba538b-cf7c-4310-ae8f-cb711ed21bcc-v9-v1"></a>

## Lixisenatide DailyMed SPL version 9

> DailyMed lists Structured Product Labeling version 9 for the reviewed Lixisenatide label family with a published date of 2019-12-10. PeptideScanner retained the exact versioned ZIP byte count and SHA-256 receipt without republishing its contents.

- Evidence object: `story:dailymed-label-lixisenatide-4bba538b-cf7c-4310-ae8f-cb711ed21bcc-v9:v1`
- Evidence domain: Regulatory
- Date in source: 2019-12-10
- Source checked: 2026-08-22
- Published by PeptideScanner: 2026-08-22
- Story landing page: https://peptidescanner.com/stories/dailymed-label-lixisenatide-4bba538b-cf7c-4310-ae8f-cb711ed21bcc-v9/
- JSON record: https://peptidescanner.com/evidence/v1/peptides/lixisenatide.json#dailymed-label-lixisenatide-4bba538b-cf7c-4310-ae8f-cb711ed21bcc-v9-v1
- Content SHA-256: `c89c71b8f5bcb998071a369914a8e8f25a0c659365a890b7a46c53d1cdcaaeef`

### Claims and source pins

#### Headline

Lixisenatide DailyMed SPL version 9 ([`dailymed-lixisenatide-4bba538b-cf7c-4310-ae8f-cb711ed21bcc-v9-history`](#source-dailymed-lixisenatide-4bba538b-cf7c-4310-ae8f-cb711ed21bcc-v9-history))

#### Summary

DailyMed lists Structured Product Labeling version 9 for the reviewed Lixisenatide label family with a published date of 2019-12-10. PeptideScanner retained the exact versioned ZIP byte count and SHA-256 receipt without republishing its contents. ([`dailymed-lixisenatide-4bba538b-cf7c-4310-ae8f-cb711ed21bcc-v9-history`](#source-dailymed-lixisenatide-4bba538b-cf7c-4310-ae8f-cb711ed21bcc-v9-history))

#### Paragraph 1

DailyMed lists Structured Product Labeling version 9 for the reviewed Lixisenatide label family with a published date of 2019-12-10. PeptideScanner retained the exact versioned ZIP byte count and SHA-256 receipt without republishing its contents. ([`dailymed-lixisenatide-4bba538b-cf7c-4310-ae8f-cb711ed21bcc-v9-history`](#source-dailymed-lixisenatide-4bba538b-cf7c-4310-ae8f-cb711ed21bcc-v9-history))

#### Paragraph 2

This page reports that DailyMed lists an available Structured Product Labeling version for the reviewed label family and links the exact historical ZIP. It does not reproduce label text, identify which sections changed, establish FDA approval, interpret safety or effectiveness, or provide medical guidance. ([`dailymed-lixisenatide-4bba538b-cf7c-4310-ae8f-cb711ed21bcc-v9-history`](#source-dailymed-lixisenatide-4bba538b-cf7c-4310-ae8f-cb711ed21bcc-v9-history))

### Sources

<a id="source-dailymed-lixisenatide-4bba538b-cf7c-4310-ae8f-cb711ed21bcc-v9-history"></a>
- **DailyMed SPL SET ID 4bba538b-cf7c-4310-ae8f-cb711ed21bcc · SPL version 9 · published 2019-12-10 · retained ZIP SHA-256 d1b99c4cf8a7d14aef61ef763e08a3392ba747daef0d8a08b09857b483d7c9f8** — DailyMed · U.S. National Library of Medicine; class A. [Open source](https://dailymed.nlm.nih.gov/dailymed/getFile.cfm?type=zip&setid=4bba538b-cf7c-4310-ae8f-cb711ed21bcc&version=9) (`dailymed-lixisenatide-4bba538b-cf7c-4310-ae8f-cb711ed21bcc-v9-history`)

### Correction lineage

No correction is recorded for this version.

### Reporting boundaries and unknowns

PeptideScanner reports the cited regulator or label record. It does not extend that record into broader safety, effectiveness, or approval claims.

- Sources outside the selected public PeptideScanner bundle may exist and are not represented by this object.
- This object does not determine whether cited records agree, corroborate one another, or establish scientific truth.
- This object does not determine safety, efficacy, causality, or suitability for any person.

Methodology: https://peptidescanner.com/methodology/
Medical disclaimer: https://peptidescanner.com/medical-disclaimer/

### Suggested citation

PeptideScanner. "Lixisenatide DailyMed SPL version 9." Version 1, published 2026-08-22. https://peptidescanner.com/evidence/v1/peptides/lixisenatide.json#dailymed-label-lixisenatide-4bba538b-cf7c-4310-ae8f-cb711ed21bcc-v9-v1 SHA-256: c89c71b8f5bcb998071a369914a8e8f25a0c659365a890b7a46c53d1cdcaaeef.

---

<a id="fda-drugs-bla208471-v1"></a>

## Drugs@FDA application BLA208471

> The official Drugs@FDA dataset lists original submission 1 for BLA 208471 with status AP dated 2016-07-27, and names lixisenatide among the application record's active ingredients.

- Evidence object: `story:fda-drugs-bla208471:v1`
- Evidence domain: Regulatory
- Date in source: 2016-07-27
- Source checked: 2026-08-14
- Published by PeptideScanner: 2026-08-14
- Story landing page: https://peptidescanner.com/stories/fda-drugs-bla208471/
- JSON record: https://peptidescanner.com/evidence/v1/peptides/lixisenatide.json#fda-drugs-bla208471-v1
- Content SHA-256: `77b212e61a993a2b2ecea6140752ef18e132cd210dbff7bfe26301ca4ec4c83d`

### Claims and source pins

#### Headline

Drugs@FDA application BLA208471 ([`fda-drugs-bla208471-2016-07-27-6e0355642026`](#source-fda-drugs-bla208471-2016-07-27-6e0355642026))

#### Summary

The official Drugs@FDA dataset lists original submission 1 for BLA 208471 with status AP dated 2016-07-27, and names lixisenatide among the application record's active ingredients. ([`fda-drugs-bla208471-2016-07-27-6e0355642026`](#source-fda-drugs-bla208471-2016-07-27-6e0355642026))

#### Paragraph 1

The official Drugs@FDA dataset lists original submission 1 for BLA 208471 with status AP dated 2016-07-27, and names lixisenatide among the application record's active ingredients. ([`fda-drugs-bla208471-2016-07-27-6e0355642026`](#source-fda-drugs-bla208471-2016-07-27-6e0355642026))

#### Paragraph 2

This page reports bounded application metadata attributed to Drugs@FDA. It does not reproduce labeling, describe an indication, compare products, or provide medical guidance. ([`fda-drugs-bla208471-2016-07-27-6e0355642026`](#source-fda-drugs-bla208471-2016-07-27-6e0355642026))

### Sources

<a id="source-fda-drugs-bla208471-2016-07-27-6e0355642026"></a>
- **Drugs@FDA application BLA208471 · original submission status AP · 2016-07-27 · dataset 2026-08-13** — Drugs@FDA via openFDA; class A. [Open source](https://api.fda.gov/drug/drugsfda.json?search=application_number%3A%22BLA208471%22&limit=1) (`fda-drugs-bla208471-2016-07-27-6e0355642026`)

### Correction lineage

No correction is recorded for this version.

### Reporting boundaries and unknowns

PeptideScanner reports the cited regulator or label record. It does not extend that record into broader safety, effectiveness, or approval claims.

- Sources outside the selected public PeptideScanner bundle may exist and are not represented by this object.
- This object does not determine whether cited records agree, corroborate one another, or establish scientific truth.
- This object does not determine safety, efficacy, causality, or suitability for any person.

Methodology: https://peptidescanner.com/methodology/
Medical disclaimer: https://peptidescanner.com/medical-disclaimer/

### Suggested citation

PeptideScanner. "Drugs@FDA application BLA208471." Version 1, published 2026-08-14. https://peptidescanner.com/evidence/v1/peptides/lixisenatide.json#fda-drugs-bla208471-v1 SHA-256: 77b212e61a993a2b2ecea6140752ef18e132cd210dbff7bfe26301ca4ec4c83d.

---

<a id="federal-register-2016-05931-v1"></a>

## Federal Register notice 2016-05931

> The Federal Register published notice 2016-05931, attributed to FDA and its parent HHS department, on 2016-03-16. Its official title is “Endocrinologic and Metabolic Drugs Advisory Committee; Notice of Meeting,” and PeptideScanner's exact reviewed identity mapping connects the document to Lixisenatide.

- Evidence object: `story:federal-register-2016-05931:v1`
- Evidence domain: Regulatory
- Date in source: 2016-03-16
- Source checked: 2026-08-21
- Published by PeptideScanner: 2026-08-21
- Story landing page: https://peptidescanner.com/stories/federal-register-2016-05931/
- JSON record: https://peptidescanner.com/evidence/v1/peptides/lixisenatide.json#federal-register-2016-05931-v1
- Content SHA-256: `04f33a2ff97308eabf68a9250a0a89e3c5261cee409eaccfea112c52c3c5ae6a`

### Claims and source pins

#### Headline

Federal Register notice 2016-05931 ([`federal-register-2016-05931-bf63eeb47140`](#source-federal-register-2016-05931-bf63eeb47140))

#### Summary

The Federal Register published notice 2016-05931, attributed to FDA and its parent HHS department, on 2016-03-16. Its official title is “Endocrinologic and Metabolic Drugs Advisory Committee; Notice of Meeting,” and PeptideScanner's exact reviewed identity mapping connects the document to Lixisenatide. ([`federal-register-2016-05931-bf63eeb47140`](#source-federal-register-2016-05931-bf63eeb47140))

#### Paragraph 1

The Federal Register published notice 2016-05931, attributed to FDA and its parent HHS department, on 2016-03-16. Its official title is “Endocrinologic and Metabolic Drugs Advisory Committee; Notice of Meeting,” and PeptideScanner's exact reviewed identity mapping connects the document to Lixisenatide. ([`federal-register-2016-05931-bf63eeb47140`](#source-federal-register-2016-05931-bf63eeb47140))

#### Paragraph 2

This page reports bounded metadata from a Federal Register document attributed to FDA and its parent HHS department, and links to the official GovInfo PDF. It does not interpret legal effect, approval, safety, effectiveness, compounding status, or medical use. ([`federal-register-2016-05931-bf63eeb47140`](#source-federal-register-2016-05931-bf63eeb47140))

### Sources

<a id="source-federal-register-2016-05931-bf63eeb47140"></a>
- **Federal Register notice 2016-05931 · published 2016-03-16 · Endocrinologic and Metabolic Drugs Advisory Committee; Notice of Meeting** — Federal Register via GovInfo; class A. [Open source](https://www.govinfo.gov/content/pkg/FR-2016-03-16/pdf/2016-05931.pdf) (`federal-register-2016-05931-bf63eeb47140`)

### Correction lineage

No correction is recorded for this version.

### Reporting boundaries and unknowns

PeptideScanner reports the cited regulator or label record. It does not extend that record into broader safety, effectiveness, or approval claims.

- Sources outside the selected public PeptideScanner bundle may exist and are not represented by this object.
- This object does not determine whether cited records agree, corroborate one another, or establish scientific truth.
- This object does not determine safety, efficacy, causality, or suitability for any person.

Methodology: https://peptidescanner.com/methodology/
Medical disclaimer: https://peptidescanner.com/medical-disclaimer/

### Suggested citation

PeptideScanner. "Federal Register notice 2016-05931." Version 1, published 2026-08-21. https://peptidescanner.com/evidence/v1/peptides/lixisenatide.json#federal-register-2016-05931-v1 SHA-256: 04f33a2ff97308eabf68a9250a0a89e3c5261cee409eaccfea112c52c3c5ae6a.

---

<a id="federal-register-2018-07256-v1"></a>

## Federal Register notice 2018-07256

> The Federal Register published notice 2018-07256, attributed to FDA and its parent HHS department, on 2018-04-10. Its official title is “Notice of Approval of Products Under Voucher: Rare Pediatric Disease Priority Review Vouchers,” and PeptideScanner's exact reviewed identity mapping connects the document to Lixisenatide.

- Evidence object: `story:federal-register-2018-07256:v1`
- Evidence domain: Regulatory
- Date in source: 2018-04-10
- Source checked: 2026-08-21
- Published by PeptideScanner: 2026-08-21
- Story landing page: https://peptidescanner.com/stories/federal-register-2018-07256/
- JSON record: https://peptidescanner.com/evidence/v1/peptides/lixisenatide.json#federal-register-2018-07256-v1
- Content SHA-256: `938ecf32b02257c0b579095cdcd0650a1825ebfaa245bea6e40046e79d2f5fba`

### Claims and source pins

#### Headline

Federal Register notice 2018-07256 ([`federal-register-2018-07256-01ae8bc7900f`](#source-federal-register-2018-07256-01ae8bc7900f))

#### Summary

The Federal Register published notice 2018-07256, attributed to FDA and its parent HHS department, on 2018-04-10. Its official title is “Notice of Approval of Products Under Voucher: Rare Pediatric Disease Priority Review Vouchers,” and PeptideScanner's exact reviewed identity mapping connects the document to Lixisenatide. ([`federal-register-2018-07256-01ae8bc7900f`](#source-federal-register-2018-07256-01ae8bc7900f))

#### Paragraph 1

The Federal Register published notice 2018-07256, attributed to FDA and its parent HHS department, on 2018-04-10. Its official title is “Notice of Approval of Products Under Voucher: Rare Pediatric Disease Priority Review Vouchers,” and PeptideScanner's exact reviewed identity mapping connects the document to Lixisenatide. ([`federal-register-2018-07256-01ae8bc7900f`](#source-federal-register-2018-07256-01ae8bc7900f))

#### Paragraph 2

This page reports bounded metadata from a Federal Register document attributed to FDA and its parent HHS department, and links to the official GovInfo PDF. It does not interpret legal effect, approval, safety, effectiveness, compounding status, or medical use. ([`federal-register-2018-07256-01ae8bc7900f`](#source-federal-register-2018-07256-01ae8bc7900f))

### Sources

<a id="source-federal-register-2018-07256-01ae8bc7900f"></a>
- **Federal Register notice 2018-07256 · published 2018-04-10 · Notice of Approval of Products Under Voucher: Rare Pediatric Disease Priority Review Vouchers** — Federal Register via GovInfo; class A. [Open source](https://www.govinfo.gov/content/pkg/FR-2018-04-10/pdf/2018-07256.pdf) (`federal-register-2018-07256-01ae8bc7900f`)

### Correction lineage

No correction is recorded for this version.

### Reporting boundaries and unknowns

PeptideScanner reports the cited regulator or label record. It does not extend that record into broader safety, effectiveness, or approval claims.

- Sources outside the selected public PeptideScanner bundle may exist and are not represented by this object.
- This object does not determine whether cited records agree, corroborate one another, or establish scientific truth.
- This object does not determine safety, efficacy, causality, or suitability for any person.

Methodology: https://peptidescanner.com/methodology/
Medical disclaimer: https://peptidescanner.com/medical-disclaimer/

### Suggested citation

PeptideScanner. "Federal Register notice 2018-07256." Version 1, published 2026-08-21. https://peptidescanner.com/evidence/v1/peptides/lixisenatide.json#federal-register-2018-07256-v1 SHA-256: 938ecf32b02257c0b579095cdcd0650a1825ebfaa245bea6e40046e79d2f5fba.

---

<a id="federal-register-2018-27805-v1"></a>

## Federal Register notice 2018-27805

> The Federal Register published notice 2018-27805, attributed to FDA and its parent HHS department, on 2018-12-26. Its official title is “Determination of Regulatory Review Period for Purposes of Patent Extension; ADLYXIN,” and PeptideScanner's exact reviewed identity mapping connects the document to Lixisenatide.

- Evidence object: `story:federal-register-2018-27805:v1`
- Evidence domain: Regulatory
- Date in source: 2018-12-26
- Source checked: 2026-08-21
- Published by PeptideScanner: 2026-08-21
- Story landing page: https://peptidescanner.com/stories/federal-register-2018-27805/
- JSON record: https://peptidescanner.com/evidence/v1/peptides/lixisenatide.json#federal-register-2018-27805-v1
- Content SHA-256: `a43bac076d57ef793910ed07e6579898a82f4d636389fb890e3cf78dea689b1b`

### Claims and source pins

#### Headline

Federal Register notice 2018-27805 ([`federal-register-2018-27805-f69cf1a19424`](#source-federal-register-2018-27805-f69cf1a19424))

#### Summary

The Federal Register published notice 2018-27805, attributed to FDA and its parent HHS department, on 2018-12-26. Its official title is “Determination of Regulatory Review Period for Purposes of Patent Extension; ADLYXIN,” and PeptideScanner's exact reviewed identity mapping connects the document to Lixisenatide. ([`federal-register-2018-27805-f69cf1a19424`](#source-federal-register-2018-27805-f69cf1a19424))

#### Paragraph 1

The Federal Register published notice 2018-27805, attributed to FDA and its parent HHS department, on 2018-12-26. Its official title is “Determination of Regulatory Review Period for Purposes of Patent Extension; ADLYXIN,” and PeptideScanner's exact reviewed identity mapping connects the document to Lixisenatide. ([`federal-register-2018-27805-f69cf1a19424`](#source-federal-register-2018-27805-f69cf1a19424))

#### Paragraph 2

This page reports bounded metadata from a Federal Register document attributed to FDA and its parent HHS department, and links to the official GovInfo PDF. It does not interpret legal effect, approval, safety, effectiveness, compounding status, or medical use. ([`federal-register-2018-27805-f69cf1a19424`](#source-federal-register-2018-27805-f69cf1a19424))

### Sources

<a id="source-federal-register-2018-27805-f69cf1a19424"></a>
- **Federal Register notice 2018-27805 · published 2018-12-26 · Determination of Regulatory Review Period for Purposes of Patent Extension; ADLYXIN** — Federal Register via GovInfo; class A. [Open source](https://www.govinfo.gov/content/pkg/FR-2018-12-26/pdf/2018-27805.pdf) (`federal-register-2018-27805-f69cf1a19424`)

### Correction lineage

No correction is recorded for this version.

### Reporting boundaries and unknowns

PeptideScanner reports the cited regulator or label record. It does not extend that record into broader safety, effectiveness, or approval claims.

- Sources outside the selected public PeptideScanner bundle may exist and are not represented by this object.
- This object does not determine whether cited records agree, corroborate one another, or establish scientific truth.
- This object does not determine safety, efficacy, causality, or suitability for any person.

Methodology: https://peptidescanner.com/methodology/
Medical disclaimer: https://peptidescanner.com/medical-disclaimer/

### Suggested citation

PeptideScanner. "Federal Register notice 2018-27805." Version 1, published 2026-08-21. https://peptidescanner.com/evidence/v1/peptides/lixisenatide.json#federal-register-2018-27805-v1 SHA-256: a43bac076d57ef793910ed07e6579898a82f4d636389fb890e3cf78dea689b1b.

---

<a id="pubmed-pmid-22564709-lixisenatide-v1"></a>

## PubMed record PMID 22564709

> PeptideScanner retained PubMed bibliographic metadata for PMID 22564709 at 2026-07-30T16:20:34.419Z. PubMed recorded a metadata revision date of 2026-05-18 and an Entrez history date of 2012-05-09. PeptideScanner associated this retained record with the identity slug lixisenatide. These dates describe PubMed metadata history, not the article's original publication date.

- Evidence object: `story:pubmed-pmid-22564709-lixisenatide:v1`
- Evidence domain: Literature metadata
- Date in source: 2026-05-18
- Source checked: 2026-07-30
- Published by PeptideScanner: 2026-08-11
- Story landing page: https://peptidescanner.com/stories/pubmed-pmid-22564709-lixisenatide/
- JSON record: https://peptidescanner.com/evidence/v1/peptides/lixisenatide.json#pubmed-pmid-22564709-lixisenatide-v1
- Content SHA-256: `099a1d66c8c9eebc0492025b04deeb1a88f86868bf589148c678499dca2f227f`

### Claims and source pins

#### Headline

PubMed record PMID 22564709 ([`pubmed-observation-pmid-22564709-2026-05-18-922275826e9d`](#source-pubmed-observation-pmid-22564709-2026-05-18-922275826e9d))

#### Summary

PeptideScanner retained PubMed bibliographic metadata for PMID 22564709 at 2026-07-30T16:20:34.419Z. PubMed recorded a metadata revision date of 2026-05-18 and an Entrez history date of 2012-05-09. PeptideScanner associated this retained record with the identity slug lixisenatide. These dates describe PubMed metadata history, not the article's original publication date. ([`pubmed-observation-pmid-22564709-2026-05-18-922275826e9d`](#source-pubmed-observation-pmid-22564709-2026-05-18-922275826e9d))

#### Paragraph 1

PeptideScanner retained PubMed bibliographic metadata for PMID 22564709 at 2026-07-30T16:20:34.419Z. PubMed recorded a metadata revision date of 2026-05-18 and an Entrez history date of 2012-05-09. PeptideScanner associated this retained record with the identity slug lixisenatide. These dates describe PubMed metadata history, not the article's original publication date. ([`pubmed-observation-pmid-22564709-2026-05-18-922275826e9d`](#source-pubmed-observation-pmid-22564709-2026-05-18-922275826e9d))

#### Paragraph 2

This page reports retained PubMed bibliographic metadata. It does not summarize the article, establish the article's publication date, or assert safety, efficacy, or scientific truth. ([`pubmed-observation-pmid-22564709-2026-05-18-922275826e9d`](#source-pubmed-observation-pmid-22564709-2026-05-18-922275826e9d))

### Sources

<a id="source-pubmed-observation-pmid-22564709-2026-05-18-922275826e9d"></a>
- **PubMed record PMID 22564709 · retained source version 1:2026-05-18:current:922275826e9d0c943dcb6ba3413379d6a51dfa30cf2a1f00d6ce4ff721178c80** — PubMed; class A. [Open source](https://pubmed.ncbi.nlm.nih.gov/22564709/) (`pubmed-observation-pmid-22564709-2026-05-18-922275826e9d`)

### Correction lineage

No correction is recorded for this version.

### Reporting boundaries and unknowns

PeptideScanner reproduces bounded bibliographic metadata attributed to PubMed. It does not summarize or endorse the article's findings.

- Sources outside the selected public PeptideScanner bundle may exist and are not represented by this object.
- This object does not determine whether cited records agree, corroborate one another, or establish scientific truth.
- This object does not determine safety, efficacy, causality, or suitability for any person.

Methodology: https://peptidescanner.com/methodology/
Medical disclaimer: https://peptidescanner.com/medical-disclaimer/

### Suggested citation

PeptideScanner. "PubMed record PMID 22564709." Version 1, published 2026-08-11. https://peptidescanner.com/evidence/v1/peptides/lixisenatide.json#pubmed-pmid-22564709-lixisenatide-v1 SHA-256: 099a1d66c8c9eebc0492025b04deeb1a88f86868bf589148c678499dca2f227f.

---

<a id="pubmed-pmid-25012990-lixisenatide-v1"></a>

## PubMed record PMID 25012990

> PeptideScanner retained PubMed bibliographic metadata for PMID 25012990 at 2026-07-30T16:30:52.644Z. PubMed recorded a metadata revision date of 2026-01-28 and an Entrez history date of 2014-07-12. PeptideScanner associated this retained record with the identity slug lixisenatide. These dates describe PubMed metadata history, not the article's original publication date.

- Evidence object: `story:pubmed-pmid-25012990-lixisenatide:v1`
- Evidence domain: Literature metadata
- Date in source: 2026-01-28
- Source checked: 2026-07-30
- Published by PeptideScanner: 2026-08-12
- Story landing page: https://peptidescanner.com/stories/pubmed-pmid-25012990-lixisenatide/
- JSON record: https://peptidescanner.com/evidence/v1/peptides/lixisenatide.json#pubmed-pmid-25012990-lixisenatide-v1
- Content SHA-256: `f0226dcc9ef463ba03c4467af6720807472ac7dd18558487490c5b791c615a6f`

### Claims and source pins

#### Headline

PubMed record PMID 25012990 ([`pubmed-observation-pmid-25012990-2026-01-28-bf56af0c033d`](#source-pubmed-observation-pmid-25012990-2026-01-28-bf56af0c033d))

#### Summary

PeptideScanner retained PubMed bibliographic metadata for PMID 25012990 at 2026-07-30T16:30:52.644Z. PubMed recorded a metadata revision date of 2026-01-28 and an Entrez history date of 2014-07-12. PeptideScanner associated this retained record with the identity slug lixisenatide. These dates describe PubMed metadata history, not the article's original publication date. ([`pubmed-observation-pmid-25012990-2026-01-28-bf56af0c033d`](#source-pubmed-observation-pmid-25012990-2026-01-28-bf56af0c033d))

#### Paragraph 1

PeptideScanner retained PubMed bibliographic metadata for PMID 25012990 at 2026-07-30T16:30:52.644Z. PubMed recorded a metadata revision date of 2026-01-28 and an Entrez history date of 2014-07-12. PeptideScanner associated this retained record with the identity slug lixisenatide. These dates describe PubMed metadata history, not the article's original publication date. ([`pubmed-observation-pmid-25012990-2026-01-28-bf56af0c033d`](#source-pubmed-observation-pmid-25012990-2026-01-28-bf56af0c033d))

#### Paragraph 2

This page reports retained PubMed bibliographic metadata. It does not summarize the article, establish the article's publication date, or assert safety, efficacy, or scientific truth. ([`pubmed-observation-pmid-25012990-2026-01-28-bf56af0c033d`](#source-pubmed-observation-pmid-25012990-2026-01-28-bf56af0c033d))

### Sources

<a id="source-pubmed-observation-pmid-25012990-2026-01-28-bf56af0c033d"></a>
- **PubMed record PMID 25012990 · retained source version 1:2026-01-28:current:bf56af0c033df1459574b310479b1ac49d1a96141d62d151ad143dfe5b2ca87e** — PubMed; class A. [Open source](https://pubmed.ncbi.nlm.nih.gov/25012990/) (`pubmed-observation-pmid-25012990-2026-01-28-bf56af0c033d`)

### Correction lineage

No correction is recorded for this version.

### Reporting boundaries and unknowns

PeptideScanner reproduces bounded bibliographic metadata attributed to PubMed. It does not summarize or endorse the article's findings.

- Sources outside the selected public PeptideScanner bundle may exist and are not represented by this object.
- This object does not determine whether cited records agree, corroborate one another, or establish scientific truth.
- This object does not determine safety, efficacy, causality, or suitability for any person.

Methodology: https://peptidescanner.com/methodology/
Medical disclaimer: https://peptidescanner.com/medical-disclaimer/

### Suggested citation

PeptideScanner. "PubMed record PMID 25012990." Version 1, published 2026-08-12. https://peptidescanner.com/evidence/v1/peptides/lixisenatide.json#pubmed-pmid-25012990-lixisenatide-v1 SHA-256: f0226dcc9ef463ba03c4467af6720807472ac7dd18558487490c5b791c615a6f.

---

<a id="pubmed-pmid-25055456-lixisenatide-v1"></a>

## PubMed record PMID 25055456

> PeptideScanner retained PubMed bibliographic metadata for PMID 25055456 at 2026-07-30T16:30:52.649Z. PubMed recorded a metadata revision date of 2026-01-28 and an Entrez history date of 2014-07-25. PeptideScanner associated this retained record with the identity slug lixisenatide. These dates describe PubMed metadata history, not the article's original publication date.

- Evidence object: `story:pubmed-pmid-25055456-lixisenatide:v1`
- Evidence domain: Literature metadata
- Date in source: 2026-01-28
- Source checked: 2026-07-30
- Published by PeptideScanner: 2026-08-12
- Story landing page: https://peptidescanner.com/stories/pubmed-pmid-25055456-lixisenatide/
- JSON record: https://peptidescanner.com/evidence/v1/peptides/lixisenatide.json#pubmed-pmid-25055456-lixisenatide-v1
- Content SHA-256: `1ef5281e4bd9ae3f3b7df22717a16fa24b74f92aad62b85d5fbec9ad69d7abac`

### Claims and source pins

#### Headline

PubMed record PMID 25055456 ([`pubmed-observation-pmid-25055456-2026-01-28-34e5122c5276`](#source-pubmed-observation-pmid-25055456-2026-01-28-34e5122c5276))

#### Summary

PeptideScanner retained PubMed bibliographic metadata for PMID 25055456 at 2026-07-30T16:30:52.649Z. PubMed recorded a metadata revision date of 2026-01-28 and an Entrez history date of 2014-07-25. PeptideScanner associated this retained record with the identity slug lixisenatide. These dates describe PubMed metadata history, not the article's original publication date. ([`pubmed-observation-pmid-25055456-2026-01-28-34e5122c5276`](#source-pubmed-observation-pmid-25055456-2026-01-28-34e5122c5276))

#### Paragraph 1

PeptideScanner retained PubMed bibliographic metadata for PMID 25055456 at 2026-07-30T16:30:52.649Z. PubMed recorded a metadata revision date of 2026-01-28 and an Entrez history date of 2014-07-25. PeptideScanner associated this retained record with the identity slug lixisenatide. These dates describe PubMed metadata history, not the article's original publication date. ([`pubmed-observation-pmid-25055456-2026-01-28-34e5122c5276`](#source-pubmed-observation-pmid-25055456-2026-01-28-34e5122c5276))

#### Paragraph 2

This page reports retained PubMed bibliographic metadata. It does not summarize the article, establish the article's publication date, or assert safety, efficacy, or scientific truth. ([`pubmed-observation-pmid-25055456-2026-01-28-34e5122c5276`](#source-pubmed-observation-pmid-25055456-2026-01-28-34e5122c5276))

### Sources

<a id="source-pubmed-observation-pmid-25055456-2026-01-28-34e5122c5276"></a>
- **PubMed record PMID 25055456 · retained source version 1:2026-01-28:current:34e5122c527673bbe00a83a47d78d6b9e2871ac19212bc521695be2e971e5065** — PubMed; class A. [Open source](https://pubmed.ncbi.nlm.nih.gov/25055456/) (`pubmed-observation-pmid-25055456-2026-01-28-34e5122c5276`)

### Correction lineage

No correction is recorded for this version.

### Reporting boundaries and unknowns

PeptideScanner reproduces bounded bibliographic metadata attributed to PubMed. It does not summarize or endorse the article's findings.

- Sources outside the selected public PeptideScanner bundle may exist and are not represented by this object.
- This object does not determine whether cited records agree, corroborate one another, or establish scientific truth.
- This object does not determine safety, efficacy, causality, or suitability for any person.

Methodology: https://peptidescanner.com/methodology/
Medical disclaimer: https://peptidescanner.com/medical-disclaimer/

### Suggested citation

PeptideScanner. "PubMed record PMID 25055456." Version 1, published 2026-08-12. https://peptidescanner.com/evidence/v1/peptides/lixisenatide.json#pubmed-pmid-25055456-lixisenatide-v1 SHA-256: 1ef5281e4bd9ae3f3b7df22717a16fa24b74f92aad62b85d5fbec9ad69d7abac.

---

<a id="pubmed-pmid-25115916-lixisenatide-v1"></a>

## PubMed record PMID 25115916

> PeptideScanner retained PubMed bibliographic metadata for PMID 25115916 at 2026-07-30T16:30:52.653Z. PubMed recorded a metadata revision date of 2026-01-28 and an Entrez history date of 2014-08-14. PeptideScanner associated this retained record with the identity slug lixisenatide. These dates describe PubMed metadata history, not the article's original publication date.

- Evidence object: `story:pubmed-pmid-25115916-lixisenatide:v1`
- Evidence domain: Literature metadata
- Date in source: 2026-01-28
- Source checked: 2026-07-30
- Published by PeptideScanner: 2026-08-12
- Story landing page: https://peptidescanner.com/stories/pubmed-pmid-25115916-lixisenatide/
- JSON record: https://peptidescanner.com/evidence/v1/peptides/lixisenatide.json#pubmed-pmid-25115916-lixisenatide-v1
- Content SHA-256: `c5559587ded520ae20ffe665389a62675842fcb91655802f8fce065f59914cce`

### Claims and source pins

#### Headline

PubMed record PMID 25115916 ([`pubmed-observation-pmid-25115916-2026-01-28-9125355d4df9`](#source-pubmed-observation-pmid-25115916-2026-01-28-9125355d4df9))

#### Summary

PeptideScanner retained PubMed bibliographic metadata for PMID 25115916 at 2026-07-30T16:30:52.653Z. PubMed recorded a metadata revision date of 2026-01-28 and an Entrez history date of 2014-08-14. PeptideScanner associated this retained record with the identity slug lixisenatide. These dates describe PubMed metadata history, not the article's original publication date. ([`pubmed-observation-pmid-25115916-2026-01-28-9125355d4df9`](#source-pubmed-observation-pmid-25115916-2026-01-28-9125355d4df9))

#### Paragraph 1

PeptideScanner retained PubMed bibliographic metadata for PMID 25115916 at 2026-07-30T16:30:52.653Z. PubMed recorded a metadata revision date of 2026-01-28 and an Entrez history date of 2014-08-14. PeptideScanner associated this retained record with the identity slug lixisenatide. These dates describe PubMed metadata history, not the article's original publication date. ([`pubmed-observation-pmid-25115916-2026-01-28-9125355d4df9`](#source-pubmed-observation-pmid-25115916-2026-01-28-9125355d4df9))

#### Paragraph 2

This page reports retained PubMed bibliographic metadata. It does not summarize the article, establish the article's publication date, or assert safety, efficacy, or scientific truth. ([`pubmed-observation-pmid-25115916-2026-01-28-9125355d4df9`](#source-pubmed-observation-pmid-25115916-2026-01-28-9125355d4df9))

### Sources

<a id="source-pubmed-observation-pmid-25115916-2026-01-28-9125355d4df9"></a>
- **PubMed record PMID 25115916 · retained source version 1:2026-01-28:current:9125355d4df9e90eb556690f2e8c57356909bd602e068f9902c2c08d67038b88** — PubMed; class A. [Open source](https://pubmed.ncbi.nlm.nih.gov/25115916/) (`pubmed-observation-pmid-25115916-2026-01-28-9125355d4df9`)

### Correction lineage

No correction is recorded for this version.

### Reporting boundaries and unknowns

PeptideScanner reproduces bounded bibliographic metadata attributed to PubMed. It does not summarize or endorse the article's findings.

- Sources outside the selected public PeptideScanner bundle may exist and are not represented by this object.
- This object does not determine whether cited records agree, corroborate one another, or establish scientific truth.
- This object does not determine safety, efficacy, causality, or suitability for any person.

Methodology: https://peptidescanner.com/methodology/
Medical disclaimer: https://peptidescanner.com/medical-disclaimer/

### Suggested citation

PeptideScanner. "PubMed record PMID 25115916." Version 1, published 2026-08-12. https://peptidescanner.com/evidence/v1/peptides/lixisenatide.json#pubmed-pmid-25115916-lixisenatide-v1 SHA-256: c5559587ded520ae20ffe665389a62675842fcb91655802f8fce065f59914cce.

---

<a id="pubmed-pmid-25130920-lixisenatide-v1"></a>

## PubMed record PMID 25130920

> PeptideScanner retained PubMed bibliographic metadata for PMID 25130920 at 2026-07-30T16:30:52.654Z. PubMed recorded a metadata revision date of 2026-01-28 and an Entrez history date of 2014-08-19. PeptideScanner associated this retained record with the identity slug lixisenatide. These dates describe PubMed metadata history, not the article's original publication date.

- Evidence object: `story:pubmed-pmid-25130920-lixisenatide:v1`
- Evidence domain: Literature metadata
- Date in source: 2026-01-28
- Source checked: 2026-07-30
- Published by PeptideScanner: 2026-08-12
- Story landing page: https://peptidescanner.com/stories/pubmed-pmid-25130920-lixisenatide/
- JSON record: https://peptidescanner.com/evidence/v1/peptides/lixisenatide.json#pubmed-pmid-25130920-lixisenatide-v1
- Content SHA-256: `da1002f04cd8b3d72069d55b283bb951b3104b6d4f888aeb6e0247d3fece1e77`

### Claims and source pins

#### Headline

PubMed record PMID 25130920 ([`pubmed-observation-pmid-25130920-2026-01-28-9db17f73635e`](#source-pubmed-observation-pmid-25130920-2026-01-28-9db17f73635e))

#### Summary

PeptideScanner retained PubMed bibliographic metadata for PMID 25130920 at 2026-07-30T16:30:52.654Z. PubMed recorded a metadata revision date of 2026-01-28 and an Entrez history date of 2014-08-19. PeptideScanner associated this retained record with the identity slug lixisenatide. These dates describe PubMed metadata history, not the article's original publication date. ([`pubmed-observation-pmid-25130920-2026-01-28-9db17f73635e`](#source-pubmed-observation-pmid-25130920-2026-01-28-9db17f73635e))

#### Paragraph 1

PeptideScanner retained PubMed bibliographic metadata for PMID 25130920 at 2026-07-30T16:30:52.654Z. PubMed recorded a metadata revision date of 2026-01-28 and an Entrez history date of 2014-08-19. PeptideScanner associated this retained record with the identity slug lixisenatide. These dates describe PubMed metadata history, not the article's original publication date. ([`pubmed-observation-pmid-25130920-2026-01-28-9db17f73635e`](#source-pubmed-observation-pmid-25130920-2026-01-28-9db17f73635e))

#### Paragraph 2

This page reports retained PubMed bibliographic metadata. It does not summarize the article, establish the article's publication date, or assert safety, efficacy, or scientific truth. ([`pubmed-observation-pmid-25130920-2026-01-28-9db17f73635e`](#source-pubmed-observation-pmid-25130920-2026-01-28-9db17f73635e))

### Sources

<a id="source-pubmed-observation-pmid-25130920-2026-01-28-9db17f73635e"></a>
- **PubMed record PMID 25130920 · retained source version 1:2026-01-28:current:9db17f73635e3805d423d65b68a3b870355124a61633d123944ec58277b844e1** — PubMed; class A. [Open source](https://pubmed.ncbi.nlm.nih.gov/25130920/) (`pubmed-observation-pmid-25130920-2026-01-28-9db17f73635e`)

### Correction lineage

No correction is recorded for this version.

### Reporting boundaries and unknowns

PeptideScanner reproduces bounded bibliographic metadata attributed to PubMed. It does not summarize or endorse the article's findings.

- Sources outside the selected public PeptideScanner bundle may exist and are not represented by this object.
- This object does not determine whether cited records agree, corroborate one another, or establish scientific truth.
- This object does not determine safety, efficacy, causality, or suitability for any person.

Methodology: https://peptidescanner.com/methodology/
Medical disclaimer: https://peptidescanner.com/medical-disclaimer/

### Suggested citation

PeptideScanner. "PubMed record PMID 25130920." Version 1, published 2026-08-12. https://peptidescanner.com/evidence/v1/peptides/lixisenatide.json#pubmed-pmid-25130920-lixisenatide-v1 SHA-256: da1002f04cd8b3d72069d55b283bb951b3104b6d4f888aeb6e0247d3fece1e77.

---

<a id="pubmed-pmid-26039935-lixisenatide-v1"></a>

## PubMed record PMID 26039935

> PeptideScanner retained PubMed bibliographic metadata for PMID 26039935 at 2026-07-30T16:30:54.214Z. PubMed recorded a metadata revision date of 2026-01-28 and an Entrez history date of 2015-06-04. PeptideScanner associated this retained record with the identity slug lixisenatide. These dates describe PubMed metadata history, not the article's original publication date.

- Evidence object: `story:pubmed-pmid-26039935-lixisenatide:v1`
- Evidence domain: Literature metadata
- Date in source: 2026-01-28
- Source checked: 2026-07-30
- Published by PeptideScanner: 2026-08-12
- Story landing page: https://peptidescanner.com/stories/pubmed-pmid-26039935-lixisenatide/
- JSON record: https://peptidescanner.com/evidence/v1/peptides/lixisenatide.json#pubmed-pmid-26039935-lixisenatide-v1
- Content SHA-256: `fdfab2dcbe34a3e967a1734e3620973e533d06ec66f874c2ea33b266a9c2b750`

### Claims and source pins

#### Headline

PubMed record PMID 26039935 ([`pubmed-observation-pmid-26039935-2026-01-28-7198630cab0a`](#source-pubmed-observation-pmid-26039935-2026-01-28-7198630cab0a))

#### Summary

PeptideScanner retained PubMed bibliographic metadata for PMID 26039935 at 2026-07-30T16:30:54.214Z. PubMed recorded a metadata revision date of 2026-01-28 and an Entrez history date of 2015-06-04. PeptideScanner associated this retained record with the identity slug lixisenatide. These dates describe PubMed metadata history, not the article's original publication date. ([`pubmed-observation-pmid-26039935-2026-01-28-7198630cab0a`](#source-pubmed-observation-pmid-26039935-2026-01-28-7198630cab0a))

#### Paragraph 1

PeptideScanner retained PubMed bibliographic metadata for PMID 26039935 at 2026-07-30T16:30:54.214Z. PubMed recorded a metadata revision date of 2026-01-28 and an Entrez history date of 2015-06-04. PeptideScanner associated this retained record with the identity slug lixisenatide. These dates describe PubMed metadata history, not the article's original publication date. ([`pubmed-observation-pmid-26039935-2026-01-28-7198630cab0a`](#source-pubmed-observation-pmid-26039935-2026-01-28-7198630cab0a))

#### Paragraph 2

This page reports retained PubMed bibliographic metadata. It does not summarize the article, establish the article's publication date, or assert safety, efficacy, or scientific truth. ([`pubmed-observation-pmid-26039935-2026-01-28-7198630cab0a`](#source-pubmed-observation-pmid-26039935-2026-01-28-7198630cab0a))

### Sources

<a id="source-pubmed-observation-pmid-26039935-2026-01-28-7198630cab0a"></a>
- **PubMed record PMID 26039935 · retained source version 1:2026-01-28:current:7198630cab0aef52da73de00999391fa3fdab6930bd4bdc6750c13d1802f42d5** — PubMed; class A. [Open source](https://pubmed.ncbi.nlm.nih.gov/26039935/) (`pubmed-observation-pmid-26039935-2026-01-28-7198630cab0a`)

### Correction lineage

No correction is recorded for this version.

### Reporting boundaries and unknowns

PeptideScanner reproduces bounded bibliographic metadata attributed to PubMed. It does not summarize or endorse the article's findings.

- Sources outside the selected public PeptideScanner bundle may exist and are not represented by this object.
- This object does not determine whether cited records agree, corroborate one another, or establish scientific truth.
- This object does not determine safety, efficacy, causality, or suitability for any person.

Methodology: https://peptidescanner.com/methodology/
Medical disclaimer: https://peptidescanner.com/medical-disclaimer/

### Suggested citation

PeptideScanner. "PubMed record PMID 26039935." Version 1, published 2026-08-12. https://peptidescanner.com/evidence/v1/peptides/lixisenatide.json#pubmed-pmid-26039935-lixisenatide-v1 SHA-256: fdfab2dcbe34a3e967a1734e3620973e533d06ec66f874c2ea33b266a9c2b750.

---

<a id="pubmed-pmid-26423184-lixisenatide-v1"></a>

## PubMed record PMID 26423184

> PeptideScanner retained PubMed bibliographic metadata for PMID 26423184 at 2026-07-30T16:30:54.263Z. PubMed recorded a metadata revision date of 2026-01-28 and an Entrez history date of 2015-10-02. PeptideScanner associated this retained record with the identity slug lixisenatide. These dates describe PubMed metadata history, not the article's original publication date.

- Evidence object: `story:pubmed-pmid-26423184-lixisenatide:v1`
- Evidence domain: Literature metadata
- Date in source: 2026-01-28
- Source checked: 2026-07-30
- Published by PeptideScanner: 2026-08-12
- Story landing page: https://peptidescanner.com/stories/pubmed-pmid-26423184-lixisenatide/
- JSON record: https://peptidescanner.com/evidence/v1/peptides/lixisenatide.json#pubmed-pmid-26423184-lixisenatide-v1
- Content SHA-256: `b7c0d825d3e576f7201e7324f00a1df4593fecbc883b193669d0738032517ef5`

### Claims and source pins

#### Headline

PubMed record PMID 26423184 ([`pubmed-observation-pmid-26423184-2026-01-28-37b332c1191b`](#source-pubmed-observation-pmid-26423184-2026-01-28-37b332c1191b))

#### Summary

PeptideScanner retained PubMed bibliographic metadata for PMID 26423184 at 2026-07-30T16:30:54.263Z. PubMed recorded a metadata revision date of 2026-01-28 and an Entrez history date of 2015-10-02. PeptideScanner associated this retained record with the identity slug lixisenatide. These dates describe PubMed metadata history, not the article's original publication date. ([`pubmed-observation-pmid-26423184-2026-01-28-37b332c1191b`](#source-pubmed-observation-pmid-26423184-2026-01-28-37b332c1191b))

#### Paragraph 1

PeptideScanner retained PubMed bibliographic metadata for PMID 26423184 at 2026-07-30T16:30:54.263Z. PubMed recorded a metadata revision date of 2026-01-28 and an Entrez history date of 2015-10-02. PeptideScanner associated this retained record with the identity slug lixisenatide. These dates describe PubMed metadata history, not the article's original publication date. ([`pubmed-observation-pmid-26423184-2026-01-28-37b332c1191b`](#source-pubmed-observation-pmid-26423184-2026-01-28-37b332c1191b))

#### Paragraph 2

This page reports retained PubMed bibliographic metadata. It does not summarize the article, establish the article's publication date, or assert safety, efficacy, or scientific truth. ([`pubmed-observation-pmid-26423184-2026-01-28-37b332c1191b`](#source-pubmed-observation-pmid-26423184-2026-01-28-37b332c1191b))

### Sources

<a id="source-pubmed-observation-pmid-26423184-2026-01-28-37b332c1191b"></a>
- **PubMed record PMID 26423184 · retained source version 1:2026-01-28:current:37b332c1191b188f872f33654c537b5761733da11a75923125a2d5aa3fd30c65** — PubMed; class A. [Open source](https://pubmed.ncbi.nlm.nih.gov/26423184/) (`pubmed-observation-pmid-26423184-2026-01-28-37b332c1191b`)

### Correction lineage

No correction is recorded for this version.

### Reporting boundaries and unknowns

PeptideScanner reproduces bounded bibliographic metadata attributed to PubMed. It does not summarize or endorse the article's findings.

- Sources outside the selected public PeptideScanner bundle may exist and are not represented by this object.
- This object does not determine whether cited records agree, corroborate one another, or establish scientific truth.
- This object does not determine safety, efficacy, causality, or suitability for any person.

Methodology: https://peptidescanner.com/methodology/
Medical disclaimer: https://peptidescanner.com/medical-disclaimer/

### Suggested citation

PeptideScanner. "PubMed record PMID 26423184." Version 1, published 2026-08-12. https://peptidescanner.com/evidence/v1/peptides/lixisenatide.json#pubmed-pmid-26423184-lixisenatide-v1 SHA-256: b7c0d825d3e576f7201e7324f00a1df4593fecbc883b193669d0738032517ef5.

---

<a id="pubmed-pmid-26981945-lixisenatide-v1"></a>

## Lixisenatide in Type 2 Diabetes and Acute Coronary Syndrome.

> PubMed lists PMID 26981945 in The New England journal of medicine as Letter, Comment, with publication-date metadata of 2016-03-17 (day precision). PeptideScanner associated the retained record with the identity slug lixisenatide. These fields reproduce attributed bibliographic metadata and do not summarize or endorse the article's findings.

- Evidence object: `story:pubmed-pmid-26981945-lixisenatide:v1`
- Evidence domain: Literature metadata
- Date in source: 2025-01-03
- Source checked: 2026-07-30
- Published by PeptideScanner: 2026-08-13
- Story landing page: https://peptidescanner.com/stories/pubmed-pmid-26981945-lixisenatide/
- JSON record: https://peptidescanner.com/evidence/v1/peptides/lixisenatide.json#pubmed-pmid-26981945-lixisenatide-v1
- Content SHA-256: `e78e5bd9ff2d5e3c8c4d6c9c8d5a3b019ede6864a0e7e0223f366bf82e39255b`

### Claims and source pins

#### Headline

Lixisenatide in Type 2 Diabetes and Acute Coronary Syndrome. ([`pubmed-observation-pmid-26981945-2025-01-03-65738778898d`](#source-pubmed-observation-pmid-26981945-2025-01-03-65738778898d))

#### Summary

PubMed lists PMID 26981945 in The New England journal of medicine as Letter, Comment, with publication-date metadata of 2016-03-17 (day precision). PeptideScanner associated the retained record with the identity slug lixisenatide. These fields reproduce attributed bibliographic metadata and do not summarize or endorse the article's findings. ([`pubmed-observation-pmid-26981945-2025-01-03-65738778898d`](#source-pubmed-observation-pmid-26981945-2025-01-03-65738778898d))

#### Paragraph 1

PubMed lists PMID 26981945 in The New England journal of medicine as Letter, Comment, with publication-date metadata of 2016-03-17 (day precision). PeptideScanner associated the retained record with the identity slug lixisenatide. These fields reproduce attributed bibliographic metadata and do not summarize or endorse the article's findings. ([`pubmed-observation-pmid-26981945-2025-01-03-65738778898d`](#source-pubmed-observation-pmid-26981945-2025-01-03-65738778898d))

#### Paragraph 2

This page reproduces bounded bibliographic metadata attributed to PubMed. Its title and publication details are source metadata, not PeptideScanner's endorsement or an assertion of safety, efficacy, or scientific truth. ([`pubmed-observation-pmid-26981945-2025-01-03-65738778898d`](#source-pubmed-observation-pmid-26981945-2025-01-03-65738778898d))

### Sources

<a id="source-pubmed-observation-pmid-26981945-2025-01-03-65738778898d"></a>
- **Lixisenatide in Type 2 Diabetes and Acute Coronary Syndrome. · retained source version 1:2025-01-03:current:65738778898d04972bd549b87072d4a04b947807f2ab38db6ca7f2b50926b399** — PubMed; class A. [Open source](https://pubmed.ncbi.nlm.nih.gov/26981945/) (`pubmed-observation-pmid-26981945-2025-01-03-65738778898d`)

### Correction lineage

No correction is recorded for this version.

### Reporting boundaries and unknowns

PeptideScanner reproduces bounded bibliographic metadata attributed to PubMed. It does not summarize or endorse the article's findings.

- Sources outside the selected public PeptideScanner bundle may exist and are not represented by this object.
- This object does not determine whether cited records agree, corroborate one another, or establish scientific truth.
- This object does not determine safety, efficacy, causality, or suitability for any person.

Methodology: https://peptidescanner.com/methodology/
Medical disclaimer: https://peptidescanner.com/medical-disclaimer/

### Suggested citation

PeptideScanner. "Lixisenatide in Type 2 Diabetes and Acute Coronary Syndrome." Version 1, published 2026-08-13. https://peptidescanner.com/evidence/v1/peptides/lixisenatide.json#pubmed-pmid-26981945-lixisenatide-v1 SHA-256: e78e5bd9ff2d5e3c8c4d6c9c8d5a3b019ede6864a0e7e0223f366bf82e39255b.

---

<a id="pubmed-pmid-26981946-lixisenatide-v1"></a>

## Lixisenatide in Type 2 Diabetes and Acute Coronary Syndrome.

> PubMed lists PMID 26981946 in The New England journal of medicine as Letter, Comment, with publication-date metadata of 2016-03-17 (day precision). PeptideScanner associated the retained record with the identity slug lixisenatide. These fields reproduce attributed bibliographic metadata and do not summarize or endorse the article's findings.

- Evidence object: `story:pubmed-pmid-26981946-lixisenatide:v1`
- Evidence domain: Literature metadata
- Date in source: 2025-01-03
- Source checked: 2026-07-30
- Published by PeptideScanner: 2026-08-13
- Story landing page: https://peptidescanner.com/stories/pubmed-pmid-26981946-lixisenatide/
- JSON record: https://peptidescanner.com/evidence/v1/peptides/lixisenatide.json#pubmed-pmid-26981946-lixisenatide-v1
- Content SHA-256: `3af7d27ce5576eff6f7ffb41bda98aa46517b6bd4a8bd8412e8970af55044fcc`

### Claims and source pins

#### Headline

Lixisenatide in Type 2 Diabetes and Acute Coronary Syndrome. ([`pubmed-observation-pmid-26981946-2025-01-03-7632e611d7c2`](#source-pubmed-observation-pmid-26981946-2025-01-03-7632e611d7c2))

#### Summary

PubMed lists PMID 26981946 in The New England journal of medicine as Letter, Comment, with publication-date metadata of 2016-03-17 (day precision). PeptideScanner associated the retained record with the identity slug lixisenatide. These fields reproduce attributed bibliographic metadata and do not summarize or endorse the article's findings. ([`pubmed-observation-pmid-26981946-2025-01-03-7632e611d7c2`](#source-pubmed-observation-pmid-26981946-2025-01-03-7632e611d7c2))

#### Paragraph 1

PubMed lists PMID 26981946 in The New England journal of medicine as Letter, Comment, with publication-date metadata of 2016-03-17 (day precision). PeptideScanner associated the retained record with the identity slug lixisenatide. These fields reproduce attributed bibliographic metadata and do not summarize or endorse the article's findings. ([`pubmed-observation-pmid-26981946-2025-01-03-7632e611d7c2`](#source-pubmed-observation-pmid-26981946-2025-01-03-7632e611d7c2))

#### Paragraph 2

This page reproduces bounded bibliographic metadata attributed to PubMed. Its title and publication details are source metadata, not PeptideScanner's endorsement or an assertion of safety, efficacy, or scientific truth. ([`pubmed-observation-pmid-26981946-2025-01-03-7632e611d7c2`](#source-pubmed-observation-pmid-26981946-2025-01-03-7632e611d7c2))

### Sources

<a id="source-pubmed-observation-pmid-26981946-2025-01-03-7632e611d7c2"></a>
- **Lixisenatide in Type 2 Diabetes and Acute Coronary Syndrome. · retained source version 1:2025-01-03:current:7632e611d7c2dfdcfa48f51bda442a225451fb55639c70298780039f8030a8ca** — PubMed; class A. [Open source](https://pubmed.ncbi.nlm.nih.gov/26981946/) (`pubmed-observation-pmid-26981946-2025-01-03-7632e611d7c2`)

### Correction lineage

No correction is recorded for this version.

### Reporting boundaries and unknowns

PeptideScanner reproduces bounded bibliographic metadata attributed to PubMed. It does not summarize or endorse the article's findings.

- Sources outside the selected public PeptideScanner bundle may exist and are not represented by this object.
- This object does not determine whether cited records agree, corroborate one another, or establish scientific truth.
- This object does not determine safety, efficacy, causality, or suitability for any person.

Methodology: https://peptidescanner.com/methodology/
Medical disclaimer: https://peptidescanner.com/medical-disclaimer/

### Suggested citation

PeptideScanner. "Lixisenatide in Type 2 Diabetes and Acute Coronary Syndrome." Version 1, published 2026-08-13. https://peptidescanner.com/evidence/v1/peptides/lixisenatide.json#pubmed-pmid-26981946-lixisenatide-v1 SHA-256: 3af7d27ce5576eff6f7ffb41bda98aa46517b6bd4a8bd8412e8970af55044fcc.

---

<a id="pubmed-pmid-26981947-lixisenatide-v1"></a>

## Lixisenatide in Type 2 Diabetes and Acute Coronary Syndrome.

> PubMed lists PMID 26981947 in The New England journal of medicine as Letter, Comment, with publication-date metadata of 2016-03-17 (day precision). PeptideScanner associated the retained record with the identity slug lixisenatide. These fields reproduce attributed bibliographic metadata and do not summarize or endorse the article's findings.

- Evidence object: `story:pubmed-pmid-26981947-lixisenatide:v1`
- Evidence domain: Literature metadata
- Date in source: 2025-01-03
- Source checked: 2026-07-30
- Published by PeptideScanner: 2026-08-13
- Story landing page: https://peptidescanner.com/stories/pubmed-pmid-26981947-lixisenatide/
- JSON record: https://peptidescanner.com/evidence/v1/peptides/lixisenatide.json#pubmed-pmid-26981947-lixisenatide-v1
- Content SHA-256: `d14532e67fc0b8fc97cac3b562fe1e8e78bc609234e66c5f5505a66cd72eb2e9`

### Claims and source pins

#### Headline

Lixisenatide in Type 2 Diabetes and Acute Coronary Syndrome. ([`pubmed-observation-pmid-26981947-2025-01-03-d47f0ab7f825`](#source-pubmed-observation-pmid-26981947-2025-01-03-d47f0ab7f825))

#### Summary

PubMed lists PMID 26981947 in The New England journal of medicine as Letter, Comment, with publication-date metadata of 2016-03-17 (day precision). PeptideScanner associated the retained record with the identity slug lixisenatide. These fields reproduce attributed bibliographic metadata and do not summarize or endorse the article's findings. ([`pubmed-observation-pmid-26981947-2025-01-03-d47f0ab7f825`](#source-pubmed-observation-pmid-26981947-2025-01-03-d47f0ab7f825))

#### Paragraph 1

PubMed lists PMID 26981947 in The New England journal of medicine as Letter, Comment, with publication-date metadata of 2016-03-17 (day precision). PeptideScanner associated the retained record with the identity slug lixisenatide. These fields reproduce attributed bibliographic metadata and do not summarize or endorse the article's findings. ([`pubmed-observation-pmid-26981947-2025-01-03-d47f0ab7f825`](#source-pubmed-observation-pmid-26981947-2025-01-03-d47f0ab7f825))

#### Paragraph 2

This page reproduces bounded bibliographic metadata attributed to PubMed. Its title and publication details are source metadata, not PeptideScanner's endorsement or an assertion of safety, efficacy, or scientific truth. ([`pubmed-observation-pmid-26981947-2025-01-03-d47f0ab7f825`](#source-pubmed-observation-pmid-26981947-2025-01-03-d47f0ab7f825))

### Sources

<a id="source-pubmed-observation-pmid-26981947-2025-01-03-d47f0ab7f825"></a>
- **Lixisenatide in Type 2 Diabetes and Acute Coronary Syndrome. · retained source version 1:2025-01-03:current:d47f0ab7f8255c56112d27b8a878950727a863add0f76bce92c171584f9e8b9c** — PubMed; class A. [Open source](https://pubmed.ncbi.nlm.nih.gov/26981947/) (`pubmed-observation-pmid-26981947-2025-01-03-d47f0ab7f825`)

### Correction lineage

No correction is recorded for this version.

### Reporting boundaries and unknowns

PeptideScanner reproduces bounded bibliographic metadata attributed to PubMed. It does not summarize or endorse the article's findings.

- Sources outside the selected public PeptideScanner bundle may exist and are not represented by this object.
- This object does not determine whether cited records agree, corroborate one another, or establish scientific truth.
- This object does not determine safety, efficacy, causality, or suitability for any person.

Methodology: https://peptidescanner.com/methodology/
Medical disclaimer: https://peptidescanner.com/medical-disclaimer/

### Suggested citation

PeptideScanner. "Lixisenatide in Type 2 Diabetes and Acute Coronary Syndrome." Version 1, published 2026-08-13. https://peptidescanner.com/evidence/v1/peptides/lixisenatide.json#pubmed-pmid-26981947-lixisenatide-v1 SHA-256: d14532e67fc0b8fc97cac3b562fe1e8e78bc609234e66c5f5505a66cd72eb2e9.

---

<a id="pubmed-pmid-27200667-lixisenatide-v1"></a>

## PubMed record PMID 27200667

> PeptideScanner retained PubMed bibliographic metadata for PMID 27200667 at 2026-07-30T21:38:23.145Z. PubMed recorded a metadata revision date of 2016-05-21 and an Entrez history date of 2016-05-21. PeptideScanner associated this retained record with the identity slug lixisenatide. These dates describe PubMed metadata history, not the article's original publication date.

- Evidence object: `story:pubmed-pmid-27200667-lixisenatide:v1`
- Evidence domain: Literature metadata
- Date in source: 2016-05-21
- Source checked: 2026-07-30
- Published by PeptideScanner: 2026-08-10
- Story landing page: https://peptidescanner.com/stories/pubmed-pmid-27200667-lixisenatide/
- JSON record: https://peptidescanner.com/evidence/v1/peptides/lixisenatide.json#pubmed-pmid-27200667-lixisenatide-v1
- Content SHA-256: `b18241011eaaf6bebae55ec6f5c2e0cd6bab16a31d314dc166ef7b9267ceae94`

### Claims and source pins

#### Headline

PubMed record PMID 27200667 ([`pubmed-observation-pmid-27200667-2016-05-21-0f753785800e`](#source-pubmed-observation-pmid-27200667-2016-05-21-0f753785800e))

#### Summary

PeptideScanner retained PubMed bibliographic metadata for PMID 27200667 at 2026-07-30T21:38:23.145Z. PubMed recorded a metadata revision date of 2016-05-21 and an Entrez history date of 2016-05-21. PeptideScanner associated this retained record with the identity slug lixisenatide. These dates describe PubMed metadata history, not the article's original publication date. ([`pubmed-observation-pmid-27200667-2016-05-21-0f753785800e`](#source-pubmed-observation-pmid-27200667-2016-05-21-0f753785800e))

#### Paragraph 1

PeptideScanner retained PubMed bibliographic metadata for PMID 27200667 at 2026-07-30T21:38:23.145Z. PubMed recorded a metadata revision date of 2016-05-21 and an Entrez history date of 2016-05-21. PeptideScanner associated this retained record with the identity slug lixisenatide. These dates describe PubMed metadata history, not the article's original publication date. ([`pubmed-observation-pmid-27200667-2016-05-21-0f753785800e`](#source-pubmed-observation-pmid-27200667-2016-05-21-0f753785800e))

#### Paragraph 2

This page reports retained PubMed bibliographic metadata. It does not summarize the article, establish the article's publication date, or assert safety, efficacy, or scientific truth. ([`pubmed-observation-pmid-27200667-2016-05-21-0f753785800e`](#source-pubmed-observation-pmid-27200667-2016-05-21-0f753785800e))

### Sources

<a id="source-pubmed-observation-pmid-27200667-2016-05-21-0f753785800e"></a>
- **PubMed record PMID 27200667 · retained source version 1:2016-05-21:current:0f753785800e5079a56457b13f2f3f0c1b0d667ed702c6a31c4d6aed8859edd2** — PubMed; class A. [Open source](https://pubmed.ncbi.nlm.nih.gov/27200667/) (`pubmed-observation-pmid-27200667-2016-05-21-0f753785800e`)

### Correction lineage

No correction is recorded for this version.

### Reporting boundaries and unknowns

PeptideScanner reproduces bounded bibliographic metadata attributed to PubMed. It does not summarize or endorse the article's findings.

- Sources outside the selected public PeptideScanner bundle may exist and are not represented by this object.
- This object does not determine whether cited records agree, corroborate one another, or establish scientific truth.
- This object does not determine safety, efficacy, causality, or suitability for any person.

Methodology: https://peptidescanner.com/methodology/
Medical disclaimer: https://peptidescanner.com/medical-disclaimer/

### Suggested citation

PeptideScanner. "PubMed record PMID 27200667." Version 1, published 2026-08-10. https://peptidescanner.com/evidence/v1/peptides/lixisenatide.json#pubmed-pmid-27200667-lixisenatide-v1 SHA-256: b18241011eaaf6bebae55ec6f5c2e0cd6bab16a31d314dc166ef7b9267ceae94.

---

<a id="pubmed-pmid-27836130-lixisenatide-v1"></a>

## Insulin degludec, Lixisenatide, and Patiromer sorbitex calcium.

> PubMed lists PMID 27836130 in Journal of the American Pharmacists Association : JAPhA as Journal Article, with publication-date metadata of 2016 Nov-Dec (source-text precision). PeptideScanner associated the retained record with the identity slug lixisenatide. These fields reproduce attributed bibliographic metadata and do not summarize or endorse the article's findings.

- Evidence object: `story:pubmed-pmid-27836130-lixisenatide:v1`
- Evidence domain: Literature metadata
- Date in source: 2026-01-27
- Source checked: 2026-07-30
- Published by PeptideScanner: 2026-08-13
- Story landing page: https://peptidescanner.com/stories/pubmed-pmid-27836130-lixisenatide/
- JSON record: https://peptidescanner.com/evidence/v1/peptides/lixisenatide.json#pubmed-pmid-27836130-lixisenatide-v1
- Content SHA-256: `18439e5e484839aa02b58b076e5d707f2c6e8d9a4d68ec735a62a47f05b190ba`

### Claims and source pins

#### Headline

Insulin degludec, Lixisenatide, and Patiromer sorbitex calcium. ([`pubmed-observation-pmid-27836130-2026-01-27-2795fc8c5bfb`](#source-pubmed-observation-pmid-27836130-2026-01-27-2795fc8c5bfb))

#### Summary

PubMed lists PMID 27836130 in Journal of the American Pharmacists Association : JAPhA as Journal Article, with publication-date metadata of 2016 Nov-Dec (source-text precision). PeptideScanner associated the retained record with the identity slug lixisenatide. These fields reproduce attributed bibliographic metadata and do not summarize or endorse the article's findings. ([`pubmed-observation-pmid-27836130-2026-01-27-2795fc8c5bfb`](#source-pubmed-observation-pmid-27836130-2026-01-27-2795fc8c5bfb))

#### Paragraph 1

PubMed lists PMID 27836130 in Journal of the American Pharmacists Association : JAPhA as Journal Article, with publication-date metadata of 2016 Nov-Dec (source-text precision). PeptideScanner associated the retained record with the identity slug lixisenatide. These fields reproduce attributed bibliographic metadata and do not summarize or endorse the article's findings. ([`pubmed-observation-pmid-27836130-2026-01-27-2795fc8c5bfb`](#source-pubmed-observation-pmid-27836130-2026-01-27-2795fc8c5bfb))

#### Paragraph 2

This page reproduces bounded bibliographic metadata attributed to PubMed. Its title and publication details are source metadata, not PeptideScanner's endorsement or an assertion of safety, efficacy, or scientific truth. ([`pubmed-observation-pmid-27836130-2026-01-27-2795fc8c5bfb`](#source-pubmed-observation-pmid-27836130-2026-01-27-2795fc8c5bfb))

### Sources

<a id="source-pubmed-observation-pmid-27836130-2026-01-27-2795fc8c5bfb"></a>
- **Insulin degludec, Lixisenatide, and Patiromer sorbitex calcium. · retained source version 1:2026-01-27:current:2795fc8c5bfbb0eae47632e759de91744faf50a98c73dee7b744e54d38d86b9b** — PubMed; class A. [Open source](https://pubmed.ncbi.nlm.nih.gov/27836130/) (`pubmed-observation-pmid-27836130-2026-01-27-2795fc8c5bfb`)

### Correction lineage

No correction is recorded for this version.

### Reporting boundaries and unknowns

PeptideScanner reproduces bounded bibliographic metadata attributed to PubMed. It does not summarize or endorse the article's findings.

- Sources outside the selected public PeptideScanner bundle may exist and are not represented by this object.
- This object does not determine whether cited records agree, corroborate one another, or establish scientific truth.
- This object does not determine safety, efficacy, causality, or suitability for any person.

Methodology: https://peptidescanner.com/methodology/
Medical disclaimer: https://peptidescanner.com/medical-disclaimer/

### Suggested citation

PeptideScanner. "Insulin degludec, Lixisenatide, and Patiromer sorbitex calcium." Version 1, published 2026-08-13. https://peptidescanner.com/evidence/v1/peptides/lixisenatide.json#pubmed-pmid-27836130-lixisenatide-v1 SHA-256: 18439e5e484839aa02b58b076e5d707f2c6e8d9a4d68ec735a62a47f05b190ba.

---

<a id="pubmed-pmid-28118649-lixisenatide-v1"></a>

## Lixisenatide for type 2 diabetes.

> PubMed lists PMID 28118649 in The Medical letter on drugs and therapeutics as Journal Article, Review, with publication-date metadata of 2017-01-30 (day precision). PeptideScanner associated the retained record with the identity slug lixisenatide. These fields reproduce attributed bibliographic metadata and do not summarize or endorse the article's findings.

- Evidence object: `story:pubmed-pmid-28118649-lixisenatide:v1`
- Evidence domain: Literature metadata
- Date in source: 2026-01-27
- Source checked: 2026-07-30
- Published by PeptideScanner: 2026-08-13
- Story landing page: https://peptidescanner.com/stories/pubmed-pmid-28118649-lixisenatide/
- JSON record: https://peptidescanner.com/evidence/v1/peptides/lixisenatide.json#pubmed-pmid-28118649-lixisenatide-v1
- Content SHA-256: `3d1da9f1046fefff03dd117fab6d7dc055be21d47aaf0bb9d3a479fd13ffd7e7`

### Claims and source pins

#### Headline

Lixisenatide for type 2 diabetes. ([`pubmed-observation-pmid-28118649-2026-01-27-8c455dbe496c`](#source-pubmed-observation-pmid-28118649-2026-01-27-8c455dbe496c))

#### Summary

PubMed lists PMID 28118649 in The Medical letter on drugs and therapeutics as Journal Article, Review, with publication-date metadata of 2017-01-30 (day precision). PeptideScanner associated the retained record with the identity slug lixisenatide. These fields reproduce attributed bibliographic metadata and do not summarize or endorse the article's findings. ([`pubmed-observation-pmid-28118649-2026-01-27-8c455dbe496c`](#source-pubmed-observation-pmid-28118649-2026-01-27-8c455dbe496c))

#### Paragraph 1

PubMed lists PMID 28118649 in The Medical letter on drugs and therapeutics as Journal Article, Review, with publication-date metadata of 2017-01-30 (day precision). PeptideScanner associated the retained record with the identity slug lixisenatide. These fields reproduce attributed bibliographic metadata and do not summarize or endorse the article's findings. ([`pubmed-observation-pmid-28118649-2026-01-27-8c455dbe496c`](#source-pubmed-observation-pmid-28118649-2026-01-27-8c455dbe496c))

#### Paragraph 2

This page reproduces bounded bibliographic metadata attributed to PubMed. Its title and publication details are source metadata, not PeptideScanner's endorsement or an assertion of safety, efficacy, or scientific truth. ([`pubmed-observation-pmid-28118649-2026-01-27-8c455dbe496c`](#source-pubmed-observation-pmid-28118649-2026-01-27-8c455dbe496c))

### Sources

<a id="source-pubmed-observation-pmid-28118649-2026-01-27-8c455dbe496c"></a>
- **Lixisenatide for type 2 diabetes. · retained source version 1:2026-01-27:current:8c455dbe496c1c83123ead569de74aab5ccefde238443fd8fab14cb2fad228c8** — PubMed; class A. [Open source](https://pubmed.ncbi.nlm.nih.gov/28118649/) (`pubmed-observation-pmid-28118649-2026-01-27-8c455dbe496c`)

### Correction lineage

No correction is recorded for this version.

### Reporting boundaries and unknowns

PeptideScanner reproduces bounded bibliographic metadata attributed to PubMed. It does not summarize or endorse the article's findings.

- Sources outside the selected public PeptideScanner bundle may exist and are not represented by this object.
- This object does not determine whether cited records agree, corroborate one another, or establish scientific truth.
- This object does not determine safety, efficacy, causality, or suitability for any person.

Methodology: https://peptidescanner.com/methodology/
Medical disclaimer: https://peptidescanner.com/medical-disclaimer/

### Suggested citation

PeptideScanner. "Lixisenatide for type 2 diabetes." Version 1, published 2026-08-13. https://peptidescanner.com/evidence/v1/peptides/lixisenatide.json#pubmed-pmid-28118649-lixisenatide-v1 SHA-256: 3d1da9f1046fefff03dd117fab6d7dc055be21d47aaf0bb9d3a479fd13ffd7e7.

---

<a id="pubmed-pmid-28179743-lixisenatide-v1"></a>

## Lixisenatide.

> PubMed lists PMID 28179743 in Hospital pharmacy as Journal Article, with publication-date metadata of 2017-01 (month precision). PeptideScanner associated the retained record with the identity slug lixisenatide. These fields reproduce attributed bibliographic metadata and do not summarize or endorse the article's findings.

- Evidence object: `story:pubmed-pmid-28179743-lixisenatide:v1`
- Evidence domain: Literature metadata
- Date in source: 2024-05-23
- Source checked: 2026-07-30
- Published by PeptideScanner: 2026-08-13
- Story landing page: https://peptidescanner.com/stories/pubmed-pmid-28179743-lixisenatide/
- JSON record: https://peptidescanner.com/evidence/v1/peptides/lixisenatide.json#pubmed-pmid-28179743-lixisenatide-v1
- Content SHA-256: `269f2fbdb10e8b13f65f6c1db4fbe10979b68e45d560c656a5694a6e3307573e`

### Claims and source pins

#### Headline

Lixisenatide. ([`pubmed-observation-pmid-28179743-2024-05-23-b33587b3ae93`](#source-pubmed-observation-pmid-28179743-2024-05-23-b33587b3ae93))

#### Summary

PubMed lists PMID 28179743 in Hospital pharmacy as Journal Article, with publication-date metadata of 2017-01 (month precision). PeptideScanner associated the retained record with the identity slug lixisenatide. These fields reproduce attributed bibliographic metadata and do not summarize or endorse the article's findings. ([`pubmed-observation-pmid-28179743-2024-05-23-b33587b3ae93`](#source-pubmed-observation-pmid-28179743-2024-05-23-b33587b3ae93))

#### Paragraph 1

PubMed lists PMID 28179743 in Hospital pharmacy as Journal Article, with publication-date metadata of 2017-01 (month precision). PeptideScanner associated the retained record with the identity slug lixisenatide. These fields reproduce attributed bibliographic metadata and do not summarize or endorse the article's findings. ([`pubmed-observation-pmid-28179743-2024-05-23-b33587b3ae93`](#source-pubmed-observation-pmid-28179743-2024-05-23-b33587b3ae93))

#### Paragraph 2

This page reproduces bounded bibliographic metadata attributed to PubMed. Its title and publication details are source metadata, not PeptideScanner's endorsement or an assertion of safety, efficacy, or scientific truth. ([`pubmed-observation-pmid-28179743-2024-05-23-b33587b3ae93`](#source-pubmed-observation-pmid-28179743-2024-05-23-b33587b3ae93))

### Sources

<a id="source-pubmed-observation-pmid-28179743-2024-05-23-b33587b3ae93"></a>
- **Lixisenatide. · retained source version 1:2024-05-23:current:b33587b3ae9322ae9bf90902711e5e4334d25a57e90020679fa48e4b65c8609c** — PubMed; class A. [Open source](https://pubmed.ncbi.nlm.nih.gov/28179743/) (`pubmed-observation-pmid-28179743-2024-05-23-b33587b3ae93`)

### Correction lineage

No correction is recorded for this version.

### Reporting boundaries and unknowns

PeptideScanner reproduces bounded bibliographic metadata attributed to PubMed. It does not summarize or endorse the article's findings.

- Sources outside the selected public PeptideScanner bundle may exist and are not represented by this object.
- This object does not determine whether cited records agree, corroborate one another, or establish scientific truth.
- This object does not determine safety, efficacy, causality, or suitability for any person.

Methodology: https://peptidescanner.com/methodology/
Medical disclaimer: https://peptidescanner.com/medical-disclaimer/

### Suggested citation

PeptideScanner. "Lixisenatide." Version 1, published 2026-08-13. https://peptidescanner.com/evidence/v1/peptides/lixisenatide.json#pubmed-pmid-28179743-lixisenatide-v1 SHA-256: 269f2fbdb10e8b13f65f6c1db4fbe10979b68e45d560c656a5694a6e3307573e.

---

<a id="pubmed-pmid-28420696-lixisenatide-v1"></a>

## PubMed record PMID 28420696

> PeptideScanner retained PubMed bibliographic metadata for PMID 28420696 at 2026-07-30T20:44:20.465Z. PubMed recorded a metadata revision date of 2019-11-20 and an Entrez history date of 2017-04-20. PeptideScanner associated this retained record with the identity slug lixisenatide. These dates describe PubMed metadata history, not the article's original publication date.

- Evidence object: `story:pubmed-pmid-28420696-lixisenatide:v1`
- Evidence domain: Literature metadata
- Date in source: 2019-11-20
- Source checked: 2026-07-30
- Published by PeptideScanner: 2026-08-11
- Story landing page: https://peptidescanner.com/stories/pubmed-pmid-28420696-lixisenatide/
- JSON record: https://peptidescanner.com/evidence/v1/peptides/lixisenatide.json#pubmed-pmid-28420696-lixisenatide-v1
- Content SHA-256: `4b7d12cc8f752bee55a22a68f99f8246a64089f1e18dc2460be7ed47af7ddef9`

### Claims and source pins

#### Headline

PubMed record PMID 28420696 ([`pubmed-observation-pmid-28420696-2019-11-20-dcf9d6808ccb`](#source-pubmed-observation-pmid-28420696-2019-11-20-dcf9d6808ccb))

#### Summary

PeptideScanner retained PubMed bibliographic metadata for PMID 28420696 at 2026-07-30T20:44:20.465Z. PubMed recorded a metadata revision date of 2019-11-20 and an Entrez history date of 2017-04-20. PeptideScanner associated this retained record with the identity slug lixisenatide. These dates describe PubMed metadata history, not the article's original publication date. ([`pubmed-observation-pmid-28420696-2019-11-20-dcf9d6808ccb`](#source-pubmed-observation-pmid-28420696-2019-11-20-dcf9d6808ccb))

#### Paragraph 1

PeptideScanner retained PubMed bibliographic metadata for PMID 28420696 at 2026-07-30T20:44:20.465Z. PubMed recorded a metadata revision date of 2019-11-20 and an Entrez history date of 2017-04-20. PeptideScanner associated this retained record with the identity slug lixisenatide. These dates describe PubMed metadata history, not the article's original publication date. ([`pubmed-observation-pmid-28420696-2019-11-20-dcf9d6808ccb`](#source-pubmed-observation-pmid-28420696-2019-11-20-dcf9d6808ccb))

#### Paragraph 2

This page reports retained PubMed bibliographic metadata. It does not summarize the article, establish the article's publication date, or assert safety, efficacy, or scientific truth. ([`pubmed-observation-pmid-28420696-2019-11-20-dcf9d6808ccb`](#source-pubmed-observation-pmid-28420696-2019-11-20-dcf9d6808ccb))

### Sources

<a id="source-pubmed-observation-pmid-28420696-2019-11-20-dcf9d6808ccb"></a>
- **PubMed record PMID 28420696 · retained source version 1:2019-11-20:current:dcf9d6808ccbb26d97534961cf338fb5676c0cb37d9d542af7cc3d81942d1c4b** — PubMed; class A. [Open source](https://pubmed.ncbi.nlm.nih.gov/28420696/) (`pubmed-observation-pmid-28420696-2019-11-20-dcf9d6808ccb`)

### Correction lineage

No correction is recorded for this version.

### Reporting boundaries and unknowns

PeptideScanner reproduces bounded bibliographic metadata attributed to PubMed. It does not summarize or endorse the article's findings.

- Sources outside the selected public PeptideScanner bundle may exist and are not represented by this object.
- This object does not determine whether cited records agree, corroborate one another, or establish scientific truth.
- This object does not determine safety, efficacy, causality, or suitability for any person.

Methodology: https://peptidescanner.com/methodology/
Medical disclaimer: https://peptidescanner.com/medical-disclaimer/

### Suggested citation

PeptideScanner. "PubMed record PMID 28420696." Version 1, published 2026-08-11. https://peptidescanner.com/evidence/v1/peptides/lixisenatide.json#pubmed-pmid-28420696-lixisenatide-v1 SHA-256: 4b7d12cc8f752bee55a22a68f99f8246a64089f1e18dc2460be7ed47af7ddef9.

---

<a id="pubmed-pmid-28428368-lixisenatide-v1"></a>

## PubMed record PMID 28428368

> PeptideScanner retained PubMed bibliographic metadata for PMID 28428368 at 2026-07-30T20:44:20.465Z. PubMed recorded a metadata revision date of 2019-11-20 and an Entrez history date of 2017-04-22. PeptideScanner associated this retained record with the identity slug lixisenatide. These dates describe PubMed metadata history, not the article's original publication date.

- Evidence object: `story:pubmed-pmid-28428368-lixisenatide:v1`
- Evidence domain: Literature metadata
- Date in source: 2019-11-20
- Source checked: 2026-07-30
- Published by PeptideScanner: 2026-08-10
- Story landing page: https://peptidescanner.com/stories/pubmed-pmid-28428368-lixisenatide/
- JSON record: https://peptidescanner.com/evidence/v1/peptides/lixisenatide.json#pubmed-pmid-28428368-lixisenatide-v1
- Content SHA-256: `78eb0d331a3da7515fac8fff72a933b6e16a75ab4c0a0a84e96b668b5d307877`

### Claims and source pins

#### Headline

PubMed record PMID 28428368 ([`pubmed-observation-pmid-28428368-2019-11-20-50363b232659`](#source-pubmed-observation-pmid-28428368-2019-11-20-50363b232659))

#### Summary

PeptideScanner retained PubMed bibliographic metadata for PMID 28428368 at 2026-07-30T20:44:20.465Z. PubMed recorded a metadata revision date of 2019-11-20 and an Entrez history date of 2017-04-22. PeptideScanner associated this retained record with the identity slug lixisenatide. These dates describe PubMed metadata history, not the article's original publication date. ([`pubmed-observation-pmid-28428368-2019-11-20-50363b232659`](#source-pubmed-observation-pmid-28428368-2019-11-20-50363b232659))

#### Paragraph 1

PeptideScanner retained PubMed bibliographic metadata for PMID 28428368 at 2026-07-30T20:44:20.465Z. PubMed recorded a metadata revision date of 2019-11-20 and an Entrez history date of 2017-04-22. PeptideScanner associated this retained record with the identity slug lixisenatide. These dates describe PubMed metadata history, not the article's original publication date. ([`pubmed-observation-pmid-28428368-2019-11-20-50363b232659`](#source-pubmed-observation-pmid-28428368-2019-11-20-50363b232659))

#### Paragraph 2

This page reports retained PubMed bibliographic metadata. It does not summarize the article, establish the article's publication date, or assert safety, efficacy, or scientific truth. ([`pubmed-observation-pmid-28428368-2019-11-20-50363b232659`](#source-pubmed-observation-pmid-28428368-2019-11-20-50363b232659))

### Sources

<a id="source-pubmed-observation-pmid-28428368-2019-11-20-50363b232659"></a>
- **PubMed record PMID 28428368 · retained source version 1:2019-11-20:current:50363b232659e931fdd652bde27977b3cab6fe17a8e9bb0d47eab741983c92f5** — PubMed; class A. [Open source](https://pubmed.ncbi.nlm.nih.gov/28428368/) (`pubmed-observation-pmid-28428368-2019-11-20-50363b232659`)

### Correction lineage

No correction is recorded for this version.

### Reporting boundaries and unknowns

PeptideScanner reproduces bounded bibliographic metadata attributed to PubMed. It does not summarize or endorse the article's findings.

- Sources outside the selected public PeptideScanner bundle may exist and are not represented by this object.
- This object does not determine whether cited records agree, corroborate one another, or establish scientific truth.
- This object does not determine safety, efficacy, causality, or suitability for any person.

Methodology: https://peptidescanner.com/methodology/
Medical disclaimer: https://peptidescanner.com/medical-disclaimer/

### Suggested citation

PeptideScanner. "PubMed record PMID 28428368." Version 1, published 2026-08-10. https://peptidescanner.com/evidence/v1/peptides/lixisenatide.json#pubmed-pmid-28428368-lixisenatide-v1 SHA-256: 78eb0d331a3da7515fac8fff72a933b6e16a75ab4c0a0a84e96b668b5d307877.

---

<a id="pubmed-pmid-28925668-lixisenatide-v1"></a>

## Lixisenatide (Adlyxin) for Type 2 Diabetes Mellitus.

> PubMed lists PMID 28925668 in American family physician as Journal Article, with publication-date metadata of 2017-08-15 (day precision). PeptideScanner associated the retained record with the identity slug lixisenatide. These fields reproduce attributed bibliographic metadata and do not summarize or endorse the article's findings.

- Evidence object: `story:pubmed-pmid-28925668-lixisenatide:v1`
- Evidence domain: Literature metadata
- Date in source: 2026-01-27
- Source checked: 2026-07-30
- Published by PeptideScanner: 2026-08-13
- Story landing page: https://peptidescanner.com/stories/pubmed-pmid-28925668-lixisenatide/
- JSON record: https://peptidescanner.com/evidence/v1/peptides/lixisenatide.json#pubmed-pmid-28925668-lixisenatide-v1
- Content SHA-256: `13fcb7283d7ba6b9dc2164a6c8e72b85f4fca5269f1e4de5d7130bf02f751dfe`

### Claims and source pins

#### Headline

Lixisenatide (Adlyxin) for Type 2 Diabetes Mellitus. ([`pubmed-observation-pmid-28925668-2026-01-27-742d57981f1b`](#source-pubmed-observation-pmid-28925668-2026-01-27-742d57981f1b))

#### Summary

PubMed lists PMID 28925668 in American family physician as Journal Article, with publication-date metadata of 2017-08-15 (day precision). PeptideScanner associated the retained record with the identity slug lixisenatide. These fields reproduce attributed bibliographic metadata and do not summarize or endorse the article's findings. ([`pubmed-observation-pmid-28925668-2026-01-27-742d57981f1b`](#source-pubmed-observation-pmid-28925668-2026-01-27-742d57981f1b))

#### Paragraph 1

PubMed lists PMID 28925668 in American family physician as Journal Article, with publication-date metadata of 2017-08-15 (day precision). PeptideScanner associated the retained record with the identity slug lixisenatide. These fields reproduce attributed bibliographic metadata and do not summarize or endorse the article's findings. ([`pubmed-observation-pmid-28925668-2026-01-27-742d57981f1b`](#source-pubmed-observation-pmid-28925668-2026-01-27-742d57981f1b))

#### Paragraph 2

This page reproduces bounded bibliographic metadata attributed to PubMed. Its title and publication details are source metadata, not PeptideScanner's endorsement or an assertion of safety, efficacy, or scientific truth. ([`pubmed-observation-pmid-28925668-2026-01-27-742d57981f1b`](#source-pubmed-observation-pmid-28925668-2026-01-27-742d57981f1b))

### Sources

<a id="source-pubmed-observation-pmid-28925668-2026-01-27-742d57981f1b"></a>
- **Lixisenatide (Adlyxin) for Type 2 Diabetes Mellitus. · retained source version 1:2026-01-27:current:742d57981f1b6feb5dafabb69d9dcfd2255af5923c7508466b660678866d8e59** — PubMed; class A. [Open source](https://pubmed.ncbi.nlm.nih.gov/28925668/) (`pubmed-observation-pmid-28925668-2026-01-27-742d57981f1b`)

### Correction lineage

No correction is recorded for this version.

### Reporting boundaries and unknowns

PeptideScanner reproduces bounded bibliographic metadata attributed to PubMed. It does not summarize or endorse the article's findings.

- Sources outside the selected public PeptideScanner bundle may exist and are not represented by this object.
- This object does not determine whether cited records agree, corroborate one another, or establish scientific truth.
- This object does not determine safety, efficacy, causality, or suitability for any person.

Methodology: https://peptidescanner.com/methodology/
Medical disclaimer: https://peptidescanner.com/medical-disclaimer/

### Suggested citation

PeptideScanner. "Lixisenatide (Adlyxin) for Type 2 Diabetes Mellitus." Version 1, published 2026-08-13. https://peptidescanner.com/evidence/v1/peptides/lixisenatide.json#pubmed-pmid-28925668-lixisenatide-v1 SHA-256: 13fcb7283d7ba6b9dc2164a6c8e72b85f4fca5269f1e4de5d7130bf02f751dfe.

---

<a id="pubmed-pmid-30206903-lixisenatide-v1"></a>

## Comprehensive Evaluation of Combination Therapy with Basal Insulin and Either Lixisenatide or Vildagliptin in Japanese Patients with Type 2 Diabetes: A Randomized, Open-Label, Parallel-Group, Multice…

> PubMed lists PMID 30206903 in Diabetes therapy : research, treatment and education of diabetes and related disorders as Journal Article, with publication-date metadata of 2018-09-11 (day precision). PeptideScanner associated the retained record with the identity slug lixisenatide. These fields reproduce attributed bibliographic metadata and do not summarize or endorse the article's findings.

- Evidence object: `story:pubmed-pmid-30206903-lixisenatide:v1`
- Evidence domain: Literature metadata
- Date in source: 2023-05-22
- Source checked: 2026-07-30
- Published by PeptideScanner: 2026-08-13
- Story landing page: https://peptidescanner.com/stories/pubmed-pmid-30206903-lixisenatide/
- JSON record: https://peptidescanner.com/evidence/v1/peptides/lixisenatide.json#pubmed-pmid-30206903-lixisenatide-v1
- Content SHA-256: `18220bf880f919b40018991f228a4e22e68198915a127d667aeee77aaab74f79`

### Claims and source pins

#### Headline

Comprehensive Evaluation of Combination Therapy with Basal Insulin and Either Lixisenatide or Vildagliptin in Japanese Patients with Type 2 Diabetes: A Randomized, Open-Label, Parallel-Group, Multice… ([`pubmed-observation-pmid-30206903-2023-05-22-502cc3c3cdd1`](#source-pubmed-observation-pmid-30206903-2023-05-22-502cc3c3cdd1))

#### Summary

PubMed lists PMID 30206903 in Diabetes therapy : research, treatment and education of diabetes and related disorders as Journal Article, with publication-date metadata of 2018-09-11 (day precision). PeptideScanner associated the retained record with the identity slug lixisenatide. These fields reproduce attributed bibliographic metadata and do not summarize or endorse the article's findings. ([`pubmed-observation-pmid-30206903-2023-05-22-502cc3c3cdd1`](#source-pubmed-observation-pmid-30206903-2023-05-22-502cc3c3cdd1))

#### Paragraph 1

PubMed lists PMID 30206903 in Diabetes therapy : research, treatment and education of diabetes and related disorders as Journal Article, with publication-date metadata of 2018-09-11 (day precision). PeptideScanner associated the retained record with the identity slug lixisenatide. These fields reproduce attributed bibliographic metadata and do not summarize or endorse the article's findings. ([`pubmed-observation-pmid-30206903-2023-05-22-502cc3c3cdd1`](#source-pubmed-observation-pmid-30206903-2023-05-22-502cc3c3cdd1))

#### Paragraph 2

This page reproduces bounded bibliographic metadata attributed to PubMed. Its title and publication details are source metadata, not PeptideScanner's endorsement or an assertion of safety, efficacy, or scientific truth. ([`pubmed-observation-pmid-30206903-2023-05-22-502cc3c3cdd1`](#source-pubmed-observation-pmid-30206903-2023-05-22-502cc3c3cdd1))

### Sources

<a id="source-pubmed-observation-pmid-30206903-2023-05-22-502cc3c3cdd1"></a>
- **Comprehensive Evaluation of Combination Therapy with Basal Insulin and Either Lixisenatide or Vildagliptin in Japanese Patients with Type 2 Diabetes: A Randomized, Open-Label, Parallel-Group, Multicenter Study. · retained source version 1:2023-05-22:current:502cc3c3cdd1b02975408a6a37541b69f2c1124087ecd4220c5cf269bfa55ebb** — PubMed; class A. [Open source](https://pubmed.ncbi.nlm.nih.gov/30206903/) (`pubmed-observation-pmid-30206903-2023-05-22-502cc3c3cdd1`)

### Correction lineage

No correction is recorded for this version.

### Reporting boundaries and unknowns

PeptideScanner reproduces bounded bibliographic metadata attributed to PubMed. It does not summarize or endorse the article's findings.

- Sources outside the selected public PeptideScanner bundle may exist and are not represented by this object.
- This object does not determine whether cited records agree, corroborate one another, or establish scientific truth.
- This object does not determine safety, efficacy, causality, or suitability for any person.

Methodology: https://peptidescanner.com/methodology/
Medical disclaimer: https://peptidescanner.com/medical-disclaimer/

### Suggested citation

PeptideScanner. "Comprehensive Evaluation of Combination Therapy with Basal Insulin and Either Lixisenatide or Vildagliptin in Japanese Patients with Type 2 Diabetes: A Randomized, Open-Label, Parallel-Group, Multice…." Version 1, published 2026-08-13. https://peptidescanner.com/evidence/v1/peptides/lixisenatide.json#pubmed-pmid-30206903-lixisenatide-v1 SHA-256: 18220bf880f919b40018991f228a4e22e68198915a127d667aeee77aaab74f79.

---

<a id="pubmed-pmid-30656523-lixisenatide-v1"></a>

## Austrian Experience with Lixisenatide Under Real-Life Conditions: A Prospective Observational Study.

> PubMed lists PMID 30656523 in Diabetes therapy : research, treatment and education of diabetes and related disorders as Journal Article, with publication-date metadata of 2019-01-17 (day precision). PeptideScanner associated the retained record with the identity slug lixisenatide. These fields reproduce attributed bibliographic metadata and do not summarize or endorse the article's findings.

- Evidence object: `story:pubmed-pmid-30656523-lixisenatide:v1`
- Evidence domain: Literature metadata
- Date in source: 2021-01-09
- Source checked: 2026-07-30
- Published by PeptideScanner: 2026-08-13
- Story landing page: https://peptidescanner.com/stories/pubmed-pmid-30656523-lixisenatide/
- JSON record: https://peptidescanner.com/evidence/v1/peptides/lixisenatide.json#pubmed-pmid-30656523-lixisenatide-v1
- Content SHA-256: `324164c6121df1d3dedd7cae4c296fc50bebbd26aa41ffdb8eab2c02f90c5d20`

### Claims and source pins

#### Headline

Austrian Experience with Lixisenatide Under Real-Life Conditions: A Prospective Observational Study. ([`pubmed-observation-pmid-30656523-2021-01-09-12fd34f9e46d`](#source-pubmed-observation-pmid-30656523-2021-01-09-12fd34f9e46d))

#### Summary

PubMed lists PMID 30656523 in Diabetes therapy : research, treatment and education of diabetes and related disorders as Journal Article, with publication-date metadata of 2019-01-17 (day precision). PeptideScanner associated the retained record with the identity slug lixisenatide. These fields reproduce attributed bibliographic metadata and do not summarize or endorse the article's findings. ([`pubmed-observation-pmid-30656523-2021-01-09-12fd34f9e46d`](#source-pubmed-observation-pmid-30656523-2021-01-09-12fd34f9e46d))

#### Paragraph 1

PubMed lists PMID 30656523 in Diabetes therapy : research, treatment and education of diabetes and related disorders as Journal Article, with publication-date metadata of 2019-01-17 (day precision). PeptideScanner associated the retained record with the identity slug lixisenatide. These fields reproduce attributed bibliographic metadata and do not summarize or endorse the article's findings. ([`pubmed-observation-pmid-30656523-2021-01-09-12fd34f9e46d`](#source-pubmed-observation-pmid-30656523-2021-01-09-12fd34f9e46d))

#### Paragraph 2

This page reproduces bounded bibliographic metadata attributed to PubMed. Its title and publication details are source metadata, not PeptideScanner's endorsement or an assertion of safety, efficacy, or scientific truth. ([`pubmed-observation-pmid-30656523-2021-01-09-12fd34f9e46d`](#source-pubmed-observation-pmid-30656523-2021-01-09-12fd34f9e46d))

### Sources

<a id="source-pubmed-observation-pmid-30656523-2021-01-09-12fd34f9e46d"></a>
- **Austrian Experience with Lixisenatide Under Real-Life Conditions: A Prospective Observational Study. · retained source version 1:2021-01-09:current:12fd34f9e46dd89177530955d8da23046910dd009f9a9525fea7956ae10e9ab1** — PubMed; class A. [Open source](https://pubmed.ncbi.nlm.nih.gov/30656523/) (`pubmed-observation-pmid-30656523-2021-01-09-12fd34f9e46d`)

### Correction lineage

No correction is recorded for this version.

### Reporting boundaries and unknowns

PeptideScanner reproduces bounded bibliographic metadata attributed to PubMed. It does not summarize or endorse the article's findings.

- Sources outside the selected public PeptideScanner bundle may exist and are not represented by this object.
- This object does not determine whether cited records agree, corroborate one another, or establish scientific truth.
- This object does not determine safety, efficacy, causality, or suitability for any person.

Methodology: https://peptidescanner.com/methodology/
Medical disclaimer: https://peptidescanner.com/medical-disclaimer/

### Suggested citation

PeptideScanner. "Austrian Experience with Lixisenatide Under Real-Life Conditions: A Prospective Observational Study." Version 1, published 2026-08-13. https://peptidescanner.com/evidence/v1/peptides/lixisenatide.json#pubmed-pmid-30656523-lixisenatide-v1 SHA-256: 324164c6121df1d3dedd7cae4c296fc50bebbd26aa41ffdb8eab2c02f90c5d20.

---

<a id="pubmed-pmid-30736157-lixisenatide-v1"></a>

## PubMed record PMID 30736157

> PeptideScanner retained PubMed bibliographic metadata for PMID 30736157 at 2026-07-30T20:44:20.586Z. PubMed recorded a metadata revision date of 2019-11-20 and an Entrez history date of 2019-02-10. PeptideScanner associated this retained record with the identity slug lixisenatide. These dates describe PubMed metadata history, not the article's original publication date.

- Evidence object: `story:pubmed-pmid-30736157-lixisenatide:v1`
- Evidence domain: Literature metadata
- Date in source: 2019-11-20
- Source checked: 2026-07-30
- Published by PeptideScanner: 2026-08-12
- Story landing page: https://peptidescanner.com/stories/pubmed-pmid-30736157-lixisenatide/
- JSON record: https://peptidescanner.com/evidence/v1/peptides/lixisenatide.json#pubmed-pmid-30736157-lixisenatide-v1
- Content SHA-256: `7bda709af9d8195b1f2e9750034aa88fc79a5c131c056fb5bcbcc6fc0498aef8`

### Claims and source pins

#### Headline

PubMed record PMID 30736157 ([`pubmed-observation-pmid-30736157-2019-11-20-6a7da782e551`](#source-pubmed-observation-pmid-30736157-2019-11-20-6a7da782e551))

#### Summary

PeptideScanner retained PubMed bibliographic metadata for PMID 30736157 at 2026-07-30T20:44:20.586Z. PubMed recorded a metadata revision date of 2019-11-20 and an Entrez history date of 2019-02-10. PeptideScanner associated this retained record with the identity slug lixisenatide. These dates describe PubMed metadata history, not the article's original publication date. ([`pubmed-observation-pmid-30736157-2019-11-20-6a7da782e551`](#source-pubmed-observation-pmid-30736157-2019-11-20-6a7da782e551))

#### Paragraph 1

PeptideScanner retained PubMed bibliographic metadata for PMID 30736157 at 2026-07-30T20:44:20.586Z. PubMed recorded a metadata revision date of 2019-11-20 and an Entrez history date of 2019-02-10. PeptideScanner associated this retained record with the identity slug lixisenatide. These dates describe PubMed metadata history, not the article's original publication date. ([`pubmed-observation-pmid-30736157-2019-11-20-6a7da782e551`](#source-pubmed-observation-pmid-30736157-2019-11-20-6a7da782e551))

#### Paragraph 2

This page reports retained PubMed bibliographic metadata. It does not summarize the article, establish the article's publication date, or assert safety, efficacy, or scientific truth. ([`pubmed-observation-pmid-30736157-2019-11-20-6a7da782e551`](#source-pubmed-observation-pmid-30736157-2019-11-20-6a7da782e551))

### Sources

<a id="source-pubmed-observation-pmid-30736157-2019-11-20-6a7da782e551"></a>
- **PubMed record PMID 30736157 · retained source version 1:2019-11-20:current:6a7da782e551594a3feaa9b85076b74422c1e075fc17995ace00b4a4ce7fd2a8** — PubMed; class A. [Open source](https://pubmed.ncbi.nlm.nih.gov/30736157/) (`pubmed-observation-pmid-30736157-2019-11-20-6a7da782e551`)

### Correction lineage

No correction is recorded for this version.

### Reporting boundaries and unknowns

PeptideScanner reproduces bounded bibliographic metadata attributed to PubMed. It does not summarize or endorse the article's findings.

- Sources outside the selected public PeptideScanner bundle may exist and are not represented by this object.
- This object does not determine whether cited records agree, corroborate one another, or establish scientific truth.
- This object does not determine safety, efficacy, causality, or suitability for any person.

Methodology: https://peptidescanner.com/methodology/
Medical disclaimer: https://peptidescanner.com/medical-disclaimer/

### Suggested citation

PeptideScanner. "PubMed record PMID 30736157." Version 1, published 2026-08-12. https://peptidescanner.com/evidence/v1/peptides/lixisenatide.json#pubmed-pmid-30736157-lixisenatide-v1 SHA-256: 7bda709af9d8195b1f2e9750034aa88fc79a5c131c056fb5bcbcc6fc0498aef8.

---

<a id="pubmed-pmid-30736158-lixisenatide-v1"></a>

## PubMed record PMID 30736158

> PeptideScanner retained PubMed bibliographic metadata for PMID 30736158 at 2026-07-30T20:44:20.587Z. PubMed recorded a metadata revision date of 2019-11-20 and an Entrez history date of 2019-02-10. PeptideScanner associated this retained record with the identity slug lixisenatide. These dates describe PubMed metadata history, not the article's original publication date.

- Evidence object: `story:pubmed-pmid-30736158-lixisenatide:v1`
- Evidence domain: Literature metadata
- Date in source: 2019-11-20
- Source checked: 2026-07-30
- Published by PeptideScanner: 2026-08-12
- Story landing page: https://peptidescanner.com/stories/pubmed-pmid-30736158-lixisenatide/
- JSON record: https://peptidescanner.com/evidence/v1/peptides/lixisenatide.json#pubmed-pmid-30736158-lixisenatide-v1
- Content SHA-256: `30f7d101beeb4fbb5ca379e6249aa8bd1ef929886b0247d19c352cff14b98348`

### Claims and source pins

#### Headline

PubMed record PMID 30736158 ([`pubmed-observation-pmid-30736158-2019-11-20-7896b86d4df9`](#source-pubmed-observation-pmid-30736158-2019-11-20-7896b86d4df9))

#### Summary

PeptideScanner retained PubMed bibliographic metadata for PMID 30736158 at 2026-07-30T20:44:20.587Z. PubMed recorded a metadata revision date of 2019-11-20 and an Entrez history date of 2019-02-10. PeptideScanner associated this retained record with the identity slug lixisenatide. These dates describe PubMed metadata history, not the article's original publication date. ([`pubmed-observation-pmid-30736158-2019-11-20-7896b86d4df9`](#source-pubmed-observation-pmid-30736158-2019-11-20-7896b86d4df9))

#### Paragraph 1

PeptideScanner retained PubMed bibliographic metadata for PMID 30736158 at 2026-07-30T20:44:20.587Z. PubMed recorded a metadata revision date of 2019-11-20 and an Entrez history date of 2019-02-10. PeptideScanner associated this retained record with the identity slug lixisenatide. These dates describe PubMed metadata history, not the article's original publication date. ([`pubmed-observation-pmid-30736158-2019-11-20-7896b86d4df9`](#source-pubmed-observation-pmid-30736158-2019-11-20-7896b86d4df9))

#### Paragraph 2

This page reports retained PubMed bibliographic metadata. It does not summarize the article, establish the article's publication date, or assert safety, efficacy, or scientific truth. ([`pubmed-observation-pmid-30736158-2019-11-20-7896b86d4df9`](#source-pubmed-observation-pmid-30736158-2019-11-20-7896b86d4df9))

### Sources

<a id="source-pubmed-observation-pmid-30736158-2019-11-20-7896b86d4df9"></a>
- **PubMed record PMID 30736158 · retained source version 1:2019-11-20:current:7896b86d4df93719ef9e8489eb290aecc7da446ce2c19bb683b9a099a9c87417** — PubMed; class A. [Open source](https://pubmed.ncbi.nlm.nih.gov/30736158/) (`pubmed-observation-pmid-30736158-2019-11-20-7896b86d4df9`)

### Correction lineage

No correction is recorded for this version.

### Reporting boundaries and unknowns

PeptideScanner reproduces bounded bibliographic metadata attributed to PubMed. It does not summarize or endorse the article's findings.

- Sources outside the selected public PeptideScanner bundle may exist and are not represented by this object.
- This object does not determine whether cited records agree, corroborate one another, or establish scientific truth.
- This object does not determine safety, efficacy, causality, or suitability for any person.

Methodology: https://peptidescanner.com/methodology/
Medical disclaimer: https://peptidescanner.com/medical-disclaimer/

### Suggested citation

PeptideScanner. "PubMed record PMID 30736158." Version 1, published 2026-08-12. https://peptidescanner.com/evidence/v1/peptides/lixisenatide.json#pubmed-pmid-30736158-lixisenatide-v1 SHA-256: 30f7d101beeb4fbb5ca379e6249aa8bd1ef929886b0247d19c352cff14b98348.

---

<a id="pubmed-pmid-31365765-lixisenatide-v1"></a>

## Glycaemic target attainment in people with Type 2 diabetes treated with insulin glargine/lixisenatide fixed-ratio combination: a post hoc analysis of the LixiLan-O and LixiLan-L trials.

> PubMed lists PMID 31365765 in Diabetic medicine : a journal of the British Diabetic Association as Journal Article, Research Support, Non-U.S. Gov't, with publication-date metadata of 2019-11-26 (day precision). PeptideScanner associated the retained record with the identity slug lixisenatide. These fields reproduce attributed bibliographic metadata and do not summarize or endorse the article's findings.

- Evidence object: `story:pubmed-pmid-31365765-lixisenatide:v1`
- Evidence domain: Literature metadata
- Date in source: 2026-01-27
- Source checked: 2026-07-30
- Published by PeptideScanner: 2026-08-13
- Story landing page: https://peptidescanner.com/stories/pubmed-pmid-31365765-lixisenatide/
- JSON record: https://peptidescanner.com/evidence/v1/peptides/lixisenatide.json#pubmed-pmid-31365765-lixisenatide-v1
- Content SHA-256: `f59c33b67558ea15fb19bfc19db21304e75f7ce2fdb978518cf030dac1976da8`

### Claims and source pins

#### Headline

Glycaemic target attainment in people with Type 2 diabetes treated with insulin glargine/lixisenatide fixed-ratio combination: a post hoc analysis of the LixiLan-O and LixiLan-L trials. ([`pubmed-observation-pmid-31365765-2026-01-27-e6483945acba`](#source-pubmed-observation-pmid-31365765-2026-01-27-e6483945acba))

#### Summary

PubMed lists PMID 31365765 in Diabetic medicine : a journal of the British Diabetic Association as Journal Article, Research Support, Non-U.S. Gov't, with publication-date metadata of 2019-11-26 (day precision). PeptideScanner associated the retained record with the identity slug lixisenatide. These fields reproduce attributed bibliographic metadata and do not summarize or endorse the article's findings. ([`pubmed-observation-pmid-31365765-2026-01-27-e6483945acba`](#source-pubmed-observation-pmid-31365765-2026-01-27-e6483945acba))

#### Paragraph 1

PubMed lists PMID 31365765 in Diabetic medicine : a journal of the British Diabetic Association as Journal Article, Research Support, Non-U.S. Gov't, with publication-date metadata of 2019-11-26 (day precision). PeptideScanner associated the retained record with the identity slug lixisenatide. These fields reproduce attributed bibliographic metadata and do not summarize or endorse the article's findings. ([`pubmed-observation-pmid-31365765-2026-01-27-e6483945acba`](#source-pubmed-observation-pmid-31365765-2026-01-27-e6483945acba))

#### Paragraph 2

This page reproduces bounded bibliographic metadata attributed to PubMed. Its title and publication details are source metadata, not PeptideScanner's endorsement or an assertion of safety, efficacy, or scientific truth. ([`pubmed-observation-pmid-31365765-2026-01-27-e6483945acba`](#source-pubmed-observation-pmid-31365765-2026-01-27-e6483945acba))

### Sources

<a id="source-pubmed-observation-pmid-31365765-2026-01-27-e6483945acba"></a>
- **Glycaemic target attainment in people with Type 2 diabetes treated with insulin glargine/lixisenatide fixed-ratio combination: a post hoc analysis of the LixiLan-O and LixiLan-L trials. · retained source version 1:2026-01-27:current:e6483945acbafb19aa5e8c24d72ca0995c20517316e4b93de46074aea7dc722a** — PubMed; class A. [Open source](https://pubmed.ncbi.nlm.nih.gov/31365765/) (`pubmed-observation-pmid-31365765-2026-01-27-e6483945acba`)

### Correction lineage

No correction is recorded for this version.

### Reporting boundaries and unknowns

PeptideScanner reproduces bounded bibliographic metadata attributed to PubMed. It does not summarize or endorse the article's findings.

- Sources outside the selected public PeptideScanner bundle may exist and are not represented by this object.
- This object does not determine whether cited records agree, corroborate one another, or establish scientific truth.
- This object does not determine safety, efficacy, causality, or suitability for any person.

Methodology: https://peptidescanner.com/methodology/
Medical disclaimer: https://peptidescanner.com/medical-disclaimer/

### Suggested citation

PeptideScanner. "Glycaemic target attainment in people with Type 2 diabetes treated with insulin glargine/lixisenatide fixed-ratio combination: a post hoc analysis of the LixiLan-O and LixiLan-L trials." Version 1, published 2026-08-13. https://peptidescanner.com/evidence/v1/peptides/lixisenatide.json#pubmed-pmid-31365765-lixisenatide-v1 SHA-256: f59c33b67558ea15fb19bfc19db21304e75f7ce2fdb978518cf030dac1976da8.

---

<a id="pubmed-pmid-31469303-lixisenatide-v1"></a>

## Lixisenatide versus insulin glulisine on top of insulin glargine in patients with type 2 diabetes mellitus: a cost-per-responder analysis in China.

> PubMed lists PMID 31469303 in Current medical research and opinion as Comparative Study, Journal Article, Research Support, Non-U.S. Gov't, with publication-date metadata of 2019-09-11 (day precision). PeptideScanner associated the retained record with the identity slug lixisenatide. These fields reproduce attributed bibliographic metadata and do not summarize or endorse the article's findings.

- Evidence object: `story:pubmed-pmid-31469303-lixisenatide:v1`
- Evidence domain: Literature metadata
- Date in source: 2026-01-27
- Source checked: 2026-07-30
- Published by PeptideScanner: 2026-08-13
- Story landing page: https://peptidescanner.com/stories/pubmed-pmid-31469303-lixisenatide/
- JSON record: https://peptidescanner.com/evidence/v1/peptides/lixisenatide.json#pubmed-pmid-31469303-lixisenatide-v1
- Content SHA-256: `f48554449be069118982a7478f9183d7045d81986365ab1219ba9f1a33916325`

### Claims and source pins

#### Headline

Lixisenatide versus insulin glulisine on top of insulin glargine in patients with type 2 diabetes mellitus: a cost-per-responder analysis in China. ([`pubmed-observation-pmid-31469303-2026-01-27-c9b88cb4cccd`](#source-pubmed-observation-pmid-31469303-2026-01-27-c9b88cb4cccd))

#### Summary

PubMed lists PMID 31469303 in Current medical research and opinion as Comparative Study, Journal Article, Research Support, Non-U.S. Gov't, with publication-date metadata of 2019-09-11 (day precision). PeptideScanner associated the retained record with the identity slug lixisenatide. These fields reproduce attributed bibliographic metadata and do not summarize or endorse the article's findings. ([`pubmed-observation-pmid-31469303-2026-01-27-c9b88cb4cccd`](#source-pubmed-observation-pmid-31469303-2026-01-27-c9b88cb4cccd))

#### Paragraph 1

PubMed lists PMID 31469303 in Current medical research and opinion as Comparative Study, Journal Article, Research Support, Non-U.S. Gov't, with publication-date metadata of 2019-09-11 (day precision). PeptideScanner associated the retained record with the identity slug lixisenatide. These fields reproduce attributed bibliographic metadata and do not summarize or endorse the article's findings. ([`pubmed-observation-pmid-31469303-2026-01-27-c9b88cb4cccd`](#source-pubmed-observation-pmid-31469303-2026-01-27-c9b88cb4cccd))

#### Paragraph 2

This page reproduces bounded bibliographic metadata attributed to PubMed. Its title and publication details are source metadata, not PeptideScanner's endorsement or an assertion of safety, efficacy, or scientific truth. ([`pubmed-observation-pmid-31469303-2026-01-27-c9b88cb4cccd`](#source-pubmed-observation-pmid-31469303-2026-01-27-c9b88cb4cccd))

### Sources

<a id="source-pubmed-observation-pmid-31469303-2026-01-27-c9b88cb4cccd"></a>
- **Lixisenatide versus insulin glulisine on top of insulin glargine in patients with type 2 diabetes mellitus: a cost-per-responder analysis in China. · retained source version 1:2026-01-27:current:c9b88cb4cccd34ff1e9f51bd0d89801f04163cfe5d267c0df257e280f5d42ea9** — PubMed; class A. [Open source](https://pubmed.ncbi.nlm.nih.gov/31469303/) (`pubmed-observation-pmid-31469303-2026-01-27-c9b88cb4cccd`)

### Correction lineage

No correction is recorded for this version.

### Reporting boundaries and unknowns

PeptideScanner reproduces bounded bibliographic metadata attributed to PubMed. It does not summarize or endorse the article's findings.

- Sources outside the selected public PeptideScanner bundle may exist and are not represented by this object.
- This object does not determine whether cited records agree, corroborate one another, or establish scientific truth.
- This object does not determine safety, efficacy, causality, or suitability for any person.

Methodology: https://peptidescanner.com/methodology/
Medical disclaimer: https://peptidescanner.com/medical-disclaimer/

### Suggested citation

PeptideScanner. "Lixisenatide versus insulin glulisine on top of insulin glargine in patients with type 2 diabetes mellitus: a cost-per-responder analysis in China." Version 1, published 2026-08-13. https://peptidescanner.com/evidence/v1/peptides/lixisenatide.json#pubmed-pmid-31469303-lixisenatide-v1 SHA-256: f48554449be069118982a7478f9183d7045d81986365ab1219ba9f1a33916325.

---

<a id="pubmed-pmid-31873867-lixisenatide-v1"></a>

## PubMed record PMID 31873867

> PeptideScanner retained PubMed bibliographic metadata for PMID 31873867 at 2026-07-30T20:33:08.013Z. PubMed recorded a metadata revision date of 2020-02-26 and an Entrez history date of 2019-12-25. PeptideScanner associated this retained record with the identity slug lixisenatide. These dates describe PubMed metadata history, not the article's original publication date.

- Evidence object: `story:pubmed-pmid-31873867-lixisenatide:v1`
- Evidence domain: Literature metadata
- Date in source: 2020-02-26
- Source checked: 2026-07-30
- Published by PeptideScanner: 2026-08-12
- Story landing page: https://peptidescanner.com/stories/pubmed-pmid-31873867-lixisenatide/
- JSON record: https://peptidescanner.com/evidence/v1/peptides/lixisenatide.json#pubmed-pmid-31873867-lixisenatide-v1
- Content SHA-256: `dc5cb79f9e5e708a5baa5ca743b58734945d489153342ebf771f0cd81e2ec45d`

### Claims and source pins

#### Headline

PubMed record PMID 31873867 ([`pubmed-observation-pmid-31873867-2020-02-26-a9323f4b0ee2`](#source-pubmed-observation-pmid-31873867-2020-02-26-a9323f4b0ee2))

#### Summary

PeptideScanner retained PubMed bibliographic metadata for PMID 31873867 at 2026-07-30T20:33:08.013Z. PubMed recorded a metadata revision date of 2020-02-26 and an Entrez history date of 2019-12-25. PeptideScanner associated this retained record with the identity slug lixisenatide. These dates describe PubMed metadata history, not the article's original publication date. ([`pubmed-observation-pmid-31873867-2020-02-26-a9323f4b0ee2`](#source-pubmed-observation-pmid-31873867-2020-02-26-a9323f4b0ee2))

#### Paragraph 1

PeptideScanner retained PubMed bibliographic metadata for PMID 31873867 at 2026-07-30T20:33:08.013Z. PubMed recorded a metadata revision date of 2020-02-26 and an Entrez history date of 2019-12-25. PeptideScanner associated this retained record with the identity slug lixisenatide. These dates describe PubMed metadata history, not the article's original publication date. ([`pubmed-observation-pmid-31873867-2020-02-26-a9323f4b0ee2`](#source-pubmed-observation-pmid-31873867-2020-02-26-a9323f4b0ee2))

#### Paragraph 2

This page reports retained PubMed bibliographic metadata. It does not summarize the article, establish the article's publication date, or assert safety, efficacy, or scientific truth. ([`pubmed-observation-pmid-31873867-2020-02-26-a9323f4b0ee2`](#source-pubmed-observation-pmid-31873867-2020-02-26-a9323f4b0ee2))

### Sources

<a id="source-pubmed-observation-pmid-31873867-2020-02-26-a9323f4b0ee2"></a>
- **PubMed record PMID 31873867 · retained source version 1:2020-02-26:current:a9323f4b0ee24d6aabff1d975fb23eea0cac4d0d3b23021af41015c2b456b90e** — PubMed; class A. [Open source](https://pubmed.ncbi.nlm.nih.gov/31873867/) (`pubmed-observation-pmid-31873867-2020-02-26-a9323f4b0ee2`)

### Correction lineage

No correction is recorded for this version.

### Reporting boundaries and unknowns

PeptideScanner reproduces bounded bibliographic metadata attributed to PubMed. It does not summarize or endorse the article's findings.

- Sources outside the selected public PeptideScanner bundle may exist and are not represented by this object.
- This object does not determine whether cited records agree, corroborate one another, or establish scientific truth.
- This object does not determine safety, efficacy, causality, or suitability for any person.

Methodology: https://peptidescanner.com/methodology/
Medical disclaimer: https://peptidescanner.com/medical-disclaimer/

### Suggested citation

PeptideScanner. "PubMed record PMID 31873867." Version 1, published 2026-08-12. https://peptidescanner.com/evidence/v1/peptides/lixisenatide.json#pubmed-pmid-31873867-lixisenatide-v1 SHA-256: dc5cb79f9e5e708a5baa5ca743b58734945d489153342ebf771f0cd81e2ec45d.

---

<a id="pubmed-pmid-32561160-lixisenatide-v1"></a>

## Mexican population sub-analysis of the lixilan clinical program with the fixed ratio combination of insulin glargine and lixisenatide (iGlarLixi).

> PubMed lists PMID 32561160 in Journal of diabetes and its complications as Clinical Trial, Phase II, Clinical Trial, Phase III, Journal Article, Randomized Controlled Trial, Research Support, Non-U.S. Gov't, with publication-date metadata of 2019-05-31 (day precision). PeptideScanner associated the retained record with the identity slug lixisenatide. These fields reproduce attributed bibliographic metadata and do not summarize or endorse the article's findings.

- Evidence object: `story:pubmed-pmid-32561160-lixisenatide:v1`
- Evidence domain: Literature metadata
- Date in source: 2026-01-27
- Source checked: 2026-07-30
- Published by PeptideScanner: 2026-08-13
- Story landing page: https://peptidescanner.com/stories/pubmed-pmid-32561160-lixisenatide/
- JSON record: https://peptidescanner.com/evidence/v1/peptides/lixisenatide.json#pubmed-pmid-32561160-lixisenatide-v1
- Content SHA-256: `c28aa0fa34503e317125de699569ef53fbde14efa59e5831a5fd07eeb72af512`

### Claims and source pins

#### Headline

Mexican population sub-analysis of the lixilan clinical program with the fixed ratio combination of insulin glargine and lixisenatide (iGlarLixi). ([`pubmed-observation-pmid-32561160-2026-01-27-0e222d6c92cd`](#source-pubmed-observation-pmid-32561160-2026-01-27-0e222d6c92cd))

#### Summary

PubMed lists PMID 32561160 in Journal of diabetes and its complications as Clinical Trial, Phase II, Clinical Trial, Phase III, Journal Article, Randomized Controlled Trial, Research Support, Non-U.S. Gov't, with publication-date metadata of 2019-05-31 (day precision). PeptideScanner associated the retained record with the identity slug lixisenatide. These fields reproduce attributed bibliographic metadata and do not summarize or endorse the article's findings. ([`pubmed-observation-pmid-32561160-2026-01-27-0e222d6c92cd`](#source-pubmed-observation-pmid-32561160-2026-01-27-0e222d6c92cd))

#### Paragraph 1

PubMed lists PMID 32561160 in Journal of diabetes and its complications as Clinical Trial, Phase II, Clinical Trial, Phase III, Journal Article, Randomized Controlled Trial, Research Support, Non-U.S. Gov't, with publication-date metadata of 2019-05-31 (day precision). PeptideScanner associated the retained record with the identity slug lixisenatide. These fields reproduce attributed bibliographic metadata and do not summarize or endorse the article's findings. ([`pubmed-observation-pmid-32561160-2026-01-27-0e222d6c92cd`](#source-pubmed-observation-pmid-32561160-2026-01-27-0e222d6c92cd))

#### Paragraph 2

This page reproduces bounded bibliographic metadata attributed to PubMed. Its title and publication details are source metadata, not PeptideScanner's endorsement or an assertion of safety, efficacy, or scientific truth. ([`pubmed-observation-pmid-32561160-2026-01-27-0e222d6c92cd`](#source-pubmed-observation-pmid-32561160-2026-01-27-0e222d6c92cd))

### Sources

<a id="source-pubmed-observation-pmid-32561160-2026-01-27-0e222d6c92cd"></a>
- **Mexican population sub-analysis of the lixilan clinical program with the fixed ratio combination of insulin glargine and lixisenatide (iGlarLixi). · retained source version 1:2026-01-27:current:0e222d6c92cd228a89a1e8d098f48b6fda3ead24587cb3807fd950cf1f7afb6c** — PubMed; class A. [Open source](https://pubmed.ncbi.nlm.nih.gov/32561160/) (`pubmed-observation-pmid-32561160-2026-01-27-0e222d6c92cd`)

### Correction lineage

No correction is recorded for this version.

### Reporting boundaries and unknowns

PeptideScanner reproduces bounded bibliographic metadata attributed to PubMed. It does not summarize or endorse the article's findings.

- Sources outside the selected public PeptideScanner bundle may exist and are not represented by this object.
- This object does not determine whether cited records agree, corroborate one another, or establish scientific truth.
- This object does not determine safety, efficacy, causality, or suitability for any person.

Methodology: https://peptidescanner.com/methodology/
Medical disclaimer: https://peptidescanner.com/medical-disclaimer/

### Suggested citation

PeptideScanner. "Mexican population sub-analysis of the lixilan clinical program with the fixed ratio combination of insulin glargine and lixisenatide (iGlarLixi)." Version 1, published 2026-08-13. https://peptidescanner.com/evidence/v1/peptides/lixisenatide.json#pubmed-pmid-32561160-lixisenatide-v1 SHA-256: c28aa0fa34503e317125de699569ef53fbde14efa59e5831a5fd07eeb72af512.

---

<a id="pubmed-pmid-32700442-lixisenatide-v1"></a>

## Insulin glargine/lixisenatide fixed-ratio combination (iGlarLixi) compared with premix or addition of meal-time insulin to basal insulin in people with type 2 diabetes: A systematic review and Bayesi…

> PubMed lists PMID 32700442 in Diabetes, obesity & metabolism as Journal Article, Research Support, Non-U.S. Gov't, Systematic Review, Network Meta-Analysis, with publication-date metadata of 2020-09-03 (day precision). PeptideScanner associated the retained record with the identity slug lixisenatide. These fields reproduce attributed bibliographic metadata and do not summarize or endorse the article's findings.

- Evidence object: `story:pubmed-pmid-32700442-lixisenatide:v1`
- Evidence domain: Literature metadata
- Date in source: 2026-01-27
- Source checked: 2026-07-30
- Published by PeptideScanner: 2026-08-13
- Story landing page: https://peptidescanner.com/stories/pubmed-pmid-32700442-lixisenatide/
- JSON record: https://peptidescanner.com/evidence/v1/peptides/lixisenatide.json#pubmed-pmid-32700442-lixisenatide-v1
- Content SHA-256: `275fe0c9bce3ea9b3697ba33fab63aaeb2d74c98692840c68ac07e55fd87e9d4`

### Claims and source pins

#### Headline

Insulin glargine/lixisenatide fixed-ratio combination (iGlarLixi) compared with premix or addition of meal-time insulin to basal insulin in people with type 2 diabetes: A systematic review and Bayesi… ([`pubmed-observation-pmid-32700442-2026-01-27-d7247fdd4d57`](#source-pubmed-observation-pmid-32700442-2026-01-27-d7247fdd4d57))

#### Summary

PubMed lists PMID 32700442 in Diabetes, obesity & metabolism as Journal Article, Research Support, Non-U.S. Gov't, Systematic Review, Network Meta-Analysis, with publication-date metadata of 2020-09-03 (day precision). PeptideScanner associated the retained record with the identity slug lixisenatide. These fields reproduce attributed bibliographic metadata and do not summarize or endorse the article's findings. ([`pubmed-observation-pmid-32700442-2026-01-27-d7247fdd4d57`](#source-pubmed-observation-pmid-32700442-2026-01-27-d7247fdd4d57))

#### Paragraph 1

PubMed lists PMID 32700442 in Diabetes, obesity & metabolism as Journal Article, Research Support, Non-U.S. Gov't, Systematic Review, Network Meta-Analysis, with publication-date metadata of 2020-09-03 (day precision). PeptideScanner associated the retained record with the identity slug lixisenatide. These fields reproduce attributed bibliographic metadata and do not summarize or endorse the article's findings. ([`pubmed-observation-pmid-32700442-2026-01-27-d7247fdd4d57`](#source-pubmed-observation-pmid-32700442-2026-01-27-d7247fdd4d57))

#### Paragraph 2

This page reproduces bounded bibliographic metadata attributed to PubMed. Its title and publication details are source metadata, not PeptideScanner's endorsement or an assertion of safety, efficacy, or scientific truth. ([`pubmed-observation-pmid-32700442-2026-01-27-d7247fdd4d57`](#source-pubmed-observation-pmid-32700442-2026-01-27-d7247fdd4d57))

### Sources

<a id="source-pubmed-observation-pmid-32700442-2026-01-27-d7247fdd4d57"></a>
- **Insulin glargine/lixisenatide fixed-ratio combination (iGlarLixi) compared with premix or addition of meal-time insulin to basal insulin in people with type 2 diabetes: A systematic review and Bayesian network meta-analysis. · retained source version 1:2026-01-27:current:d7247fdd4d57938d859f9e82d712bb1f0bc5b45402267f72631cdabf3db6ccb6** — PubMed; class A. [Open source](https://pubmed.ncbi.nlm.nih.gov/32700442/) (`pubmed-observation-pmid-32700442-2026-01-27-d7247fdd4d57`)

### Correction lineage

No correction is recorded for this version.

### Reporting boundaries and unknowns

PeptideScanner reproduces bounded bibliographic metadata attributed to PubMed. It does not summarize or endorse the article's findings.

- Sources outside the selected public PeptideScanner bundle may exist and are not represented by this object.
- This object does not determine whether cited records agree, corroborate one another, or establish scientific truth.
- This object does not determine safety, efficacy, causality, or suitability for any person.

Methodology: https://peptidescanner.com/methodology/
Medical disclaimer: https://peptidescanner.com/medical-disclaimer/

### Suggested citation

PeptideScanner. "Insulin glargine/lixisenatide fixed-ratio combination (iGlarLixi) compared with premix or addition of meal-time insulin to basal insulin in people with type 2 diabetes: A systematic review and Bayesi…." Version 1, published 2026-08-13. https://peptidescanner.com/evidence/v1/peptides/lixisenatide.json#pubmed-pmid-32700442-lixisenatide-v1 SHA-256: 275fe0c9bce3ea9b3697ba33fab63aaeb2d74c98692840c68ac07e55fd87e9d4.

---

<a id="pubmed-pmid-38685598-lixisenatide-v1"></a>

## PubMed record PMID 38685598

> PeptideScanner retained PubMed bibliographic metadata for PMID 38685598 at 2026-07-30T16:14:06.932Z. PubMed recorded a metadata revision date of 2026-06-18 and an Entrez history date of 2024-04-30. PeptideScanner associated this retained record with the identity slug lixisenatide. These dates describe PubMed metadata history, not the article's original publication date.

- Evidence object: `story:pubmed-pmid-38685598-lixisenatide:v1`
- Evidence domain: Literature metadata
- Date in source: 2026-06-18
- Source checked: 2026-07-30
- Published by PeptideScanner: 2026-08-10
- Story landing page: https://peptidescanner.com/stories/pubmed-pmid-38685598-lixisenatide/
- JSON record: https://peptidescanner.com/evidence/v1/peptides/lixisenatide.json#pubmed-pmid-38685598-lixisenatide-v1
- Content SHA-256: `8c498c7387ed1b830bee380dba022666c452fb54bc6a90456e70e1558b3794b2`

### Claims and source pins

#### Headline

PubMed record PMID 38685598 ([`pubmed-observation-pmid-38685598-2026-06-18-8ae5f1c0dc16`](#source-pubmed-observation-pmid-38685598-2026-06-18-8ae5f1c0dc16))

#### Summary

PeptideScanner retained PubMed bibliographic metadata for PMID 38685598 at 2026-07-30T16:14:06.932Z. PubMed recorded a metadata revision date of 2026-06-18 and an Entrez history date of 2024-04-30. PeptideScanner associated this retained record with the identity slug lixisenatide. These dates describe PubMed metadata history, not the article's original publication date. ([`pubmed-observation-pmid-38685598-2026-06-18-8ae5f1c0dc16`](#source-pubmed-observation-pmid-38685598-2026-06-18-8ae5f1c0dc16))

#### Paragraph 1

PeptideScanner retained PubMed bibliographic metadata for PMID 38685598 at 2026-07-30T16:14:06.932Z. PubMed recorded a metadata revision date of 2026-06-18 and an Entrez history date of 2024-04-30. PeptideScanner associated this retained record with the identity slug lixisenatide. These dates describe PubMed metadata history, not the article's original publication date. ([`pubmed-observation-pmid-38685598-2026-06-18-8ae5f1c0dc16`](#source-pubmed-observation-pmid-38685598-2026-06-18-8ae5f1c0dc16))

#### Paragraph 2

This page reports retained PubMed bibliographic metadata. It does not summarize the article, establish the article's publication date, or assert safety, efficacy, or scientific truth. ([`pubmed-observation-pmid-38685598-2026-06-18-8ae5f1c0dc16`](#source-pubmed-observation-pmid-38685598-2026-06-18-8ae5f1c0dc16))

### Sources

<a id="source-pubmed-observation-pmid-38685598-2026-06-18-8ae5f1c0dc16"></a>
- **PubMed record PMID 38685598 · retained source version 1:2026-06-18:current:8ae5f1c0dc166fa06173990fbe55d39d9a07f05543595a497b947cd242a435fb** — PubMed; class A. [Open source](https://pubmed.ncbi.nlm.nih.gov/38685598/) (`pubmed-observation-pmid-38685598-2026-06-18-8ae5f1c0dc16`)

### Correction lineage

No correction is recorded for this version.

### Reporting boundaries and unknowns

PeptideScanner reproduces bounded bibliographic metadata attributed to PubMed. It does not summarize or endorse the article's findings.

- Sources outside the selected public PeptideScanner bundle may exist and are not represented by this object.
- This object does not determine whether cited records agree, corroborate one another, or establish scientific truth.
- This object does not determine safety, efficacy, causality, or suitability for any person.

Methodology: https://peptidescanner.com/methodology/
Medical disclaimer: https://peptidescanner.com/medical-disclaimer/

### Suggested citation

PeptideScanner. "PubMed record PMID 38685598." Version 1, published 2026-08-10. https://peptidescanner.com/evidence/v1/peptides/lixisenatide.json#pubmed-pmid-38685598-lixisenatide-v1 SHA-256: 8c498c7387ed1b830bee380dba022666c452fb54bc6a90456e70e1558b3794b2.

---

<a id="pubmed-pmid-38870730-lixisenatide-v1"></a>

## PubMed record PMID 38870730

> PeptideScanner retained PubMed bibliographic metadata for PMID 38870730 at 2026-08-10T18:13:32.367Z. PubMed recorded a metadata revision date of 2026-07-02 and an Entrez history date of 2024-06-13. PeptideScanner associated this retained record with the identity slug lixisenatide. These dates describe PubMed metadata history, not the article's original publication date.

- Evidence object: `story:pubmed-pmid-38870730-lixisenatide:v1`
- Evidence domain: Literature metadata
- Date in source: 2026-07-02
- Source checked: 2026-08-10
- Published by PeptideScanner: 2026-08-10
- Story landing page: https://peptidescanner.com/stories/pubmed-pmid-38870730-lixisenatide/
- JSON record: https://peptidescanner.com/evidence/v1/peptides/lixisenatide.json#pubmed-pmid-38870730-lixisenatide-v1
- Content SHA-256: `ddb60bf610087f6ad860aa8d33c5598077cc59499a6bc0549b6484884340f2bb`

### Claims and source pins

#### Headline

PubMed record PMID 38870730 ([`pubmed-observation-pmid-38870730-2026-07-02-6186ed6d988d`](#source-pubmed-observation-pmid-38870730-2026-07-02-6186ed6d988d))

#### Summary

PeptideScanner retained PubMed bibliographic metadata for PMID 38870730 at 2026-08-10T18:13:32.367Z. PubMed recorded a metadata revision date of 2026-07-02 and an Entrez history date of 2024-06-13. PeptideScanner associated this retained record with the identity slug lixisenatide. These dates describe PubMed metadata history, not the article's original publication date. ([`pubmed-observation-pmid-38870730-2026-07-02-6186ed6d988d`](#source-pubmed-observation-pmid-38870730-2026-07-02-6186ed6d988d))

#### Paragraph 1

PeptideScanner retained PubMed bibliographic metadata for PMID 38870730 at 2026-08-10T18:13:32.367Z. PubMed recorded a metadata revision date of 2026-07-02 and an Entrez history date of 2024-06-13. PeptideScanner associated this retained record with the identity slug lixisenatide. These dates describe PubMed metadata history, not the article's original publication date. ([`pubmed-observation-pmid-38870730-2026-07-02-6186ed6d988d`](#source-pubmed-observation-pmid-38870730-2026-07-02-6186ed6d988d))

#### Paragraph 2

This page reports retained PubMed bibliographic metadata. It does not summarize the article, establish the article's publication date, or assert safety, efficacy, or scientific truth. ([`pubmed-observation-pmid-38870730-2026-07-02-6186ed6d988d`](#source-pubmed-observation-pmid-38870730-2026-07-02-6186ed6d988d))

### Sources

<a id="source-pubmed-observation-pmid-38870730-2026-07-02-6186ed6d988d"></a>
- **PubMed record PMID 38870730 · retained source version 1:2026-07-02:current:6186ed6d988dd6fb7dba574b7dc737d2ebedd967d577e75a0292813f3c8d0c8d** — PubMed; class A. [Open source](https://pubmed.ncbi.nlm.nih.gov/38870730/) (`pubmed-observation-pmid-38870730-2026-07-02-6186ed6d988d`)

### Correction lineage

No correction is recorded for this version.

### Reporting boundaries and unknowns

PeptideScanner reproduces bounded bibliographic metadata attributed to PubMed. It does not summarize or endorse the article's findings.

- Sources outside the selected public PeptideScanner bundle may exist and are not represented by this object.
- This object does not determine whether cited records agree, corroborate one another, or establish scientific truth.
- This object does not determine safety, efficacy, causality, or suitability for any person.

Methodology: https://peptidescanner.com/methodology/
Medical disclaimer: https://peptidescanner.com/medical-disclaimer/

### Suggested citation

PeptideScanner. "PubMed record PMID 38870730." Version 1, published 2026-08-10. https://peptidescanner.com/evidence/v1/peptides/lixisenatide.json#pubmed-pmid-38870730-lixisenatide-v1 SHA-256: ddb60bf610087f6ad860aa8d33c5598077cc59499a6bc0549b6484884340f2bb.

---

<a id="pubmed-pmid-38877681-lixisenatide-v1"></a>

## PubMed record PMID 38877681

> PeptideScanner retained PubMed bibliographic metadata for PMID 38877681 at 2026-07-30T16:20:38.897Z. PubMed recorded a metadata revision date of 2026-05-31 and an Entrez history date of 2024-06-15. PeptideScanner associated this retained record with the identity slug lixisenatide. These dates describe PubMed metadata history, not the article's original publication date.

- Evidence object: `story:pubmed-pmid-38877681-lixisenatide:v1`
- Evidence domain: Literature metadata
- Date in source: 2026-05-31
- Source checked: 2026-07-30
- Published by PeptideScanner: 2026-08-11
- Story landing page: https://peptidescanner.com/stories/pubmed-pmid-38877681-lixisenatide/
- JSON record: https://peptidescanner.com/evidence/v1/peptides/lixisenatide.json#pubmed-pmid-38877681-lixisenatide-v1
- Content SHA-256: `67072e9ac636730f995850e6694f3503dbb366fc98c0167a1a7f845e0822e8b2`

### Claims and source pins

#### Headline

PubMed record PMID 38877681 ([`pubmed-observation-pmid-38877681-2026-05-31-b4373aeed12a`](#source-pubmed-observation-pmid-38877681-2026-05-31-b4373aeed12a))

#### Summary

PeptideScanner retained PubMed bibliographic metadata for PMID 38877681 at 2026-07-30T16:20:38.897Z. PubMed recorded a metadata revision date of 2026-05-31 and an Entrez history date of 2024-06-15. PeptideScanner associated this retained record with the identity slug lixisenatide. These dates describe PubMed metadata history, not the article's original publication date. ([`pubmed-observation-pmid-38877681-2026-05-31-b4373aeed12a`](#source-pubmed-observation-pmid-38877681-2026-05-31-b4373aeed12a))

#### Paragraph 1

PeptideScanner retained PubMed bibliographic metadata for PMID 38877681 at 2026-07-30T16:20:38.897Z. PubMed recorded a metadata revision date of 2026-05-31 and an Entrez history date of 2024-06-15. PeptideScanner associated this retained record with the identity slug lixisenatide. These dates describe PubMed metadata history, not the article's original publication date. ([`pubmed-observation-pmid-38877681-2026-05-31-b4373aeed12a`](#source-pubmed-observation-pmid-38877681-2026-05-31-b4373aeed12a))

#### Paragraph 2

This page reports retained PubMed bibliographic metadata. It does not summarize the article, establish the article's publication date, or assert safety, efficacy, or scientific truth. ([`pubmed-observation-pmid-38877681-2026-05-31-b4373aeed12a`](#source-pubmed-observation-pmid-38877681-2026-05-31-b4373aeed12a))

### Sources

<a id="source-pubmed-observation-pmid-38877681-2026-05-31-b4373aeed12a"></a>
- **PubMed record PMID 38877681 · retained source version 1:2026-05-31:current:b4373aeed12a7af0fbb6c25d7770c2cabc3f74fcec974ed67286d4045a8c2f94** — PubMed; class A. [Open source](https://pubmed.ncbi.nlm.nih.gov/38877681/) (`pubmed-observation-pmid-38877681-2026-05-31-b4373aeed12a`)

### Correction lineage

No correction is recorded for this version.

### Reporting boundaries and unknowns

PeptideScanner reproduces bounded bibliographic metadata attributed to PubMed. It does not summarize or endorse the article's findings.

- Sources outside the selected public PeptideScanner bundle may exist and are not represented by this object.
- This object does not determine whether cited records agree, corroborate one another, or establish scientific truth.
- This object does not determine safety, efficacy, causality, or suitability for any person.

Methodology: https://peptidescanner.com/methodology/
Medical disclaimer: https://peptidescanner.com/medical-disclaimer/

### Suggested citation

PeptideScanner. "PubMed record PMID 38877681." Version 1, published 2026-08-11. https://peptidescanner.com/evidence/v1/peptides/lixisenatide.json#pubmed-pmid-38877681-lixisenatide-v1 SHA-256: 67072e9ac636730f995850e6694f3503dbb366fc98c0167a1a7f845e0822e8b2.

---

<a id="pubmed-pmid-38949062-lixisenatide-v1"></a>

## Poly(l-threonine-co-l-threonine Succinate) Thermogels for Sustained Release of Lixisenatide.

> PubMed lists PMID 38949062 in Biomacromolecules as Journal Article, Research Support, Non-U.S. Gov't, with publication-date metadata of 2024-07-01 (day precision). PeptideScanner associated the retained record with the identity slug lixisenatide. These fields reproduce attributed bibliographic metadata and do not summarize or endorse the article's findings.

- Evidence object: `story:pubmed-pmid-38949062-lixisenatide:v1`
- Evidence domain: Literature metadata
- Date in source: 2024-10-31
- Source checked: 2026-07-30
- Published by PeptideScanner: 2026-08-13
- Story landing page: https://peptidescanner.com/stories/pubmed-pmid-38949062-lixisenatide/
- JSON record: https://peptidescanner.com/evidence/v1/peptides/lixisenatide.json#pubmed-pmid-38949062-lixisenatide-v1
- Content SHA-256: `f24224433300aaf2f49b35f06df2b21b053b46afde991b43555bc637ed2d9ca0`

### Claims and source pins

#### Headline

Poly(l-threonine-co-l-threonine Succinate) Thermogels for Sustained Release of Lixisenatide. ([`pubmed-observation-pmid-38949062-2024-10-31-976b348c1d91`](#source-pubmed-observation-pmid-38949062-2024-10-31-976b348c1d91))

#### Summary

PubMed lists PMID 38949062 in Biomacromolecules as Journal Article, Research Support, Non-U.S. Gov't, with publication-date metadata of 2024-07-01 (day precision). PeptideScanner associated the retained record with the identity slug lixisenatide. These fields reproduce attributed bibliographic metadata and do not summarize or endorse the article's findings. ([`pubmed-observation-pmid-38949062-2024-10-31-976b348c1d91`](#source-pubmed-observation-pmid-38949062-2024-10-31-976b348c1d91))

#### Paragraph 1

PubMed lists PMID 38949062 in Biomacromolecules as Journal Article, Research Support, Non-U.S. Gov't, with publication-date metadata of 2024-07-01 (day precision). PeptideScanner associated the retained record with the identity slug lixisenatide. These fields reproduce attributed bibliographic metadata and do not summarize or endorse the article's findings. ([`pubmed-observation-pmid-38949062-2024-10-31-976b348c1d91`](#source-pubmed-observation-pmid-38949062-2024-10-31-976b348c1d91))

#### Paragraph 2

This page reproduces bounded bibliographic metadata attributed to PubMed. Its title and publication details are source metadata, not PeptideScanner's endorsement or an assertion of safety, efficacy, or scientific truth. ([`pubmed-observation-pmid-38949062-2024-10-31-976b348c1d91`](#source-pubmed-observation-pmid-38949062-2024-10-31-976b348c1d91))

### Sources

<a id="source-pubmed-observation-pmid-38949062-2024-10-31-976b348c1d91"></a>
- **Poly(l-threonine-co-l-threonine Succinate) Thermogels for Sustained Release of Lixisenatide. · retained source version 1:2024-10-31:current:976b348c1d9174e60e56027e1e97f6b4f5a27999bb01a0f65a4bbd0b18a980d1** — PubMed; class A. [Open source](https://pubmed.ncbi.nlm.nih.gov/38949062/) (`pubmed-observation-pmid-38949062-2024-10-31-976b348c1d91`)

### Correction lineage

No correction is recorded for this version.

### Reporting boundaries and unknowns

PeptideScanner reproduces bounded bibliographic metadata attributed to PubMed. It does not summarize or endorse the article's findings.

- Sources outside the selected public PeptideScanner bundle may exist and are not represented by this object.
- This object does not determine whether cited records agree, corroborate one another, or establish scientific truth.
- This object does not determine safety, efficacy, causality, or suitability for any person.

Methodology: https://peptidescanner.com/methodology/
Medical disclaimer: https://peptidescanner.com/medical-disclaimer/

### Suggested citation

PeptideScanner. "Poly(l-threonine-co-l-threonine Succinate) Thermogels for Sustained Release of Lixisenatide." Version 1, published 2026-08-13. https://peptidescanner.com/evidence/v1/peptides/lixisenatide.json#pubmed-pmid-38949062-lixisenatide-v1 SHA-256: f24224433300aaf2f49b35f06df2b21b053b46afde991b43555bc637ed2d9ca0.

---

<a id="pubmed-pmid-39157869-lixisenatide-v1"></a>

## PubMed record PMID 39157869

> PeptideScanner retained PubMed bibliographic metadata for PMID 39157869 at 2026-07-30T16:23:36.341Z. PubMed recorded a metadata revision date of 2026-03-23 and an Entrez history date of 2024-08-19. PeptideScanner associated this retained record with the identity slug lixisenatide. These dates describe PubMed metadata history, not the article's original publication date.

- Evidence object: `story:pubmed-pmid-39157869-lixisenatide:v1`
- Evidence domain: Literature metadata
- Date in source: 2026-03-23
- Source checked: 2026-07-30
- Published by PeptideScanner: 2026-08-12
- Story landing page: https://peptidescanner.com/stories/pubmed-pmid-39157869-lixisenatide/
- JSON record: https://peptidescanner.com/evidence/v1/peptides/lixisenatide.json#pubmed-pmid-39157869-lixisenatide-v1
- Content SHA-256: `7a4dcebf41fbfacb5b5d2177fc1dccc62e46dba8105dd4e81357ced61fe20ed8`

### Claims and source pins

#### Headline

PubMed record PMID 39157869 ([`pubmed-observation-pmid-39157869-2026-03-23-b562dbf4a242`](#source-pubmed-observation-pmid-39157869-2026-03-23-b562dbf4a242))

#### Summary

PeptideScanner retained PubMed bibliographic metadata for PMID 39157869 at 2026-07-30T16:23:36.341Z. PubMed recorded a metadata revision date of 2026-03-23 and an Entrez history date of 2024-08-19. PeptideScanner associated this retained record with the identity slug lixisenatide. These dates describe PubMed metadata history, not the article's original publication date. ([`pubmed-observation-pmid-39157869-2026-03-23-b562dbf4a242`](#source-pubmed-observation-pmid-39157869-2026-03-23-b562dbf4a242))

#### Paragraph 1

PeptideScanner retained PubMed bibliographic metadata for PMID 39157869 at 2026-07-30T16:23:36.341Z. PubMed recorded a metadata revision date of 2026-03-23 and an Entrez history date of 2024-08-19. PeptideScanner associated this retained record with the identity slug lixisenatide. These dates describe PubMed metadata history, not the article's original publication date. ([`pubmed-observation-pmid-39157869-2026-03-23-b562dbf4a242`](#source-pubmed-observation-pmid-39157869-2026-03-23-b562dbf4a242))

#### Paragraph 2

This page reports retained PubMed bibliographic metadata. It does not summarize the article, establish the article's publication date, or assert safety, efficacy, or scientific truth. ([`pubmed-observation-pmid-39157869-2026-03-23-b562dbf4a242`](#source-pubmed-observation-pmid-39157869-2026-03-23-b562dbf4a242))

### Sources

<a id="source-pubmed-observation-pmid-39157869-2026-03-23-b562dbf4a242"></a>
- **PubMed record PMID 39157869 · retained source version 1:2026-03-23:current:b562dbf4a2422604a268ada2e24b32733d1c3a73eb8e8d15b66114b2f96befa5** — PubMed; class A. [Open source](https://pubmed.ncbi.nlm.nih.gov/39157869/) (`pubmed-observation-pmid-39157869-2026-03-23-b562dbf4a242`)

### Correction lineage

No correction is recorded for this version.

### Reporting boundaries and unknowns

PeptideScanner reproduces bounded bibliographic metadata attributed to PubMed. It does not summarize or endorse the article's findings.

- Sources outside the selected public PeptideScanner bundle may exist and are not represented by this object.
- This object does not determine whether cited records agree, corroborate one another, or establish scientific truth.
- This object does not determine safety, efficacy, causality, or suitability for any person.

Methodology: https://peptidescanner.com/methodology/
Medical disclaimer: https://peptidescanner.com/medical-disclaimer/

### Suggested citation

PeptideScanner. "PubMed record PMID 39157869." Version 1, published 2026-08-12. https://peptidescanner.com/evidence/v1/peptides/lixisenatide.json#pubmed-pmid-39157869-lixisenatide-v1 SHA-256: 7a4dcebf41fbfacb5b5d2177fc1dccc62e46dba8105dd4e81357ced61fe20ed8.

---

<a id="pubmed-pmid-39407425-lixisenatide-v1"></a>

## PubMed record PMID 39407425

> PeptideScanner retained PubMed bibliographic metadata for PMID 39407425 at 2026-07-30T16:20:39.038Z. PubMed recorded a metadata revision date of 2026-05-31 and an Entrez history date of 2024-10-16. PeptideScanner associated this retained record with the identity slug lixisenatide. These dates describe PubMed metadata history, not the article's original publication date.

- Evidence object: `story:pubmed-pmid-39407425-lixisenatide:v1`
- Evidence domain: Literature metadata
- Date in source: 2026-05-31
- Source checked: 2026-07-30
- Published by PeptideScanner: 2026-08-11
- Story landing page: https://peptidescanner.com/stories/pubmed-pmid-39407425-lixisenatide/
- JSON record: https://peptidescanner.com/evidence/v1/peptides/lixisenatide.json#pubmed-pmid-39407425-lixisenatide-v1
- Content SHA-256: `cac2dd297537b06469f5eae2b0b4bfc586fb83c9aa4500dee0baaafce8ba63b5`

### Claims and source pins

#### Headline

PubMed record PMID 39407425 ([`pubmed-observation-pmid-39407425-2026-05-31-294ee153f5b8`](#source-pubmed-observation-pmid-39407425-2026-05-31-294ee153f5b8))

#### Summary

PeptideScanner retained PubMed bibliographic metadata for PMID 39407425 at 2026-07-30T16:20:39.038Z. PubMed recorded a metadata revision date of 2026-05-31 and an Entrez history date of 2024-10-16. PeptideScanner associated this retained record with the identity slug lixisenatide. These dates describe PubMed metadata history, not the article's original publication date. ([`pubmed-observation-pmid-39407425-2026-05-31-294ee153f5b8`](#source-pubmed-observation-pmid-39407425-2026-05-31-294ee153f5b8))

#### Paragraph 1

PeptideScanner retained PubMed bibliographic metadata for PMID 39407425 at 2026-07-30T16:20:39.038Z. PubMed recorded a metadata revision date of 2026-05-31 and an Entrez history date of 2024-10-16. PeptideScanner associated this retained record with the identity slug lixisenatide. These dates describe PubMed metadata history, not the article's original publication date. ([`pubmed-observation-pmid-39407425-2026-05-31-294ee153f5b8`](#source-pubmed-observation-pmid-39407425-2026-05-31-294ee153f5b8))

#### Paragraph 2

This page reports retained PubMed bibliographic metadata. It does not summarize the article, establish the article's publication date, or assert safety, efficacy, or scientific truth. ([`pubmed-observation-pmid-39407425-2026-05-31-294ee153f5b8`](#source-pubmed-observation-pmid-39407425-2026-05-31-294ee153f5b8))

### Sources

<a id="source-pubmed-observation-pmid-39407425-2026-05-31-294ee153f5b8"></a>
- **PubMed record PMID 39407425 · retained source version 1:2026-05-31:current:294ee153f5b8f3dd224eb420b2ea4a0b4f182778292884d8614a6f48e612fc1a** — PubMed; class A. [Open source](https://pubmed.ncbi.nlm.nih.gov/39407425/) (`pubmed-observation-pmid-39407425-2026-05-31-294ee153f5b8`)

### Correction lineage

No correction is recorded for this version.

### Reporting boundaries and unknowns

PeptideScanner reproduces bounded bibliographic metadata attributed to PubMed. It does not summarize or endorse the article's findings.

- Sources outside the selected public PeptideScanner bundle may exist and are not represented by this object.
- This object does not determine whether cited records agree, corroborate one another, or establish scientific truth.
- This object does not determine safety, efficacy, causality, or suitability for any person.

Methodology: https://peptidescanner.com/methodology/
Medical disclaimer: https://peptidescanner.com/medical-disclaimer/

### Suggested citation

PeptideScanner. "PubMed record PMID 39407425." Version 1, published 2026-08-11. https://peptidescanner.com/evidence/v1/peptides/lixisenatide.json#pubmed-pmid-39407425-lixisenatide-v1 SHA-256: cac2dd297537b06469f5eae2b0b4bfc586fb83c9aa4500dee0baaafce8ba63b5.

---

<a id="pubmed-pmid-39604042-lixisenatide-v1"></a>

## PubMed record PMID 39604042

> PeptideScanner retained PubMed bibliographic metadata for PMID 39604042 at 2026-07-30T16:31:16.748Z. PubMed recorded a metadata revision date of 2026-07-30 and an Entrez history date of 2024-11-27. PeptideScanner associated this retained record with the identity slug lixisenatide. These dates describe PubMed metadata history, not the article's original publication date.

- Evidence object: `story:pubmed-pmid-39604042-lixisenatide:v1`
- Evidence domain: Literature metadata
- Date in source: 2026-07-30
- Source checked: 2026-07-30
- Published by PeptideScanner: 2026-08-10
- Story landing page: https://peptidescanner.com/stories/pubmed-pmid-39604042-lixisenatide/
- JSON record: https://peptidescanner.com/evidence/v1/peptides/lixisenatide.json#pubmed-pmid-39604042-lixisenatide-v1
- Content SHA-256: `a8a23b002565939b2101225ef622d7146684dd50b55c076ea7f2bf2093c06ce3`

### Claims and source pins

#### Headline

PubMed record PMID 39604042 ([`pubmed-observation-pmid-39604042-2026-07-30-ca98d06b1e51`](#source-pubmed-observation-pmid-39604042-2026-07-30-ca98d06b1e51))

#### Summary

PeptideScanner retained PubMed bibliographic metadata for PMID 39604042 at 2026-07-30T16:31:16.748Z. PubMed recorded a metadata revision date of 2026-07-30 and an Entrez history date of 2024-11-27. PeptideScanner associated this retained record with the identity slug lixisenatide. These dates describe PubMed metadata history, not the article's original publication date. ([`pubmed-observation-pmid-39604042-2026-07-30-ca98d06b1e51`](#source-pubmed-observation-pmid-39604042-2026-07-30-ca98d06b1e51))

#### Paragraph 1

PeptideScanner retained PubMed bibliographic metadata for PMID 39604042 at 2026-07-30T16:31:16.748Z. PubMed recorded a metadata revision date of 2026-07-30 and an Entrez history date of 2024-11-27. PeptideScanner associated this retained record with the identity slug lixisenatide. These dates describe PubMed metadata history, not the article's original publication date. ([`pubmed-observation-pmid-39604042-2026-07-30-ca98d06b1e51`](#source-pubmed-observation-pmid-39604042-2026-07-30-ca98d06b1e51))

#### Paragraph 2

This page reports retained PubMed bibliographic metadata. It does not summarize the article, establish the article's publication date, or assert safety, efficacy, or scientific truth. ([`pubmed-observation-pmid-39604042-2026-07-30-ca98d06b1e51`](#source-pubmed-observation-pmid-39604042-2026-07-30-ca98d06b1e51))

### Sources

<a id="source-pubmed-observation-pmid-39604042-2026-07-30-ca98d06b1e51"></a>
- **PubMed record PMID 39604042 · retained source version 1:2026-07-30:current:ca98d06b1e51c0fb564db9c83cb9e347b8f3323b3916a6d4c0e89a3f0078dabc** — PubMed; class A. [Open source](https://pubmed.ncbi.nlm.nih.gov/39604042/) (`pubmed-observation-pmid-39604042-2026-07-30-ca98d06b1e51`)

### Correction lineage

No correction is recorded for this version.

### Reporting boundaries and unknowns

PeptideScanner reproduces bounded bibliographic metadata attributed to PubMed. It does not summarize or endorse the article's findings.

- Sources outside the selected public PeptideScanner bundle may exist and are not represented by this object.
- This object does not determine whether cited records agree, corroborate one another, or establish scientific truth.
- This object does not determine safety, efficacy, causality, or suitability for any person.

Methodology: https://peptidescanner.com/methodology/
Medical disclaimer: https://peptidescanner.com/medical-disclaimer/

### Suggested citation

PeptideScanner. "PubMed record PMID 39604042." Version 1, published 2026-08-10. https://peptidescanner.com/evidence/v1/peptides/lixisenatide.json#pubmed-pmid-39604042-lixisenatide-v1 SHA-256: a8a23b002565939b2101225ef622d7146684dd50b55c076ea7f2bf2093c06ce3.

---

<a id="pubmed-pmid-41623754-lixisenatide-v1"></a>

## PubMed record PMID 41623754

> PeptideScanner retained PubMed bibliographic metadata for PMID 41623754 at 2026-07-30T16:25:14.225Z. PubMed recorded a metadata revision date of 2026-02-04 and an Entrez history date of 2026-02-02. PeptideScanner associated this retained record with the identity slug lixisenatide. These dates describe PubMed metadata history, not the article's original publication date.

- Evidence object: `story:pubmed-pmid-41623754-lixisenatide:v1`
- Evidence domain: Literature metadata
- Date in source: 2026-02-04
- Source checked: 2026-07-30
- Published by PeptideScanner: 2026-08-12
- Story landing page: https://peptidescanner.com/stories/pubmed-pmid-41623754-lixisenatide/
- JSON record: https://peptidescanner.com/evidence/v1/peptides/lixisenatide.json#pubmed-pmid-41623754-lixisenatide-v1
- Content SHA-256: `4f5a847a76424fb8ebb1a7f2e6ae811a9bbff300581ebb4913c1e2549a7c84af`

### Claims and source pins

#### Headline

PubMed record PMID 41623754 ([`pubmed-observation-pmid-41623754-2026-02-04-57125184b6d2`](#source-pubmed-observation-pmid-41623754-2026-02-04-57125184b6d2))

#### Summary

PeptideScanner retained PubMed bibliographic metadata for PMID 41623754 at 2026-07-30T16:25:14.225Z. PubMed recorded a metadata revision date of 2026-02-04 and an Entrez history date of 2026-02-02. PeptideScanner associated this retained record with the identity slug lixisenatide. These dates describe PubMed metadata history, not the article's original publication date. ([`pubmed-observation-pmid-41623754-2026-02-04-57125184b6d2`](#source-pubmed-observation-pmid-41623754-2026-02-04-57125184b6d2))

#### Paragraph 1

PeptideScanner retained PubMed bibliographic metadata for PMID 41623754 at 2026-07-30T16:25:14.225Z. PubMed recorded a metadata revision date of 2026-02-04 and an Entrez history date of 2026-02-02. PeptideScanner associated this retained record with the identity slug lixisenatide. These dates describe PubMed metadata history, not the article's original publication date. ([`pubmed-observation-pmid-41623754-2026-02-04-57125184b6d2`](#source-pubmed-observation-pmid-41623754-2026-02-04-57125184b6d2))

#### Paragraph 2

This page reports retained PubMed bibliographic metadata. It does not summarize the article, establish the article's publication date, or assert safety, efficacy, or scientific truth. ([`pubmed-observation-pmid-41623754-2026-02-04-57125184b6d2`](#source-pubmed-observation-pmid-41623754-2026-02-04-57125184b6d2))

### Sources

<a id="source-pubmed-observation-pmid-41623754-2026-02-04-57125184b6d2"></a>
- **PubMed record PMID 41623754 · retained source version 1:2026-02-04:current:57125184b6d2881468270a71667d7a3b3d1335ca3f90c9bce1a989b90b14d82e** — PubMed; class A. [Open source](https://pubmed.ncbi.nlm.nih.gov/41623754/) (`pubmed-observation-pmid-41623754-2026-02-04-57125184b6d2`)

### Correction lineage

No correction is recorded for this version.

### Reporting boundaries and unknowns

PeptideScanner reproduces bounded bibliographic metadata attributed to PubMed. It does not summarize or endorse the article's findings.

- Sources outside the selected public PeptideScanner bundle may exist and are not represented by this object.
- This object does not determine whether cited records agree, corroborate one another, or establish scientific truth.
- This object does not determine safety, efficacy, causality, or suitability for any person.

Methodology: https://peptidescanner.com/methodology/
Medical disclaimer: https://peptidescanner.com/medical-disclaimer/

### Suggested citation

PeptideScanner. "PubMed record PMID 41623754." Version 1, published 2026-08-12. https://peptidescanner.com/evidence/v1/peptides/lixisenatide.json#pubmed-pmid-41623754-lixisenatide-v1 SHA-256: 4f5a847a76424fb8ebb1a7f2e6ae811a9bbff300581ebb4913c1e2549a7c84af.

